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Two studies on evaluation of diagnostic and therapeutic strategies in reproductive 
medicine are presented in this thesis. The first subject is about the diagnostic 
strategy and describes the results of a pragmatic multicenter randomized controlled 
trial comparing fertility work-ups with or without hysterosalpingography (HSG) to 
assess the value of HSG prior to laparoscopy and dye in a routine clinical setting. 
The second subject focusses on therapy in reproductive medicine and is based on a 
study on assisted conception to clarify whether adverse perinatal outcome is related 
to assisted conception or other maternal risk factors and whether this is for both 
singleton and twin pregnancies.
First all backgrounds are given in this chapter on the history and evolution of the 
Cochrane Collaboration followed by an overview of diagnostic and therapeutic 
strategies in reproductive medicine. At the end of the chapter an outline of this thesis 
is summarized.
1.1  Evidence based medicine in Obstetrics, Gynaecology and Reproductive 
Medicine
In 1979 the epidemiologist Archie Cochrane (1908-1988) published an essay, in 
which he suggested that “It is surely a great criticism of our profession that we have 
not organised a critical summary, by specialty or subspecialty, adapted periodically, 
of all relevant randomised controlled trials”1. He also designated Obstetrics 
the least scientific medical specialty although his words were also applicable for 
Gynaecology and the emerging field of Reproductive Medicine (www.cochrane.
org/docs/cchronol.htm). This statement, combined with direct funding from the 
World Health Organisation and the English Department of Health, led to a register 
of controlled trials in perinatal medicine, which was located in the National Perinatal 
Epidemiology Unit, Oxford. Based on this register an international collaboration 
established an institute that enabled physicians and scientists to prepare systematic 
reviews of controlled trials on intervention in pregnancy, childbirth, and the neonatal 
period. In 1988 and 1989 the collaborative work was brought together in publications 
called ‘The Oxford Database of Perinatal Trials’ (ODPT)2, ‘Effective care in 
Pregnancy and Childbirth (ECPC)3 and ‘a guide to effective care in Pregnancy and 
Childbirth’ (GECPC)4 composed by Ian Chalmers, Murray Enkin, and Marc Keirse. 
This monumental work was the launch of the Cochrane Collaboration established 
by Ian Chalmers in 1993. The Cochrane Collaboration is an international non-
profit and independent organisation, dedicated to making up-to-date, accurate, and 
readily available summaries on the effects of healthcare interventions. It produces 
and disseminates systematic reviews of healthcare interventions and promotes the 
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search for evidence by clinical trials and other studies of interventions. As part of the 
Cochrane Collaboration, the specialty of Obstetrics & Gynaecology registered their 
subspecialties: the Pregnancy & Childbirth group and the Subfertility group (1992), 
the Neonatal group (1993), the Menstrual Disorders group (1995), the Gynaecological 
Cancer group (1996) and the Fertility Regulation group (1997). Together with the 
development of systematic reviews in this period of time, not only the quantity, but 
also the quality of randomised controlled trials, the basis of the Cochrane systematic 
reviews, increased greatly5.
Allocation concealment is a technique used to prevent selection bias by concealing 
the allocation sequence from those assigning participants to intervention groups, 
until the moment of assignment6. Allocation concealment prevents researchers from 
(unconsciously or otherwise) influencing which participants are assigned to a given 
intervention group. In 1994, Schulz et al.7 reported that only 23% of the randomised 
controlled trials published in obstetrics and gynaecology journals contained 
information about adequate allocation concealment.
Figure 1.  Proportion of randomized controlled trials with adequate allocation concealment that are 
included in published Cochrane reviews in four content areas, by years. FRG, fertility 
regulation; Subf, subfertility; P&C, pregnancy and childbirth, and heart (Helmerhorst 
et al., Contraception 2006) 
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Since then the proportion of included trials with documentation of adequate allocation 
concealment has been progressively increasing in the subspecialties subfertility, 
perinatology, and fertility regulation5. 
1.1.1 Randomised controlled trial
The randomised controlled trial is by large the best tool we have, to demonstrate the 
possible benefits of an intervention, especially when a small difference in outcome 
between the two arms is expected. In 1999, Haynes8 referred to Archie Cochrane 
for the differentiation between the three concepts related to testing healthcare 
interventions: efficacy, effectiveness and efficiency. “Efficacy is the extent to 
which an intervention does more good than harm under ideal circumstances (“Can 
it work?”). Effectiveness assesses whether an intervention does more good than 
harm when provided under usual circumstances of healthcare practice (“Does it 
work in practice?”). Efficiency measures the effect of an intervention in relation 
to the resources it consumes (“Is it worth it?”). Trials of efficacy and effectiveness 
have also been described as explanatory and management trials, respectively, and 
efficiency trials are more often called cost effectiveness or cost benefit studies.”
1.1.2 Observational studies
In his commentary on ‘Balancing benefits and harms in health care’, Vandenbroucke9 
stood up “for the world of pharmacoepidemiology, which mainly investigates the 
harms of the same treatments” by showing that “observational data on harm should 
complement systematic reviews of benefit”. Observational data are considered 
as intrinsically problematic. Evidence hierarchies have been proposed with the 
randomised trial at the apex and the observational studies dangling far behind it10. 
However, for the identification of unintended, infrequently occurring adverse effects, 
only observational methodology, such as case control and cohort studies, can help us. 
Reconfirmation of these results surfaced by observational studies can be established 
by randomised controlled trials, as we have seen for venous thromboembolism in the 
Women’s Health Initiative studies on hormonal replacement therapy11.
1.1.3 Background of thesis 
There are many arguments why HSG should or should not be part of the standard 
diagnostic fertility work-up based on its diagnostic value, conception rates afterwards, 
pain, and costs. Therefore, a pragmatic multicenter randomised controlled trial 
comparing fertility work-ups with or without HSG was conducted at Leiden University 
Medical Center in collaboration with Westeinde Hospital (The Hague) and Groene 
Hart Hospital (Gouda) to assess the value of HSG prior to laparoscopy and dye in 
a routine clinical setting. A randomised comparison of two infertility protocols that 
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were identical except for inclusion and exclusion of HSG was conducted. Thus, the 
entity of a diagnostic method together with the decision for a therapy, was tested with 
the primary, hard clinical outcome ‘pregnancy’. This procedure reflects the situation 
in the clinic and is called a pragmatic trial. It was this approach that was considered 
applicable for testing the routine use of hysterosalpingography prior to laparoscopy 
in the fertility workup, being the first subject of investigation as presented in this 
thesis.
In 1978, Louise Brown was born as first IVF baby12. Since then assisted reproductive 
technologies have improved with increasing pregnancy rates. However, outcomes 
other than live birth rates have become more important. As early as 1985, the Australian 
In Vitro Fertilisation Collaborative Group has shown increased adverse perinatal 
outcomes (such as preterm birth and low birthweight) in singleton pregnancies 
conceived after assisted conception compared to naturally conceived pregnancies13. 
But it was unclear by what extent the adverse perinatal outcomes were related to 
assisted conception or to confounding factors, such as maternal age and parity. After 
1985, several cohort studies have confirmed the findings from Australia14-16 but some 
studies found an opposite trend17,18. Moreover, for twin pregnancies the general 
consensus, with few exceptions19-21, seemed to be that twin pregnancies conceived 
after assisted conception have outcomes that are either similar to or slightly better 
than those conceived naturally14,17,22-25. 
However, no systematic reviews were available to clarify whether perinatal outcome 
was related to assisted conception or other maternal risk factors, and whether this 
was for both singleton and twin pregnancies. We performed a systematic review of 25 
controlled studies published between 1985 and 2002, to examine whether there are 
differences in outcome between assisted and natural conceptions and whether they 
apply to both singleton and twin pregnancies. This subject is the second investigation 
of this thesis.
1.2 Diagnostic strategies in reproductive medicine
1.2.1 Diagnostic fertility work-up
A couple is proclaimed subfertile when they have one year of regular, unprotected 
intercourse without conception. The prevalence of subfertility in the Netherlands is 
about 10-17% depending on the age of women26. The basic diagnostic investigations 
for both men and female in the fertility work-up as recommended in the National 
Institute for Clinical Excellence (NICE) guidelines27, exist of history taking, clinical 
examination, semen analysis, ovulation detection and assessment of tubal damage. 
Here we discuss several techniques for assessing tubal function, laparoscopy and dye 
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as the reference standard, hysterosalpingography (HSG) and Chlamydia antibody 
testing (CAT).
1.2.2 Assessment of tubal pathology 
Laparoscopy and dye
The first gynaecologic laparoscopy was performed by Raoul Palmer in 1944. About 25 
years later, in the late 1960s, the diagnostic laparoscopy became a routine procedure 
in gynaecological practices. Laparoscopy and dye, also called dye hydrotubation, 
dye insufflation, dye pertubation, chromopertubation, or chromolaparoscopy, allows 
direct visualisation of the fallopian tubes. The laparoscopy enables assessment of 
tubal patency, peritubal adhesions, and endometriosis. Laparoscopy is applied under 
general anaesthesia and it is an invasive procedure with risks between 0.06% and 
0.20% for vascular, intestinal, and urological injuries28. Anaesthetic complications 
and methylene blue toxicity have also been reported, but are extremely rare29. 
Laparoscopy is generally regarded as the definitive test for the evaluation of tubal 
pathology. Additionally, laparoscopic treatments such as coagulation of endometriosis 
grade I/II, adhesiolysis, or cystectomy, can be performed in the same session. There 
is a possible fecundity enhancing effect after laparoscopic coagulation of minimal 
and mild endometriosis plus adhesiolysis (www.eshre.com). Although laparoscopy 
and dye is the reference standard in the diagnosis of tubal pathology according to 
World Health Organisation (WHO) criteria30, it is not beyond criticism31. Moreover, 
laparoscopy sometimes returns false positive results, meaning that women sometimes 
do conceive after bilateral obstruction according to laparoscopy.
The risk of having peritubal abnormalities or endometriosis in subfertile women who 
are asymptomatic, have normal physical examination, and have bilateral tubal patency 
at HSG, is low. In these women laparoscopy could be delayed or abandoned because 
only in a small minority of women severe tubal pathology will be revealed27,32. 
Moreover, women with co-morbidities, such as endometriosis or history of pelvic 
inflammatory disease or ectopic pregnancy should be offered a laparoscopy and 
dye early in the fertility work-up, according to RCOG and NICE guidelines27,32. 
Whether flushing of the fallopian tubes enhances fertility by laparoscopy and dye is 
not known. One randomized controlled trial showed no difference in pregnancy rate 
between laparoscopic chromopertubation with oil contrast medium or water soluble 
contrast medium33.
Hysterosalpingography 
In 1910, Rindfleisch described the visualisation of the uterine cavity by delivering 
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a bismuth solution through the vagina34. In 1920, Rubin introduced the tubal 
insufflation test using carbon dioxide to investigate tubal patency35. In 1925, Heuser 
performed the first hysterosalpingography with oil soluble contrast media36.
At hysterosalpingography (HSG) contrast dye is injected through the cervical canal 
into the uterine cavity. Subsequent X-ray imaging visualizes the uterine cavity and 
the fallopian tubes. HSG is being used predominantly in the fertility work-up for the 
evaluation of uterine cavity and fallopian tubes. Other indications for HSG include 
the evaluation of uterine anomalies in women with a history of recurrent pregnancy 
loss and the postoperative evaluation of tubal patency or blockage. 
Because patients may experience cramping during the HSG, women are recommended 
to take a nonsteroidal anti-inflammatory drug (NSAID) before the procedure to 
reduce discomfort. 
Contraindications to HSG are iodine allergy37 and active pelvic infection. Prophylactic 
antibiotics should be considered for patients having history of pelvic infections, 
positive result Chlamydia antibody testing38 or tubal pathology assumed at HSG. 
However, it is not clear from the literature whether antibiotic prophylaxis following 
transcervical intrauterine procedures protects against infection. The risk of infection 
after hysterosalpingography is about 1-3%39. 
Traditionally HSGs were performed with oil-soluble contrast media. These oil-
soluble contrast media have gradually been replaced by water-soluble contrast 
media. There are a number of reasons for using water-soluble contrast media in stead 
of oil-soluble contrast media: 
1. Water soluble contrast media are generally cheaper than oil-soluble contrast 
media.
2. Water soluble contrast media have better imaging of the tubal mucosal folds and 
ampullary ruggae than oil-soluble contrast media40. 
3. Water soluble contrast media have a low viscosity which results in quick filling 
of the fallopian tubes and dispersion in the pelvis, therefore a delayed film is 
performed within one hour. In contrast with oil contrast medium what is more 
viscous and disperses very slowly in the pelvis, therefore a delayed film should 
be performed after 24 hours.
4. Less severe adverse events have been reported with water-soluble contrast 
media, inclusing pulmonary embolus, cerebral embolus, granuloma formation, 
anaphylaxis, and even death as result of intravasation. Since the introduction of 
low-viscosity oil contrast media, these serious pulmonary complications due to 
oil-soluble contrast media are extremely rare nowadays41. However, a significant 
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lower probability of immediate pain, prolonged pain, and post-procedure pain 
occurs with oil-soluble contrast media compared to water-soluble contrast 
media42.
Most fertility centers have moved towards the use of HSG with water soluble contrast 
media rather than oil-soluble contrast media for the beneficial reasons outlined 
above43. 
Whether oil-soluble or water-soluble contrast media might have a fertility enhancing 
effect, has been under debate for half a century. A meta-analysis of randomised 
controlled trials showed a significant increase in pregnancy and live birth rates by 
flushing the tubes with oil-soluble media when compared with no intervention42. 
No such data exist for water-soluble contrast media versus no intervention. There 
are no randomized trials of good quality for the comparison of tubal flushing with 
oil-soluble media versus tubal flushing with water-soluble media, regarding the odds 
of pregnancy or live birth rates. The underlying mechanism of the possible fertility 
enhancing effect of oil-soluble media, whether this is a ‘tubal flushing’ phenomenon, 
an effect on the intraperitoneal environment, or an implantation enhancing effect on 
the endometrium, is still unclear44,45.
HSG plays a role in the diagnostic evaluation of abnormalities relating to the uterus 
and fallopian tubes:
1.  Uterine abnormalities that can be detected with HSG include congenital 
malformations (like uterus unicornuate, septate, bicornuate, and didelphys), 
polyps, submucous leiomyomas and adhesions. Uterine cavity abnormalities 
with a prevalence of about 10-15% in subfertile women can be visualized by 
HSG. Other methods for assessing the uterine cavity are transvaginal sonography, 
saline infusion sonography and hysteroscopy. Hysteroscopy (as gold standard) is 
generally used for confirmation and treatment of uterine cavity abnormalities 
found on HSG. It is important to bear in mind that the effectiveness of surgical 
treatment of uterine abnormalities to enhance pregnancy rates has not yet been 
established27. 
The endovaginal ultrasound has been demonstrated as a reliable alternative for 
HSG in detecting uterine cavity pathology46-47. Ultrasonography compared to 
hysterosalpingography is less invasive and more easily performed in a short period 
without roentgen radiation. It can also be applied in the visualization of pelvic 
pathology such as endometriosis or ovarian pathology. 
2. The most important role of HSG is the assessment of tubal pathology. Tubal 
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abnormalities that can be detected include proximal tubal occlusion, salpingitis 
isthmica nodosa, hydrosalpinx, and peritubal adhesions. The tubal abnormalities 
seen at HSG can be either a congenital anomaly or due to cornual spasm, 
occlusion, or infection. At radiology, tubal spasm can not be distinguished from 
proximal tubal occlusion. 
Laparoscopy and HSG
Several authors have compared HSG with laparoscopy as the reference standard 
for tubal patency. A meta-analysis of 20 studies between 1968 and 1994 concluded 
that while a normal HSG without tubal blockage will not rule out tubal disease, an 
abnormal HSG with tubal blockage is good at ruling in tubal pathology48. Therefore, 
with point estimates of 65% of sensitivity and 83% of specificity, HSG has moderate 
sensitivity and specificity in predicting tubal patency compared to laparoscopy 
and dye48. This meta-analysis also showed a very poor performance of HSG for 
predicting peritubal adhesions. 
In daily practise many clinicians perform a laparoscopy soon after HSG, if at HSG 
tubal pathology is assumed. If HSG showes no tubal pathology and the woman does 
not conceive within six months, a laparoscopy and dye followes after six month. 
This is according to the RCOG and NICE guidelines27,32 in which HSG has been 
considered as a screening test for tubal patency in low-risk couples.
Further, considerable variability in the interpretation as well as in clinical 
management of HSG abnormalities, has been shown among practitioners49,50. As 
might be expected, the probability of treatment-independent pregnancy is best 
when HSG reveals absence of tubal occlusion, substantially lower when there is 
two-sided occlusion, and only slightly reduced in the case of one-sided occlusion at 
HSG31,51,52.
HSG with water-soluble contrast media remains the only trustworthy method for 
examining tubal mucosal fold configuration, especially when tubal microsurgery 
(e.g. salpingostomy) is considered53, albeit that HSG then can be better carried out 
after laparoscopy. 
Chlamydia trachomatis antibody testing
Chlamydia trachomatis is the most common sexually transmitted disease worldwide 
and remains asymptomatic in up to 80% of women54. Thus, women may remain 
untreated for years leading to long-term sequelae such as ectopic pregnancy and 
tubal subfertility. Pelvic inflammatory disease caused by Chlamydia trachomatis is 
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the major cause of tubal subfertility (http://www.who.int/vaccine_research/diseases/
soa_std/en/index.html) and results in distal tubal obstruction and pelvic adhesions. 
Since the association between Chlamydia trachomatis antibodies in serum and tubal 
pathology was noticed in 197955, Chlamydia trachomatis antibody testing (CAT) 
has been introduced for large-scale screening purposes in the fertility work-up. 
Although both laparoscopy and hysterosalpingography are frequently used in the 
diagnostic fertility work-up of tubal pelvic damage, they are costly and invasive 
procedures. CAT is nowadays commonly used to assess the risk of tubal pathology 
in subfertile women in an inexpensive and non-invasive way. Because of the high 
negative predictive value of CAT in subfertile women (85–90%)56, the presence of 
tubal pathology in patients with a negative CAT is unlikely. The positive predictive 
value of CAT in subfertile women is lower than the NPV and ranges from 30 to 
65%56. The results reported on the diagnostic accuracy of CAT are heterogenous 
because of differences in CAT tests, threshold levels for a positive test, reference 
standard and definition of tubal pathology used. However, the simplicity and limited 
inconvenience of CAT serology enables its wide use in infertility practise to screen 
for tubal damage57. 
CAT and HSG provide risk estimates of tubal pathology prior to laparoscopy, but 
the diagnosis tubal pathology can only be made with laparoscopy and dye. Until 
now, there is no consensus on which tests should be used routinely for the diagnostic 
work-up of tubal pathology.
New diagnostic procedures
There are other new diagnostic investigations for assessing tubal damage, like 
hysterosalpingo-contrast-sonography or transvaginal laparoscopy. It is beyond this 
thesis to explain these procedures in more details. 
1.3 Therapeutic strategies in reproductive medicine
1.3.1 Types of assisted reproductive treatments (ART)
In the last two decennia, assisted reproductive  treatments (ART) such as ovarian 
stimulation, intra-uterine insemination (IUI), in vitro fertilization (IVF), and 
intracytoplasmatic sperm injection (ICSI), have become widely applied methods in 
the treatment of subfertile couples. These treatments will be explained briefly.
Ovarian stimulation
Two methods of ovarian stimulation should be distinguished. Mono-follicle 
development is attempted in anovulatory women and secondly, ovarian 
hyperstimulation is usually used to treat ovulatory women with the aim to induce 
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development of more than one dominant follicle to facilitate assisted conception. 
Ovarian hyperstimulation is sometimes combined with intra-uterine insemination, 
and nearly always before in vitro fertilization and intracytoplasmatic sperm 
injection. 
Intra-uterine insemination (IUI)
Intra-uterine insemination means artificial insemination of in vitro selected motile 
spermatozoa. IUI treatment is widely used in subfertile couples with unexplained 
subfertility problems, minimal to mild endometriosis and mild male factor fertility 
problems27. IUI is often offered before IVF because IUI is less invasive, requires 
less intensive monitoring, and is associated with lower risks of hyperstimulation and 
multiple pregnancy. 
The IUI procedure implies monitoring follicular growth development (1-3 follicles) 
by ovarian ultrasound. IUI can be performed with or without controlled ovarian 
hyperstimulation to increase the number of follicles slightly. Insemination is 
performed around the time of ovulation. The processed semen is inseminated directly 
into the uterine cavity through a small catheter bypassing the cervical canal, after 
which fertilization takes place in vivo.
In vitro fertilization (IVF)
In vitro fertilization is an assisted reproductive technique in which fertilization of the 
oocyte takes place in vitro by inseminating the oocyte with processed spermatozoa. 
After fertilization, one or more embryo(s) are transferred into the uterine cavity. 
Indications for IVF are tubal pathology, unexplained subfertility, endometriosis, mild 
male subfertility and failure to conceive after ovarian stimulation or after intrauterine 
insemination (http://www.nvog-documenten.nl/uploaded/docs/09_indicaties_ivf.
pdf).
The controlled ovarian stimulation technique used in IVF is designed to induce 
multifollicular growth in order to maximize the yield of oocytes for fertilization 
to enhance the probability of achieving a pregnancy. Oocyte retrieval is performed 
by ultrasound guided transvaginal follicle aspiration. The oocytes are inseminated 
in vitro with processed semen after which the embryos are cultured for a variable 
number of days before the embryos will be transferred transcervical to the uterine 
cavity. Surplus transferable embryos will be cryopreserved. 
Intracytoplasmatic sperm injection (ICSI)
Intracytoplasmatic sperm injection is an assisted reproductive technique in which 
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oocytes are retrieved and become mechanically injected in vitro with one single 
spermatozoon per oocyte. After this, fertilization takes place in vitro and the embryo 
is transferred into the uterine cavity. The indications for ICSI treatment are severe 
male factor or no fertilization after IVF procedure. Couples undergoing the ICSI 
treatment have similar procedures for ovarian stimulation, oocyte retrieval and 
embryo transfer as IVF treatment. The difference between ICSI and IVF is the oocyte 
fertilization procedure. Both treatments are in vitro but with ICSI, the oocytes are 
injected with one spermatozoon, while with IVF the oocytes are inseminated with 
many thousands of spermatozoa. 
1.3.2 Risks and complications of ART
Numerous studies have shown that ART is an efficacious treatment in subfertile 
couples. In spite of its established efficacy, little attention has been paid so far to the 
safety of ART, i.e. to its adverse events and complications to the female patient and 
the offspring. 
Complications to the female patient 
The adverse effects of ART for the female patient are mainly ovarian hyperstimulation 
syndrome (OHSS) and multiple pregnancy. 
- Ovarian hyperstimulation syndrome (OHSS)
The most serious and potentially lethal -iatrogenic- complication of ovarian 
stimulation is ovarian hyperstimulation syndrome (OHSS)58. OHSS is a self-limiting 
syndrome and ranges from mild to severe. The incidence of the severe form of OHSS 
in patients undergoing ART is about 1% but this is increasing due to the expansion 
of ART for the last years59.
- Multiple pregnancy
One of the most important complications of ART treatments is the high percentage 
of multiple pregnancies. The number of twin births increased rapidly since the mid-
1970s in the Netherlands from 10/1000 births to 18/1000 births in the year 2000, 
but this is decreasing to 16/1000 births in 2005 (www.cbs.nl). Also the number of 
triplets and higher order gestations increased from the mid-1970s (0.15/1000 births) 
to 1994 (0.6/1000 births), but since then this number is decreasing to 0.2/1000 births 
in 2005 (www.cbs.nl). 
Increase in delayed childbearing and increasing use of assisted reproductive 
treatments (like IVF) are the most important contributors to the almost 2-fold 
increase in twin birth between 1975 and 2000. Older women are at increased risk for 
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multiple gestations in naturally conceived pregnancies. They are also at increased 
risk of being infertile and of using ART, placing them at higher risk of multiple 
gestations. The increase of triplets and higher order gestations between 1975 and 
1995 was partly due to the high numbers of embryos (four or five) transferred after 
IVF/ICSI. In the early 1990s this number was reduced to two or three embryos and 
resulted in mainly a reduction of triplets and higher order births. Possibly due to 
the application of single embryo transfers in IVF/ICSI, a decrease in twin birth 
rate is notified since 200460. Multiple pregnancies are nowadays considered as the 
most important complication resulting from ART and are related with maternal and 
perinatal mortality and morbidity. 
- Maternal mortality
The causes of maternal death in developed countries are mainly due to hypertensive 
disorders, thromboembolism and haemorrhage61. Advanced maternal age increases 
the risk of maternal mortality rate in IVF (and other related assisted reproductive 
technologies) pregnancies. 
- Maternal morbidity
One of the major maternal complications associated with multiple pregnancies are 
higher incidence of pregnancy-related hypertensive conditions, like eclampsia and 
preeclampsia. This risk is two times greater for a twin pregnancy than for a singleton 
pregnancy, and a 3-fold greater risk for a triplet pregnancy62. 
Maternal morbidity is also significantly increased in multiple compared to singleton 
pregnancies due to pregnancy complications like venous thromboembolism, 
antepartum haemorrhage from placenta praevia and placenta abruption, anaemia, 
gestational diabetes, delivery by Caesarean section, preterm delivery and postpartum 
haemorrhage63-66.
- Long-term effects of ART on women
The long-term effects of hormonal ovarian stimulation on the risk of breast cancer 
and cancers of the female genital tract have been investigated in cohort studies where 
infertile women exposed to ovarian stimulation treatment were compared with 
infertile women without ovarian stimulation67-70. These studies showed no increased 
risk for cancer of the breast or ovary in women who received hormonal ovarian 
stimulation and those who did not. Also a lower incidence of cancer of the breast and 
carcinoma in situ of the cervix was found in women with live birth following IVF 
treatment compared with women with live birth without IVF71. The average follow-
up time in most studies was relatively short, further studies are necessary to include 




Perinatal mortality rate for multiple pregnancy is higher compared to singleton 
pregnancy. This rate increases with the number of gestation72 due to a higher rate 
of prematurity and low birth weights in children. The perinatal outcome of ART 
pregnancies shows that singleton ART pregnancies have a slightly increased perinatal 
morbidity and mortality compared to naturally conceived singleton pregnancies 13-16. 
Although perinatal outcomes are similar for twins conceived by ART and naturally 
conceived twins14,17,22-25 the twin pregnancy itself is the main course of the overall 
poorer perinatal outcome of twins. 
Many perinatal complications can be addressed to prematurity and low birth weight. 
Therefore longer treatment is required in neonatal intensive care unit for twins 
compared to singletons with more health costs73.
- Long term consequences on offspring
Long term consequences on neurlogical sequelae in IVF/ICSI pregnancies is still 
unclear. Two population based studies showed that twins born after assisted conception 
have a similar risk of neurological sequelae (cerebral palsy) as naturally conceived 
twins and singletons after IVF or ICSI74,75. A recent review showed no increased risk 
of imprinting diseases in children born after use of assisted reproductive technologies 
compared with children born after naturally conception76. 
- Health of male offspring
Concern has also been expressed about the health of boys born to couples with male 
factor subfertility. Genetic causes of male factor subfertility include: congenital 
bilateral absence of the vas deference (CBAVD)/cystic fibrosis, Y-chromosomal 
microdeletions, X-chromosomal and autosomal aberrations (i.e. Robertsonian 
translocations), syndromal disorders featuring infertility (i.e. Kallmann´s syndrome) 
and ultrastructural sperm defects with a genetic basis. It is theoretically possible 
that with ICSI these genetic abnormalities may be transmitted to the following male 
generation77. However, more large prospective studies are needed to address this 
theory.
The incidence of de-novo sex chromosomal aberrations is higher after ICSI than in 
the general population78. Also the major malformation rate (eg hypospadias) after 
ICSI might be higher as compared with natural conception79. This may be due to the 
infertility per se, rather than the ART technique. Despite concern about the health 




1.4 Outline of the thesis
In this thesis two subjects of investigation on evaluation of diagnosis and therapy 
in reproductive medicine are presented. The evaluation of diagnosis in reproductive 
medicine is based on a study on hysterosalpingography (HSG) (chapters 2 to 5) 
and describes the results of a pragmatic multicenter randomized controlled trial 
comparing fertility work-ups with or without HSG to assess the value of HSG prior 
to laparoscopy and dye in a routine clinical setting. The question whether HSG 
should be maintained as a tool in the basic fertility work-up is of major interest as 
otherwise many subfertile women will continue to undergo a diagnostic procedure 
with questionable utility. The second subject of this thesis focusses on therapy in 
reproductive medicine and is based on a study on assisted conception (chapter 6) to 
clarify whether adverse perinatal outcome is related to assisted conception or other 
maternal risk factors, and whether this is for both singleton and twin pregnancies.
In chapter two, the effect of HSG on cumulative pregnancy rate is assessed. We 
performed a randomized trial to investigate the influence of routine use of HSG at 
an early stage in the fertility work-up prior to laparoscopy and dye on cumulative 
pregnancy rate, compared with routine use of laparoscopy without HSG. In chapter 
three we evaluate pain and patient satisfaction of women undergoing an HSG or 
laparoscopy and dye as routine diagnostic procedures in the fertility work-up in a 
cohort study of subfertile women nested in the randomized controlled trial. Chapter 
four describes the diagnostic properties of HSG and Chlamydia antibody testing. 
Nested in the randomized controlled trial, the value of Chlamydia antibody testing 
is assessed as alternative test for HSG. In chapter five the results of recruitment 
difficulties in a randomized trial involving HSG are described. Chapter six describes 
the results of a systematic review of controlled studies to examine whether there 
are genuine differences in outcome between assisted and natural conceptions and 
whether they apply to both singleton and twin pregnancies. Finally, in chapter seven 
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Background: A multicenter randomised controlled trial with or without hystero-
salpingo graphy (HSG) was conducted to assess the usefulness of HSG as a routine 
investigation in the fertility workup prior to laparoscopy and dye. 
Methods: From 1 April 1997 to 1 April 2002, subfertile women were allocated by a 
computer–based 1 : 1 ratio randomisation procedure, either for an HSG followed by 
laparoscopy and dye (the intervention group) of for laparoscopy and dye only (the 
control group) as a part of their fertility workup. Cumulative pregnancy rate (CPR) 
within 18 months after randomisation was the primary outcome of interest. 
Results: 344 women were randomised to the intervention group (n = 169) and the 
control group (n = 175). There was no significant difference in CPR at 18 months in 
the intervention group (49.1%) [95% confidence interval (CI) 41.6 to 56.6] and the 
control group (50.3%) (95% CI 42.8 to 57.8), a difference of –1.2% (95% CI –11.8% 
to 9.5%). 
Conclusion: The routine use of HSG at an early stage in the fertility workup prior 
to laparoscopy and dye does not influence CPR, compared with the routine use of 
laparoscopy and dye without HSG. 
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Introduction 
After history taking, physical examination, semen analysis and investigation 
of ovulation, assessment of tubal patency is the next step in the standard 
examination of the subfertile couple. Owing to the noninvasive nature and low cost, 
hysterosalpingography (HSG) is widely used as a first-line approach to assess the 
patency of the Fallopian tubes in routine fertility workup1,2, although laparoscopy 
and dye is considered the gold standard3,4. 
A reason for performing HSG instead of or prior to laparoscopy and dye cannot be 
found in the test characteristics of HSG. Comparing the accuracy of HSG with that of 
laparoscopy and dye in the diagnosis of tubal pathology, a meta-analysis demonstrated 
point estimates of 65% of sensitivity and 83% of specificity4. Furthermore, 
considerable variability in the interpretation as well as clinical consequences of HSG 
abnormalities has been shown among practitioners5,6. Advantages of HSG relative 
to laparoscopy are the short outpatient procedure and the enhancement of pregnancy 
with oil-soluble contrast medium7, although water-soluble media are mostly used8. 
The therapeutic effect of tubal flushing with water-soluble media is, however, still 
unknown9. 
The relative merits of HSG and laparoscopy in screening for tubal factors have been 
discussed for more than 30 years, but so far no randomised controlled trial has been 
reported1. To assess the value of HSG prior to laparoscopy and dye in a routine 
clinical setting, we performed a pragmatic multicenter randomised controlled trial 
comparing fertility workups with or without HSG. In a pragmatic trial, effectiveness 
of an intervention is assessed under usual circumstances, in contrast to efficacy trials 
in which the intervention is examined under ideal conditions10. Is the patient better 
off with or without the extra intervention (in this case, HSG)? We compared the two 
strategies, with pregnancy as a clinical endpoint, in terms of cumulative pregnancy 
rate (CPR). 
Subjects and methods 
Patients and randomisation procedure 
The study was performed in three teaching hospitals in The Netherlands. All newly 
referred and admitted subfertile women who visited the Department of Reproductive 
Medicine of Leiden University Medical Center (April 1997 to April 2002), the 
Department of Obstetrics and Gynaecology of the Medical Center Haaglanden, The 
Hague (April 1997 to April 2002) or the Department of Obstetrics and Gynaecology 
of the Groene Hart Hospital, Gouda, The Netherlands (April 1999 to April 2000) 
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were eligible for inclusion in the trial. 
Exclusion criteria were subfertility less than 1 year, woman older than 37 years at 
the time of first visit, anovulation despite clomiphene citrate or bromocriptine use, 
abnormal semen analysis according to World Health Organization (WHO)11 criteria 
or testing of tubal patency performed in the past. The institutional review boards 
of each of the three hospitals approved the study protocol. Women were asked to 
participate in the study by their treating gynaecologist at the time that HSG would 
normally be planned, and informed consent was obtained. The treating gynaecologist 
telephoned the secretariat of Medical Center Haaglanden at The Hague to perform 
randomisation. A computer-based 1 : 1 ratio randomisation procedure was used 
to allocate the women into two groups. Randomisation was stratified for each 
participating hospital. All women routinely received vaginal ultrasound before 
randomisation. The intervention group underwent HSG first, and if the HSG showed 
normal uterine cavity and no tubal pathology and if the woman did not conceive 
within 6 months, a laparoscopy and dye followed after 6 months. When tubal 
pathology was assumed, laparoscopy was performed within 1–2 months after the 
HSG. The control group received a laparoscopy and dye immediately. If pathology 
of the uterine cavity was presumed by HSG or by vaginal ultrasound, hysteroscopy 
could be performed together with the laparoscopy. Moreover, a history of recurrent 
miscarriages or diethylstilboestrol (DES) exposure was an additional reason to 
perform a hysteroscopy during laparoscopy. 
Because our trial was designed to determine the effectiveness of HSG in the routine 
fertility workup, we ensured that HSG and laparoscopy results were uniformly 
interpreted in all participating hospitals. At the same time, the study protocol 
intentionally allowed normal clinical freedom and a variety of choices and protocols 
after HSG and laparoscopy. Hence, the participating hospitals used their own 
protocol for therapeutic reproductive surgery and assisted reproductive treatments 
[e.g. intrauterine insemination (IUI) or IVF]. The primary analysis was conducted 
on an intention-to-treat basis. The primary outcome parameter in our study was 
occurrence of pregnancy within 18 months after randomisation. The diagnosis of 
pregnancy was based on a positive urine or serum pregnancy test in association with 
the presence of an intrauterine gestation sac on ultrasound scan. 
HSG and laparoscopy and dye 
All hysterosalpingographies were performed in the outpatient clinic of the department 
of radiology shortly after the menstrual period. A water-soluble contrast medium 
(Omnipaque 300®) was used. One photograph was taken of the phase when the 
cavity and tubes were just filled and one when there was overflow at both sides or 
when there was maximal filling of the tubes without overflow. After 30 min, a late 
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film was made to detect contrast depots. Findings of tubal pathology at HSG were 
classified according to2, as normal, one-sided abnormality or two-sided abnormality. 
Additional intracavity abnormalities were scored separately. The results of HSG 
were interpreted in a weekly meeting by staff members specialized in reproductive 
medicine, who also decided whether laparoscopy and dye should be performed with 
or without delay. 
Laparoscopy and dye was performed in the follicular phase and under general 
anaesthesia. After making pneumoperitoneum, a thorough inspection of the pelvis, 
internal genitalia, appendix and liver region was performed, followed by testing the 
patency of the Fallopian tubes using dye. A dilute solution of Methylene Blue was 
injected through the cervix. During laparoscopy, we determined adhesions, structural 
abnormalities of the uterus, endometriosis, periadnexal disease and Fallopian 
tube occlusion. Tubal pathology at laparoscopy was defined according to Mol et 
al.2, as normal, one-sided abnormality or two-sided abnormality. Furthermore, 
endometriosis detected at laparoscopy was classified according to the classification of 
the American Fertility Society12. Therapeutic reproductive surgery could be applied 
during laparoscopy, such as coagulation of endometriosis grade I/II, laparoscopic 
adhesiolysis or laparoscopic cystectomy.
Statistical methods 
Descriptive statistics were used to assess the similarity of the groups. Categorical 
data were assessed by the chi-square test and continuous variables by Student’s t-test. 
CPRs were calculated using standard time-to-event analysis (Kaplan–Meier survival 
analysis). For comparison of the different CPR curves, the log-rank statistic was 
used. On the basis of local unpublished data of Leiden University Medical Center, 
we calculated that for a subfertile couple the probability of getting pregnant after 
1 year from intake, including artificial interference, is about 45%. With a smallest 
difference in CPR arbitrarily set at 10% (55% in the intervention group and 45% in 
the control group), an alpha error of 0.05 and a beta error of 0.20 (power of the study 
set at 80%), we calculated that at least 375 women should be included in each arm 
(a total of 750 women). 
Results 
A total of 344 women were randomised, 169 to the intervention group and 175 to 
the control group. Follow-up either to pregnancy or for 18 months was complete 
for all subjects in both groups. Figure 1 shows the flow chart of participants. At the 
end of the study, HSG had been performed in 152 of the 169 (90%) women in the 
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intervention group. In the control group, 10 of the 175 (6%) women had undergone 
an HSG. Laparoscopies had been performed on 94 of the 169 (56%) women in the 
intervention group and on 150 of the 175 (86%) women in the control group. To 
deal with this, our analysis was based on the groups as randomised, following the 
intention-totreat principle. 
Table I summarizes the baseline characteristics of the women participating in the 
study. When comparing the women in the intervention and control groups, there 
were no significant differences between the groups regarding age, duration of 
subfertility, parity, history of pelvic inflammatory disease, intrauterine device, 
sexually transmitted disease or tubal surgery. 
A total of 152 women in the intervention group underwent HSG, and in 58 women 
no additional laparoscopy was performed. In 40 of these 58 women, this was due 
to occurrence of pregnancy within 6 months after HSG. Hence, the pregnancy 
rate within 6 months after performing HSG was 26%. Of the other 18 women, no 
laparoscopy was performed for unknown reasons. 
At HSG, 23 (15%) showed one-sided abnormalities and 23 (15%) showed two-sided 
abnormalities. In 10 of 152 women, HSG showed intracavity abnormalities, a reason 
why hysteroscopy was performed during laparoscopy. 
Ninety-four laparoscopies were performed in the intervention group. At laparoscopy, 
12 (13%) showed one-sided abnormalities and 15 (16%) showed two-sided 
abnormalities. Endometriosis was detected in 21 women (22%). The laparoscopic 
D.A.M.Perquin et al.
2
Gynaecology of the Medical Centre Haaglanden, The Hague (April
1997 to April 2002) or the Department of Obstetrics and Gynaecology
of the Groene Hart Hospital, Gouda, The Netherlands (April 1999 to
April 2000) were eligible for inclusion in the trial.
Exclusion criteria were subfertility less than 1 year, woman older
than 37 years at the time of first visit, anovulation despite clomiphene
citrate or bromocriptine use, abnormal semen analysis according to
World Health Organization (WHO) (World Health Organization,
1999) criteria or testing of tubal patency performed in the past. The
institutional review boards of each of the three hospitals approved the
study protocol. Women were asked to participate in the study by their
treating gynaecologist at the time that HSG would normally be
planned, and informed consent was obtained. The treating gynaecolo-
gist telephoned the secretariat of Medical Centre Haaglanden at The
Hague to perform randomization. A computer-based 1 : 1 ratio rand-
omization procedure was used to allocate the women into two groups.
Randomization was stratified for each participating hospital. All
women routinely received vaginal ultrasound before randomization.
The intervention group underwent HSG first, and if the HSG showed
normal uterine cavity and no tubal pathology and if the woman did not
conceive within 6 months, a laparoscopy and dye followed after
6 months. When tubal pathology was assumed, laparoscopy was per-
formed within 1–2 months after the HSG. The control group received
a laparoscopy and dye immediately. If pathology of the uterine cavity
was presumed by HSG or by vaginal ultrasound, hysteroscopy could
be performed together with the laparoscopy. Moreover, a history of
recurrent miscarriages or diethylstilboestrol (DES) exposure was an
additional reason to perform a hysteroscopy during laparoscopy.
Because our trial was designed to determine the effectiveness of
HSG in the routine fertility workup, we ensured that HSG and lapar-
oscopy results were uniformly interpreted in all participating hospi-
tals. At the same time, the study protocol intentionally allowed normal
clinical freedom and a variety of choices and protocols after HSG and
laparoscopy. Hence, the participating hospitals used their own proto-
col for therapeutic reproductive surgery and assisted reproductive
treatments [e.g. intrauterine insemination (IUI) or IVF]. The primary
analysis was conducted on an intention-to-treat basis. The primary
outcome parameter in our study was occurrence of pregnancy within
18 months after randomization. The diagnosis of pregnancy was based
on a positive urine or serum pregnancy test in association with the
presence of an intrauterine gestation sac on ultrasound scan.
HSG and laparoscopy and dye
All hysterosalpingographies were performed in the outpatient clinic of
the department of radiology shortly after the menstrual period.
A water-soluble contrast medium (Omnipaque 300®) was used. One
photograph was taken of the phase when the cavity and tubes were
just filled and one when there was overflow at both sides or when
there was maximal filling of the tubes without overflow. After 30 min,
a late film was made to detect contrast depots. Findings of tubal
pathology at HSG were classified according to Mol et al. (2001), as
normal, one-sided abnormality or two-sided abnormality. Additional
intracavity abnormalities were scored separately. The results of HSG
were interpreted in a weekly meeting by staff members specialized in
reproductive medicine, who also decided whether laparoscopy and
dye should be performed with or without delay.
Laparoscopy and dye was performed in the follicular phase and under
general anaesthesia. After making pneumoperitoneum, a thorough
inspection of the pelvis, internal genitalia, appendix and liver region
was performed, followed by testing the patency of the Fallopian tubes
using dye. A dilute solution of Methylene Blue was injected through
the cervix. During laparoscopy, we determined adhesions, structural
abnormalities of the uterus, endometriosis, periadnexal disease and
Fallopian tube occlusion. Tubal pathology at laparoscopy was defined
according to Mol et al. (2001), as normal, one-sided abnormality or
two-sided abnormality. Furthermore, endometriosis detected at lapar-
oscopy was classified according to the classification of the American
Fertility Society (1985). Therapeutic reproductive surgery could be
applied during laparoscopy, such as coagulation of endometriosis
grade I/II, laparoscopic adhesiolysis or laparoscopic cystectomy.
Statistical methods
Descriptive statistics were used to assess the similarity of the groups.
Categorical data were assessed by the chi-square test and continuous
variables by Student’s t-test. CPRs were calculated using standard
time-to-event analysis (Kaplan–Meier survival analysis). For compar-
ison of the different CPR curves, the log-rank statistic was used. On
the basis of local unpublished data of Leiden University Medical
Centre, we calculated that for a subfertile couple the probability of
getting pregnant after 1 year from intake, including artificial interfer-
ence, is about 45%. With a smallest difference in CPR arbitrarily set at
10% (55% in the intervention group and 45% in the control group), an
alpha error of 0.05 and a beta error of 0.20 (power of the study set at
80%), we calculated that at least 375 women should be included in
each arm (a total of 750 women).
Results
A total of 344 women were randomized, 169 to the interven-
tion group and 175 to the control group. Follow-up either to
pregnancy or for 18 months was complete for all subjects in
both groups. Figure 1 shows the flow chart of participants. At
the end of the study, HSG had been performed in 152 of the
169 (90%) women in the intervention group. In the control
group, 10 of the 175 (6%) women had undergone an HSG.
Laparoscopies had been performed on 94 of the 169 (56%)
women in the intervention group and on 150 of the 175 (86%)
women in the control group. To deal with this, our analysis was
based on the groups as randomized, following the intention-to-
treat principle.
Figure 1. Flow chart of participants.
Figure 1.
Flow chart of participants. 
35
Routine use of hysterosalpingography prior to laparoscopy in the fertility workup
therapeutic interventions applied in the intervention group are summarized in Table 
II. 
In 150 of 175 women in the control group, a laparoscopy and dye was performed. 
Seven of these 150 women also had a hysteroscopy performed during laparoscopy. 
At laparoscopy, 13 (9%) showed one-sided abnormalities and 16 (11%) showed 
two-sided abnormalities. Endometriosis was detected in 43 women (29%). Different 
laparoscopic therapeutic interventions could be applied when abnormal findings 
were seen (Table II). Table II shows that there were no significant differences in 
numbers of laparoscopic therapeutic interventions between both groups. 
Table III shows the numbers of assisted reproductive treatments applied during the 
study in the intervention group and in the control group. There were no significant 
differences in numbers of applied assisted reproductive treatments between both 
groups. 
In the intervention group, 83 pregnancies occurred in follow-up time of 2115 months, 
whereas in the control group 88 pregnancies occurred in 2257 months of follow-up. 
Therefore, the annualized pregnancy rate was 0.47 [95% confidence interval (CI) 
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Table I summarizes the baseline characteristics of the women
participating in the study. When comparing the women in the
intervention and control groups, there were no significant dif-
ferences between the groups regarding age, duration of subfer-
tility, parity, history of pelvic inflammatory disease, intrauterine
device, sexually transmitted disease or tubal surgery.
A total of 152 women in the intervention group underwent
HSG, and in 58 women no additional laparoscopy was per-
formed. In 40 of these 58 women, this was due to occurrence of
pregnancy within 6 months after HSG. Hence, the pregnancy
rate within 6 months after performing HSG was 26%. Of the
other 18 women, no laparoscopy was performed for unknown
reasons.
At HSG, 23 (15%) showed one-sided abnormalities and 23
(15%) showed two-sided abnormalities. In 10 of 152 women,
HSG showed intracavity abnormalities, a reason why hysteros-
copy was performed during laparoscopy.
Ninety-four laparoscopies were performed in the intervention
group. At laparoscopy, 12 (13%) showed one-sided abnormalities
and 15 (16%) showed two-sided abnormalities. Endometriosis
was detected in 21 women (22%). The laparoscopic therapeutic
interventions applied in the intervention group are summarized
in Table II.
In 150 of 175 women in the control group, a laparoscopy
and dye was performed. Seven of these 150 women also had a
hysteroscopy performed during laparoscopy. At laparoscopy,
13 (9%) showed one-sided abnormalities and 16 (11%) showed
two-sided abnormalities. Endometriosis was detected in 43
women (29%). Different laparoscopic therapeutic interventions
could be applied when abnormal findings were seen (Table II).
Table II shows that there were no significant differences in
numbers of laparoscopic therapeutic interventions between
both groups.
Table III shows the numbers of assisted reproductive treat-
ments applied during the study in the intervention group and in
the control group. There were no significant differences in
numbers of applied assisted reproductive treatments between
both groups.
In the intervention group, 83 pregnancies occurred in follow-up
time of 2115 months, whereas in the control group 88 pregnan-
cies occurred in 2257 months of follow-up. Therefore, the annu-
alized pregnancy rate was 0.47 [95% confidence interval (CI)
0.37 to 0.57] in the intervention group and 0.47 (95% CI 0.37 to
0.57) in the control group. The CPR at 18 months was 49.1%
(95% CI 41.6 to 56.6) in the intervention group and 50.3%
(95% CI 42.8 to 57.8) in the control group, a difference of –1.2%
(95% CI –11.8 to 9.5). Pregnancy rates at given times through-
out the study were also not significantly different (Figure 2).
No difference in primary or secondary subfertility was found. Of
the 31 multiparous women in the intervention group, 15 were
pregnant at the end of follow-up, compared with 17 of
Table I. Baseline characteristics of women participating in the study
Values are expressed as number (percentage) unless otherwise specified.
Characteristics Intervention 
group (n = 169)
Control 
group (n = 175)
Age (years) (mean ± SD) 30 ± 4.0 30 ± 4.0
Duration of subfertility (years) 
(mean ± SD)
2.0 ± 1.1 2.0 ± 0.8
Nulliparous 138 (82) 145 (83)
History of
Pelvic inflammatory disease 5 (3) 5 (3)
Intrauterine device 4 (2) 5 (3)
Sexually transmitted disease 6 (4) 7 (4)
Tubal surgery 2 (1) 1 (1)
Ovulatory disorder 31 (18) 25 (14)
Table II. Therapeutic reproductive surgery applied in the intervention and 
control groups
Values are expressed as number (percentage).
Surgery Intervention 
group (n = 94)
Control 
group (n = 150)
None 65 (69) 102 (68)
Coagulation of endometriosis grade I/II 23 (25) 41 (27)
Laparoscopic adhesiolysis 5 (5) 5 (4)
Laparoscopic cystectomy 1 (1) 2 (1)
Table III. Assisted reproductive treatment applied in the intervention and 
control groups
Values are expressed as number (percentage).
Treatment Intervention 
group (n = 169)
Control 
group (n = 175)
None 94 (56) 101 (58)
Intrauterine insemination 60 (35) 61 (35)
IVF 15 (9) 13 (7)
Figure 2. Cumulative pregnancy rates for the intervention group,
which included hysterosalpingography (HSG), and control group,
which excluded HSG.
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Table I summarizes the baseline characteristics of the women
participating in the study. When comparing the women in the
intervention and control groups, there were no significant dif-
ferences between the groups regarding age, duration of subfer-
tility, parity, history of pelvic inflammatory disease, intrauterine
device, sexually transmitted disease or tubal surgery.
A total of 152 women in the intervention group underwent
HSG, and in 58 women no additional laparoscopy was per-
formed. In 40 of these 58 women, this was due to occurrence of
pregnancy within 6 months after HSG. Hence, the pregnancy
rate within 6 months after performing HSG was 26%. Of the
other 18 women, no laparoscopy was performed for unknown
reasons.
At HSG, 23 (15%) showed one-sided abnormalities and 23
(15%) showed two-sided abnormalities. In 10 of 152 women,
HSG showed intracavity abnormalities, a reason why hysteros-
copy was performed during laparoscopy.
Ninety-four laparoscopies were performed in the intervention
group. At laparoscopy, 12 (13%) showed one-sided abnormalities
and 15 (16%) showed two-sided abnormalities. Endometriosis
was detected in 21 women (22%). The laparoscopic therapeutic
interventions applied in the intervention group are summarized
in Table II.
In 150 of 175 women in the control group, a laparoscopy
and dye was performed. Seven of these 150 women also had a
hysteroscopy performed during laparoscopy. At laparoscopy,
13 (9%) showed one-sided abnormalities and 16 (11%) showed
two-sided abnormalities. Endometriosis was detected in 43
women (29%). Different laparoscopic therapeutic interventions
could be applied when abnormal findings were seen (Table II).
Table II shows that there were no significant differences in
numbers of laparoscopic therapeutic interventions between
both groups.
Table III shows the numbers of assisted reproductive treat-
ments applied during the study in the intervention group and in
the control group. There were no significant differences in
numbers of applied assisted reproductive treatments between
both groups.
In the intervention group, 83 pregnancies occurred in follow-up
time of 2115 months, whereas in the control group 88 pregnan-
cies occurred in 2257 months of follow-up. Therefore, the annu-
alized pregnancy rate was 0.47 [95% confidence interval (CI)
0.37 to 0.57] in the intervention group and 0.47 (95% CI 0.37 to
0.57) in the control group. The CPR at 18 months was 49.1%
(95% CI 41.6 to 56.6) in the intervention group and 50.3%
(95% CI 42.8 to 57.8) in the control group, a difference of –1.2%
(95% CI –11.8 to 9.5). Pregnancy rates at given times through-
out the study were also not significantly different (Figure 2).
No difference in primary or secondary subfertility was found. Of
the 31 multiparous women in the intervention group, 15 were
pregnant at the end of follow-up, compared with 17 of
Table I. Baseline characteristics of women participating in the study
Values are expressed as number (percentage) unless otherwise specified.
Characteristics Intervention 
group (n = 169)
Control 
group (n = 175)
Age (years) (mean ± SD) 30 ± 4.0 30 ± 4.0
Duration of subfertility (years) 
(mean ± SD)
2.0 ± 1.1 2.0 ± 0.8
Nulliparous 138 (82) 145 (83)
History of
Pelvic inflammatory disease 5 (3) 5 (3)
Intrauterine device 4 (2) 5 (3)
Sexually transmitted disease 6 (4) 7 (4)
Tubal surgery 2 (1) 1 (1)
Ovulatory disorder 31 (18) 25 (14)
Table II. Therapeutic reproductive surgery applied in the intervention and 
control groups
Values are expressed as number (percentage).
Surgery Intervention 
group (n = 94)
Control 
group (n = 150)
None 65 (69) 102 (68)
Coagulation of endometriosis grade I/II 23 (25) 41 (27)
Laparoscopic adhesiolysis 5 (5) 5 (4)
Laparoscopic cystectomy 1 (1) 2 (1)
Table III. Assisted reproductive treatment applied in the intervention and 
control groups
Values are expressed as number (percentage).
Treatment Intervention 
group (n = 169)
Control 
group (n = 175)
None 94 (56) 101 (58)
Intrauterine insemination 60 (35) 61 (35)
IVF 15 (9) 13 (7)
Figure 2. Cumulative pregnancy rates for the intervention group,
which included hysterosalpingography (HSG), and control group,
which excluded HSG.


































0.37 to 0.57] in the intervention group and 0.47 (95% CI 0.37 to 0.57) in the control 
group. The CPR at 18 months was 49.1% (95% CI 41.6 to 56.6) in the intervention 
group and 50.3% (95% CI 42.8 to 57.8) in the control group, a difference of –1.2% 
(95% CI –11.8 to 9.5). Pregnancy rates at given times throughout the study were 
also not significantly different (Figure 2). No difference in primary or secondary 
subfertility was found. Of the 31 multiparous women in the intervention group, 15 
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intervention and control groups, there were no significant dif-
ferences between the groups regarding age, duration of subfer-
tility, parity, history of pelvic inflammatory disease, intrauterine
device, sexually transmitted disease or tubal surgery.
A total of 152 women in the intervention group underwent
HSG, and in 58 women no additional laparoscopy was per-
formed. In 40 of these 58 women, this was due to occurrence of
pregnancy within 6 months after HSG. Hence, the pregnancy
rate within 6 months after performing HSG was 26%. Of the
other 18 women, no laparoscopy was performed for unknown
reasons.
At HSG, 23 (15%) showed one-sided abnormalities and 23
(15%) showed two-sided abnormalities. In 10 of 152 women,
HSG showed intracavity abnormalities, a reason why hysteros-
copy was performed during laparoscopy.
Ninety-four laparoscopies were performed in the intervention
group. At laparoscopy, 12 (13%) showed one-sided abnormaliti s
and 15 (16%) showed two-sided abnormalities. Endometriosis
was detected in 21 women (22%). The laparoscopic therapeutic
interventions applied in the intervention group are summarized
in Table II.
In 150 of 175 women in the control group, a laparoscopy
and dye was performed. Seven of these 150 women also had a
hysteroscopy performed during laparoscopy. At laparoscopy,
13 (9%) showed one-sided abnormalities and 16 (11%) showed
two-sided abnormalities. Endometriosis was detected in 43
women (29%). Different laparoscopic therapeutic interventions
could be applied when abnormal findings were seen (Table II).
Table II shows that there were no significant differences in
numbers of laparoscopic therapeutic interventions between
both groups.
Table III shows the numbers of assisted reproductive treat-
ments applied during the study in the intervention group and in
the control group. There were no significant differences in
numbers of applied assisted reproductive treatments between
both groups.
In the intervention group, 83 pregnancies occurred in follow-up
time of 2115 months, whereas in the control group 88 pregnan-
cies occurred in 2257 months of follow-up. Therefore, the annu-
alized pregnancy rate was 0.47 [95% confidence interval (CI)
0.37 to 0.57] in the intervention group and 0.47 (95% CI 0.37 to
0.57) in the control group. The CPR at 18 months was 49.1%
(95% CI 41.6 to 56.6) in the intervention group and 50.3%
(95% CI 42.8 to 57.8) in the control group, a difference of –1.2%
(95% CI –11.8 to 9.5). Pregnancy rates at given times through-
out the study were also not significantly different (Figure 2).
No difference in primary or secondary subfertility was found. Of
the 31 multiparous women in the intervention group, 15 were
pregnant at the end of follow-up, compared with 17 of
Table I. Baseline characteristics of women participating in the study
Values are expressed as number (percentage) unless otherwise specified.
Characteristics Intervention 
group (n = 169)
Control 
group (n = 175)
Age (years) (mean ± SD) 30 ± 4.0 30 ± 4.0
Duration of subfertility (years) 
(mean ± SD)
2.0 ± 1.1 2.0 ± 0.8
Nulliparous 138 (82) 145 (83)
History of
Pelvic inflammatory disease 5 (3) 5 (3)
Intrauterine device 4 (2) 5 (3)
Sexually transmitted disease 6 (4) 7 (4)
Tubal surgery 2 (1) 1 (1)
Ovulatory disorder 31 (18) 25 (14)
Table II. Therapeutic reproductive surgery applied in the intervention and 
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Values are expressed as number (percentage).
Surgery Intervention 
group (n = 94)
Control 
group (n = 150)
None 65 (69) 102 (68)
Coagulation of endometriosis grade I/II 23 (25) 41 (27)
Laparoscopic adhesiolysis 5 (5) 5 (4)
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Table III. Assisted reproductive treatment applied in the intervention and 
control groups
Values are expressed as number (percentage).
Treatment Intervention 
group (n = 169)
Control 
group (n = 175)
None 94 (56) 101 (58)
Intrauterine insemination 60 (35) 61 (35)
IVF 15 (9) 13 (7)
Figure 2. Cumulative pregnancy rates for the intervention group,
which included hysterosalpingography (HSG), and control group,
which excluded HSG.
































Hysterosalpingography prior to laparoscopy in fertility workup
3
Table I summarizes the baseline characteristics of the women
participati g in the study. When comparing the women in the
interv ntion and control groups, there w re no significant dif-
ferences between the groups reg rding age, duration of subfer-
tility, parity, his ory of pelvic inflammatory disease, intrauterine
device, sexually transmitted disease or tubal su gery.
A total of 152 women in the ntervention group underw nt
HSG, and in 58 women no additional laparoscopy was per-
formed. In 40 of these 58 women, this was du  to occurrence of
pr gnancy withi  6 months a ter HSG. Hence, the pregnancy
rat  within 6 mo ths after performing HSG was 26%. Of the
other 18 women, no laparoscopy was performed for unknown
reasons.
At HSG, 23 (15%) showed one-s ded abnormalities and 23
(15%) showed two-s ded abnormalities. In 10 of 152 women,
HSG show d intracavity abnormalities, a reason why hysteros-
copy was performed during laparoscopy.
Ninety-fou  laparoscopies were perform d in the i terven on
group. At laparoscopy, 12 (13%) showed one-sided abnormalities
and 15 (16%) sho ed two-sided abnorm lities. Endometriosis
was detected in 21 women (22%). The laparoscopic therapeutic
interventions applied in the intervention group are summarized
in Table II.
In 150 of 175 women in the control group, a laparoscopy
and dye was rf r . Seven of these 150 women lso had a
hysteroscopy performed during l paro copy. At laparoscopy,
13 (9%) showed one-sided abnormalitie  and 16 (11%) showed
two-sided abnormalities. Endometriosis was detected in 43
women (29%). Diff rent laparoscopic therapeutic i terventions
could be applied when abnormal find ngs were seen (Table II).
Table II shows that there were no significant differences in
numbers of laparoscopic therapeutic interventions between
both groups.
Table III shows the numbers of assisted reproductive treat-
ments app ied during the study in the interve tion group and in
the control group. There were no significant differences in
numbers of applied assisted reproductive treatments between
both groups.
In the intervention group, 83 pregnancies occurred in follow-up
t me of 2115 months, whereas in the control g oup 88 pregnan-
c es occurred in 2257 months of follow-up. Ther fore, the annu-
alized pregna cy rate was 0.47 [95% confidence interval (CI)
0.37 to 0.57] in he intervention group and 0.47 (95% CI 0.37 to
0. 7) in the control group. The CPR at 18 months was 49.1%
(95% CI 41.6 to 56.6) in the inte vention group and 50.3
(95  I 42.8 to 57 8  in the control group, a difference of –1.2%
(95% CI –11.8 to 9.5). Pregnancy rates at giv n times th ough-
out th  study were lso not significantly different (Figure 2).
No difference in primary or secondary subfertility was found. Of
the 31 mul iparous women in the intervention group, 15 were
pregnant at the end of follow-up, compared with 17 of
Table I. Baseline characteristics of women participating in the study
Values are expressed as number (percentage) unless otherwise specified.
Characteristics Intervention 
group (n = 169)
Control 
group (n = 175)
Age (years) (mean ± SD) 30 ± 4.0 30 ± 4.0
Duration of subfertility (years) 
(mean ± SD)
2.0 ± 1.1 2.0 ± 0.8
Nulliparous 138 (82) 145 (83)
History of
Pelvic inflammatory disease 5 (3) 5 (3)
Intrauterine device 4 (2) 5 (3)
Sexually transmitted disease 6 (4) 7 (4)
Tubal surgery 2 (1) 1 (1)
Ovulatory disorder 31 (18) 25 (14)
Table II. Therapeutic reproductive surgery applied in the intervention and 
control groups
Values are expressed as number (percentage).
Surgery Intervention 
group (n = 94)
Control 
group (n = 150)
None 65 (69) 102 (68)
Coagulation of endometriosis grade I/II 23 (25) 41 (27)
Laparoscopic adhesiolysis 5 (5) 5 (4)
Laparoscopic cystectomy 1 (1) 2 (1)
Table III. Assisted reproductive treatment applied in the intervention and 
control groups
Values are expressed as number (percentage).
Treatment Intervention 
group (n = 169)
Control 
group (n = 175)
None 94 (56) 101 (58)
Intrauterine insemination 60 (35) 61 (35)
IVF 15 (9) 13 (7)
Figure 2. Cumulative pregnancy rates for the intervention group,
which included hysterosalpingography (HSG), and control group,
which excluded HSG.

































Routine use of hysterosalpingography prior to laparoscopy in the fertility workup
were pregnant at the end of follow-up, compared with 17 of 30 multiparous women in 
the control group. Moreover, 69% of women in the intervention group who received 
assisted reproductive treatment were pregnant at the end of follow-up, compared 
with 63% in the control group. The 6% difference between study groups was not 
statistically significant (95% CI –8 to 21). 
Directly after randomisation, it appeared that 14 couples were inappropriately 
randomised. The reasons were as follows: abnormal semen analysis (n=9), maternal 
age (n=2) and immediate withdrawal of women from participation in the trial but 
they agreed to be followed up for pregnancy (n=3). In the remaining 330 women, 
the CPR at 18 months was 50% (95% CI 42 to 58) in 160 women in the intervention 
group and 51% (95% CI 43 to 59) in 170 women in the control group. This difference 
of –1% was not significant (95% CI –12 to 10). 
When excluding all women who did not receive the allocated intervention, 17 in the 
intervention group and 25 in the control group, the CPR at 18 months was 46% (95% 
CI 38 to 54) in the 152 women in the intervention group and 45% (95% CI 37 to 53) 
in the 150 women in the control group. 
Discussion 
Here, we report results from a randomised controlled trial assessing the usefulness 
of HSG as a conventional diagnostic investigation in the subfertility workup prior to 
laparoscopy, the gold standard for detecting tubal pathology. There was no difference 
in CPRs at 18 months between the intervention group (49.1%) and the control group 
(50.3%). We demonstrated that routine use of HSG prior to laparoscopy and dye in 
the fertility workup did not result in a significant effect on the incidence of pregnancy, 
compared with routine use of laparoscopy without HSG. 
The distribution of laparoscopic therapeutic interventions and additional assisted 
reproductive treatments was equal between the intervention and control groups (Tables 
II and III). Hence, it is unlikely that these laparoscopic therapeutic interventions 
and additional assisted reproductive treatments affected the difference between both 
groups. Where early laparoscopy is not routine, the trial results also show that a 
protocol that begins with HSG and proceeds to laparoscopy when indicated has a 
similar yield to that of early routine laparoscopy. 
A flaw of this study is the limited number of women who entered the trial. Our 
original power calculation envisaged 375 women in each group. We ended enrolment 
of women after 5 years because of difficulties in recruitment, thereby accepting a 
lower power for the study. By that time, 344 women were participating, each group 
containing about 200 less than the original power calculations required. Given the 
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absolute equality of a close to 50% pregnancy rate in both groups, a pregnancy rate 
of about 65% would have been required in the next 200 women in the intervention 
group to achieve overall significance at the 5% level. The chances of this happening 
were very small, given a success rate of about 50% in the first 169 women. As the 
binomial probability of such an occurrence is less than 1 in 100, it is extremely 
unlikely that continuing the study would have altered the conclusions that can be 
drawn from it. 
The additional value of HSG compared with laparoscopy in the fertility workup 
is particularly the assessment of the uterine cavity. Uterine cavity malformations 
with a frequency of about 10–15% in subfertile women can be visualized by 
HSG, although the effectiveness of surgical treatment at enhancing pregnancy 
rates is not established9. The endovaginal ultrasound has been demonstrated as a 
reliable alternative for detecting uterine cavity pathology13. It can also be used in 
the visualization of pelvic pathology such as endometriosis or ovarian pathology. 
Ultrasonography in comparison with HSG is less invasive and easily performed in a 
short period without roentgen radiation. HSG, though, remains the only trustworthy 
method for examining tubal mucosal fold configuration, especially when tubal 
microsurgery (e.g. salpingostomy) is considered14, albeit that HSG then can be 
better carried out after laparoscopy. The reason that HSG is performed early in the 
fertility workup is based more on tradition and personal preference, rather than on 
the demonstrated usefulness of its components1. In these circumstances, oil-soluble 
contrast medium can be used to improve pregnancy rates, although HSG with oil-
soluble contrast medium is associated with an increased risk of granuloma formation 
and embolism; mortality in connection with embolism has been reported15. 
Chlamydia antibody testing (CAT) may replace HSG as screening test that can be 
used for estimating the risk of tubal pathology prior to laparoscopy. Several studies 
have shown that CAT might be as accurate as HSG in diagnosing tubal pathology 
16-19. 
In conclusion, this study shows that routine use of HSG at an early stage in the fertility 
workup prior to laparoscopy and dye does not influence cumulative pregnancy rate. 
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Objectives: To evaluate pain and patient satisfaction of women undergoing 
hysterosalpingography (HSG) or laparoscopy and dye as routine diagnostic 
procedures in the fertility work-up.
Study design: One hundred and thirty-six subfertile women were randomized to 
HSG or laparoscopy. Pain was assessed before the procedure and again after the 
procedure at time of discharge by using a visual analogue scale (VAS) and the 
McGill Pain Questionnaire-Dutch Language Version (MPQ-DLV). One week after 
the procedure, physical complaints, analgesic usage, and overall judgment of the 
procedure was assessed by a postal questionnaire.
Results: Shortly after the procedure, women who underwent an HSG (n=73) reported 
the procedure to be significantly more painful compared to women who underwent 
laparoscopy (n=50). Women who underwent laparoscopy had significantly more 
complaints (shoulder pain, sore throat, and muscular pain), required more analgesics, 
and were unable to return to normal daily activities for a longer interval of time. 
Results of the overall judgment of the procedure favored laparoscopy over HSG. 
Conclusions: The HSG procedure is experienced as more painful while laparoscopy 
and dye is related with more post-procedure complaints. The overall judgment of 
women undergoing the procedures favors laparoscopy.
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Introduction
Hysterosalpingography (HSG) and laparoscopy and dye are two widely used 
diagnostic interventions in the fertility work-up. Due to the non-invasive, outpatient 
procedure and low cost, HSG is usually applied as first-line approach to assess 
tubal pathology1,2. However, according to the World Health Organization (WHO) 
criteria, laparoscopy and dye is generally considered the gold standard3. Almost 
80% of U.S. board-certified reproductive endocrinologists routinely perform HSG 
and laparoscopy4.
HSG has been criticized for its moderate sensitivity and specificity in the diagnosis 
of tubal factor subfertility compared to laparoscopy and dye5. Moreover, one of 
the drawbacks of the HSG procedure is the painful nature of the intervention6. 
We prospectively evaluated pain and patient satisfaction of women undergoing an 
HSG or laparoscopy and dye as diagnostic intervention in the fertility work-up. In 
a group of women who underwent either HSG or laparoscopy and dye we assessed 
pain after the intervention, and evaluated physical complaints, use of analgesics, 
and overall judgment of the procedure one week after the procedure. 
Material and methods
Subjects
All women in our study participated in a multicenter randomized controlled trial 
to assess the usefulness of HSG as routine investigation in the fertility work-up 
prior to laparoscopy and dye. Recruitment strategy, description of subjects, and 
main results of the study have been published elsewhere7. In short, the trial was 
performed in three teaching hospitals in the Netherlands. All newly referred and 
admitted subfertile women who visited one of the three hospitals between April 
1997 and April 2002 were eligible for inclusion. Exclusion criteria were subfertility 
less than 1 year, age of woman older than 37 years, anovulation in spite of clomifene 
citrate or bromocriptin use, abnormal semen analysis according to WHO criteria8, or 
testing of tubal patency performed in the past. A total number of 344 women were 
randomized, 169 to the HSG group and 175 to the laparoscopy group. The HSG 
group received an HSG, which was followed by a laparoscopy and dye after six 
months unless pregnancy occurred. The laparoscopy group received a laparoscopy 
and dye immediately. For the present analysis we used data of the first intervention, 
which was either the HSG or the laparoscopy. Laparoscopies performed after the 
HSG were not included in the analysis. All subjects gave informed consent. The 
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Institutional Review Boards of each of the three hospitals approved all stages of 
the study. 
HSG and laparoscopy and dye
Women were asked to participate in the trial by their treating gynaecologist at the 
time that HSG would normally be planned and counseled them about performing 
an HSG or laparoscopy. A detailed standardized patient information sheet on both 
procedures was given to all women when the procedure was planned. All women 
who underwent HSG received a prescription for three tablets of naproxennatrium 
275 mg and were instructed to take two tablets 30-60 minutes before HSG and 
one tablet directly after HSG. A senior resident in gynaecology or a consultant 
specialized in reproductive medicine performed HSG at the department of Radiology. 
A suction Semm cup (A, B or C) was placed over the cervix and suction was applied 
via a vacuum pump. In less than 5% of all HSGs adequate suction could not be 
maintained. In that case a tenaculum was applied by grasping the anterior lip of 
the cervix and a Foley balloon catheter or metallic Whitehead cannula was applied 
to align the cervical canal. A water-soluble contrast medium (Omnipaque 300; 
Nycomed Ltd, Birmingham, UK) was used. Dye was injected slowly to potentially 
minimize discomfort. The amount of contrast used was at most 10 ml and depended 
on the time necessary to assess tubal status. 
Laparoscopy and dye was performed by a senior resident in gynaecology 
supervised by a consultant specialized in reproductive medicine. All women had 
general anaesthesia, the majority was induced and maintained with propofol and 
remifentanyl. No preoperative analgesics or sedatives were given. After induction 
of general anaesthesia, a double puncture (peri-umbilical and suprapubic) technique 
was used with a 10-mm 0 degree non-disposable laparoscope and one 5 mm trocar. A 
balloon-tipped catheter was placed inside the cervical canal for testing tubal patency 
with methylene blue dye. A pneumoperitoneum was created by insufflating carbon 
dioxide. After completion of the procedure, carbon dioxide was allowed to fully 
escape. Pelvic findings were recorded on a standardized datasheet. All women were 
given standardized treatment for postoperative pain (paracetamol and nonsteroidial 
anti-inflammatory drugs). Anti-emetic drugs were not given routinely.
Pain scores and questionnaire
Subjects rated their overall pain by using a visual analogue scale (VAS) and the 
McGill Pain Questionnaire, Dutch language version (MPQ-DLV). The VAS was 
drawn as a 10-cm line, anchored by word descriptions at zero cm “no pain” and at 
10 cm “worst pain imaginable”. It had 1 cm major tick marks, and 1 mm minor tick 
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marks. At each major tick mark the corresponding number was printed. 
The McGill Pain Questionnaire (MPQ)9 is a standardized questionnaire and has been 
translated into Dutch (McGill Pain Questionnaire, Dutch language version (MPQ-
DLV))10. This translated questionnaire is considered to be highly reliable10. The 
lists of pain descriptors were given to the patients who were asked to choose one 
word in each subscale (sensory, items 1 through 12; affective, items 13 through 17; 
evaluative, item 18 through 20) that best described their pain. The frequency with 
which each descriptor was chosen by the patients and the total number of words 
chosen (NWC) were assessed. Subscale pain rating index (PRI) was calculated by 
summing item scores within a subscale. A total PRI was also calculated by summing 
all subscale scores. 
The patients were asked to fill in the VAS and the MPQ-DLV before the procedure 
and again after the procedure at time of discharge. The first pain score (“pre-
procedure score”) was measured before the procedure to obtain a baseline value. This 
pain score consisted of the mean and maximal abdominal pain experienced during 
the first day of the last menstrual period. The second pain score (“post-procedure 
score”) was assessed after the procedure at time of discharge. On this occasion, 
both pain experienced during the procedure and pain at the time of assessment were 
measured. The patient was asked to rate the mean and maximum abdominal pain 
during the procedure itself and their pain at the moment of completion the pain 
scores. All subjects themselves recorded the pain scores on the VAS and the MPQ-
DLV.
One week after the procedure a questionnaire was sent by post addressing issues 
like assessment of physical complaints during the last week (10 items), analgesic 
usage, and overall judgment of the procedure (3 statements). The three statements 
assessing the overall judgment of women who experienced either HSG or laparoscopy 
were as follows: procedure turned out badly, no repeat of procedure under same 
circumstances if required, and advice against procedure to a well known friend. All 
complaints were rated on a five-point scale of none, mild, moderate, severe, or very 
severe. 
Statistical methods
Descriptive statistics were used to assess similarity of intervention groups. 
Categorical data were assessed by Chi-square tests and continuous variables by 
Student’s t-test. Responses to the pain scores and questionnaire were assessed with 
paired t-tests. We dichotomized the rating of complaints by combining none and 
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mild outcomes into one category and moderate, severe, and very severe in an other 
category. P-values <0.05 were considered significant.
Results
We assessed pain and patient satisfaction in a convenience sample of 123 women. 
There were no differences between the women who were included and women who 
were not included in the present analysis, except for parity (89% of included women 
were nulliparous vs 79% of women who were not included, p=0.03) and subfertility 
(80% of included women had primary subfertility vs 68% of women who were not 
included, p=0.02). No significant differences in baseline characteristics were found 
between the 73 women in the HSG group and the 50 women in the laparoscopy 
group (table 1).
The pre- and post procedure VAS pain scores and current pain intensity for the HSG 
and laparoscopy group are shown in table 2. As expected, there were no differences 
in the mean and maximal pre-procedure pain scores between both study groups. 
After the intervention, women who underwent an HSG reported the procedure to be 
more painful compared to women who underwent a laparoscopy and dye (mean VAS 
pain score, 46.7 vs 35.7 mm; p=0.004 and maximal VAS pain score, 66.4 vs 51.0 
mm; p<0.001). However, the pain experienced at the time of the assessment (current 
pain intensity) was significantly lower in the HSG group than in the laparoscopy 
group (23.4 vs. 31.3 mm; p=0.016). 
Table 3 shows the increase in the score of the sensory, affective, and evaluative 
dimensions of the number of words chosen and the pain-rating index of the MPQ-
DLV for the HSG and laparoscopy group. All scores on the pain dimensions in the 
HSG group were positive, indicating a worsening of pain experience. All scores 
on the pain dimensions in the laparoscopy group were negative. Five of the eight 
comparisons between the two groups yielded a p-value <0.1, of which one was 
<0.05.
Table 1. Baseline characteristics of the 123 women who were included in the study.
Characteristics HSG (n = 73) Laparoscopy (n = 50)
Age (years), mean ± SD 29.8 ± 4.0 30.2 ± 3.4
Duration of subfertility (years), mean ± SD 2.0 ± 1.4 2.0 ± 0.9
Nulliparous 61 (84) 45 (90)
Primary subfertility 56 (77) 41 (82)
Values are expressed as number (percentage) unless otherwise specified.
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Table 2. VAS pain scores pre- and post procedure for HSG and laparoscopy group.
Pain score HSG (n = 73) Laparoscopy (n = 50) P-value
Mean pain (SE)
Pre-procedure 30.7 (2.3) 32.0 (2.7) 0.72
Post-procedure 46.7 (2.8) 35.7 (2.2) 0.004
Increase 16.0 (3.2) 3.7 (2.8) 0.006
Maximal pain (SE)
Pre-procedure 41.5 (3.0) 45.8 (3.1) 0.33
Post-procedure 66.4 (2.8) 51.0 (2.9) <0.001
Increase 24.9 (3.4) 5.2 (3.6) <0.001
Current pain intensity (SE) 23.4 (2.3) 31.3 (2.2) 0.016
SE = Std. Error 
Values are expressed as number (percentage) unless otherwise specified.
Pre-procedure is the measurement, before the procedure, of abdominal pain experienced during the first day 
of the last menstrual period; Post-procedure means, after the procedure, measurement of overall pain related 
to the procedure.
Table 3.  Difference in pre- and post procedure painscores for HSG and laparoscopy groups 
measured by MPQ-DLV.
HSG (n = 73) Laparoscopy (n = 50) P-value
NWC (SE)
NWC-s 0.35 (0.31) -0.15 (0.38) 0.31
NWC-a 0.04 (0.15) -0.54 (0.20) 0.02*
NWC-e 0.08 (0.11) -0.15 (0.12) 0.16
NWC-t 0.47 (0.48) -0.84 (0.61) 0.09
PRI (SE)
PRI-s 0.58 (0.55) -1.00 (0.65) 0.07
PRI-a 0.15 (0.23) -0.59 (0.33) 0.06
PRI-e 0.25 (0.30) -0.25 (0.32) 0.26
PRI-t 0.99 (0.92) -1.80 (1.20) 0.06
MPQ-DLV= McGill Pain Questionnaire – Dutch Language Version
NWC-s. –a, -e, -t = Numbers of words chosen-sensory, -affective, -evaluative, and total scale
PRI -s. –a, -e, -t = Pain rating index-sensory, -affective, -evaluative, and total scale
SE = standard error
* = Significant difference between two groups
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Table 4 shows the physical complaints experienced during the first week after the 
performance of HSG or laparoscopy. Almost 50% of women in both groups had 
abdominal pain after the intervention. The most frequently reported complaints 
in the HSG group were abdominal pain (49%) and tiredness (37%), and in the 
laparoscopy group shoulder pain (68%), abdominal pain (46%), and tiredness (46%). 
Significantly more complaints were mentioned after laparoscopy and dye than HSG 
for shoulder pain (p<0.01), sore throat (p<0.01), and muscular pain (p<0.01). Women 
in the laparoscopy group needed more analgesics (p<0.001) and were unable to 
return to normal daily activities for a longer interval of time (p<0.001). All three 
statements regarding patient satisfaction were statistically significant in favor of the 
laparoscopy. 
Table 4. One week evaluation of HSG and laparoscopy.
HSG (n = 73) Laparoscopy (n = 50) P-value
Complaints
Abdominal pain 36 (49) 23 (46) 0.72
Vaginal blood loss 13 (18) 14 (28) 0.18
Shoulder pain 7 (10) 34 (68) <0.001
Nausea 5 (7) 6 (21) 0.33
Vomiting 2 (3) 2 (4) 0.70
Dizziness 5(7) 9 (18) 0.06
Headache 13 (18) 7 (14) 0.57
Sore throat 7 (10) 21 (42) <0.001
Muscular pain 8 (11) 19 (38) <0.001
Tiredness 27 (37) 23 (46) 0.32
Use of pain medication 15 (21) 24 (48) <0.001
Mean no. of days unable to perform 
daily activities ( ± SE) 1.3 (0.3) 3.5 (0.2) <0.001
Patient satisfaction
Procedure turned out badly 26 (36) 7 (14) <0.01
No repeat of procedure under same 
circumstances if required 17 (23) 3 (6) 0.01
Advise against procedure
to a well known friend 14 (19) 3 (6) 0.04
SE = standard error 
Values are expressed as number (percentage) unless otherwise specified
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Comment
We evaluated pain and patient satisfaction of women undergoing an HSG or 
laparoscopy and dye as routine diagnostic investigation in the fertility work-up. After 
the procedure, HSG was experienced as a more painful procedure than laparoscopy. 
One week after the procedure women who underwent laparoscopy had significantly 
more complaints (shoulder pain, sore throat, and muscular pain), required more 
analgesics, and were unable to return to normal daily activities for a longer interval 
of time. Patient satisfaction indicated that women favored laparoscopy over HSG. 
We assessed, under usual circumstances, the experience of HSG or laparoscopy and 
dye in an effectiveness trial. In an effectiveness trial the intervention is assessed 
under usual circumstances. This is in contrast with an efficacy trial in which the 
intervention is examined under ideal conditions11. Pragmatism was also the reason 
that the post procedure pain score was assessed after a shorter time in the HSG 
group relative to the laparoscopy group. The time of pain assessment was usually 
30 min after the HSG procedure, whereas women in the laparoscopy group filled in 
their pain scores at time of discharge usually 4-5 hours after the procedure when the 
effect of most narcotics has worn off. 
The overall mean and maximal visual analogue scale (VAS) pain scores were 
significantly higher in the HSG group, whereas pain experienced at the moment of 
VAS completion was significantly higher in the laparoscopy group. This observation 
can be explained by the peak tissue reaction caused by the abrupt injection of the 
contrast medium during HSG that dies out shortly thereafter12.
Reasons of pain experienced during HSG are related with the phase of the procedure: 
cervical instrumentation, uterine distension with contrast media, and peritoneal 
irritation a result of contrast spill into the peritoneal cavity13. The cervical cup 
cannula appears to be superior in decreasing discomfort compared to the traditional 
metal cannula14. Second choice was the use of the Foley balloon catheter or the 
metal cannula. We performed all HSGs with water-soluble contrast medium, which 
is common practice15. Two randomized studies have demonstrated no difference in 
pain experience between oil- and water-soluble contrast media16,17. The presence 
of tubal blockage on HSG, which may cause severe pain, was also documented. 
This had no significant effect on pain scores, which is in agreement with other 
studies12,16,18.
HSG and laparoscopy are experienced as highly stressful procedures and cause 
physical complaints in more than half of women6,19. Age, duration, and type of 
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subfertility appear to have no significant effect on physical complaints. Adequate 
counselling may reduce fear and may increase pain tolerance20 e.g. by focusing 
on realistical positive expectations21. Although effective analgesia during HSG is 
important, two prospective studies showed no difference in pain experience with or 
without intrauterine topical local anesthetic at HSG12,22.
Shoulder pain (65%) was the most mentioned complaint one week after laparoscopy. 
This finding, which is in line with other studies21, is thought to be due to residual gas 
irritating the peritoneum under the diaphragm, where it can remain for up to 3 days. 
Women in the laparoscopy group needed also significantly more analgesics than 
women in the HSG group and were more days unable to perform daily activities 
than women in the HSG group, that might also related to pneumoperitoneum. If 
post-operative nausea is to be avoided in ambulatory gynecological patients, it may 
be necessary to decrease or eliminate the use of narcotics in anesthetic induction. 
Epidural anesthesia may be an alternative to general anesthesia in gynecologic 
laparoscopy to reduce abdominal pain and better postoperative recovery, although 
the pain during manipulation might hinder the procedure24.
The one-week evaluation indicated that women who underwent HSG had less 
physical complaints than women who underwent laparoscopy and dye. Eimers et 
al.6 came to opposite conclusions. That study was about physical complaints and 
emotional stress related to routine diagnostic procedures in the fertility work-up and 
was not randomized and described a heterogeneous group.
Compared with laparoscopy, HSG is less invasive with no risk to anesthetic and 
surgical complications. The additional value of HSG is the assessment of the uterine 
cavity but the effectiveness of surgical treatment to enhance pregnancy rates has 
not been established25. If tubal pathology has been detected and microsurgery is 
considered, HSG is the only method to evaluate mucosal fold configuration. One of 
the main disadvantages of HSG is that it has moderate diagnostic accuracy for tubal 
patency compared to laparoscopy5. 
Laparoscopy and dye is the reference standard for assessing tubal status and enables 
direct inspection of the pelvis including endometriosis and pelvic adhesions. 
Additionally, laparoscopic treatments such as diathermy of endometriosis or 
adhesiolysis may be applied at the same time. The risk of having peritubal 
abnormalities or endometriosis in subfertile women who are asymptomatic, have 
normal physical examination and bilateral tubal patency at HSG is low. On these 
issues laparoscopy could be delayed or abandoned because in a minority of women 
severe tubal pathology will be revealed25-27.
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In conclusion, HSG is experienced as more painful than laparoscopy and dye, 
however laparoscopy is related with more post-procedure complaints. The overall 
judgment of women who experienced either HSG or laparoscopy is in favor of 
laparoscopy and dye. 
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We assessed two diagnostic methods, Chlamydia trachomatis–specific IgG and 
hysterosalpingography (HSG), as a screening test for the likelihood of tubal damage 
or occurrence of pregnancy before laparoscopy in 178 subfertile women who were 
randomly assigned to HSG followed by laparoscopy or immediate laparoscopy. 
The diagnostic accuracy and prognostic value of both C. trachomatis–specific IgG 
antibody testing and HSG are comparable but show poor performance. 
Introduction
Tubal pathology accounts for approximately 14% of the causes of subfertility1. 
Therefore, assessment of the tubal status has become a routine part of the fertility 
work-up. Several diagnostic tests can be used to assess tubal status, of which 
Chlamydia antibody testing (CAT) and hysterosalpingography (HSG) comprise the 
first-line approach. These tests are usually followed by the gold standard laparoscopy 
and dye2. The CAT and HSG tests provide risk estimates of tubal pathology before 
laparoscopy, but the diagnosis of tubal pathology can only be made with laparoscopy 
and dye. The diagnostic accuracy of CAT and HSG compared with laparoscopy 
and dye is well established3–7. Most studies have shown that CAT performs just as 
well or better than HSG. However, the prognostic value of both tests in predicting 
occurrence of pregnancy is not well known. Idahl et al.8 showed that there were no 
differences in achieving pregnancy between C. trachomatis IgG negative or positive 
women. Moreover, as shown by several studies, the prognostic value of HSG also 
is low9–13. 
Material and methods
The aim of the present study was twofold. First, we assessed the diagnostic accuracy 
of C. trachomatis–specific IgG (CtsIgG) and HSG compared with laparoscopy and 
dye in a large group of subfertile women. Second, we used both tests as prognostic 
indicator to assess occurrence of pregnancy. 
All women in this study participated in a multicenter, randomized controlled trial 
with or without the performance of HSG to assess the usefulness of HSG as routine 
investigation in the fertility work-up before laparoscopy and dye. Recruitment 
strategy, description of subjects, and the main results of this study have been 
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published elsewhere14. The present part of the trial took place only at the Division 
of Reproductive Medicine, Department of Gynecology, Leiden University Medical 
Center. The institutional review board of the hospital approved all stages of the 
study. 
As part of the fertility work-up, blood was drawn at the patient’s first visit. All spare 
serum was cryopreserved. For the present study, the spare serum of the participating 
women was thawed to perform a species-specific peptidebased serologic assay for the 
presence of IgG antibodies to C. trachomatis (SeroCT; Savyon Diagnostics, Ashdod, 
Israel). The results of CtsIgG antibody testing were compared with the findings of 
HSG in the diagnosis of tubal pathology using laparoscopy and dye as the reference 
standard. The results of both tests were also compared with occurrence of pregnancy 
within 18 months after randomisation as the clinical end point in terms of cumulative 
pregnancy rate. The diagnosis of clinical ongoing pregnancy was based on positive 
urine or serum pregnancy test in association with an intact intrauterine gestation sac 
on ultrasound scans. 
The HSG was performed with a water-soluble contrast medium (Omnipaque 300, 
Nycomed Ltd, Birmingham, UK). An HSG was considered abnormal if there was 
occlusion of one or both tubes or peritubal adhesions without tubal occlusion. 
Laparoscopy and tubal testing was performed with methylene blue dye. Laparoscopic 
findings of tubal factor subfertility were defined as extensive periadnexal adhesions 
and/or distal occlusion of one or both tubes15. Endometriosis was not included. 
The SeroCT IgG assay and calculation were performed according to the 
manufacturer’s instructions. The qualitative outcome of the assay (cut-off index) 
was categorized as negative (< 1.0) or positive (> 1.10). Values in the equivocal zone 
(optical densities between the values for negativity and positivity) were considered 
as negative results in the calculations when a second sample was also borderline or 
negative. 
The diagnostic accuracy of CtsIgG and HSG compared with laparoscopy were 
assessed by calculating sensitivity, specificity, and likelihood ratios. The prognostic 
value of CtsIgG and HSG in predicting occurrence of pregnancies was assessed with 
Kaplan-Meier survival analysis and Cox proportional hazard models. P values of 




A total of 178 subfertile women participated in the present study. Sixty-five women 
underwent both HSG and laparoscopy, 25 women only HSG, and 88 women only 
laparoscopy. Therefore, the CtsIgG results could be compared with laparoscopy in 
153 women, whereas the HSG results could be compared with laparoscopy in 65 
Figure 1.  Cumulative pregnancy rates between CtslgG result and HSG findings.
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women. Out of all 153 women, 9 (6%) showed unilateral occlusion, 14 (9%) showed 
bilateral occlusion, and 8 (5%) showed peritubal adhesions without tubal occlusion 
at laparoscopy. 
In 35 out of 153 women studied (23%), CtsIgG was positive; 14 of these seropositive 
women (40%) had tubal pathology according to laparoscopy. Out of the 118 CtsIgG-
negative women, 17 had tubal pathology (14%). The sensitivity, specificity, positive 
likelihood ratio, and negative likelihood ratio for CtsIgG in predicting tubal pathology 
were 45%, 83%, 2.6, and 0.7, respectively. 
In 65 out of 153 women, an HSG and laparoscopy were performed. A total of 41 
women had a normal HSG, and 24 had an abnormal HSG. Fifteen women (23%) 
showed unilateral occlusion, eight (12%) showed bilateral occlusion, and one 
(2%) showed peritubal adhesions without tubal occlusion. In 11 out of 24 women 
with abnormal HSG (46%), tubal pathology was found at laparoscopy. Out of the 
41 women with normal HSG, 5 had tubal pathology at laparoscopy (12%). The 
sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio for 
HSG were 69%, 73%, 2.6, and 0.4, respectively. 
For women who achieved pregnancy during the trial period, whether spontaneous or 
treatment related, there were no statistically significant differences found in cumulative 
pregnancy rate between CtsIgG-negative and CtsIgG-positive results (hazard ratio 
0.73, 95% confidence interval [CI] 0.42–1.25; P .25) (Fig. 1A). Pregnancy rates at 
given times throughout the study were also not significantly different. There was also 
no significant difference in cumulative pregnancy rate between normal and abnormal 
findings at HSG (hazard ratio 1.33, 95% CI 0.73–2.41; P .35) (Fig. 1B). 
Discussion
The main strength of the present study is the prospective design. All women included 
had a diagnostic laparoscopy for evaluation of tubal status. An allocation concealment 
was applied with 0% loss to follow-up. The shortcoming of the study is that the 
diagnostic or prognostic value of CAT and HSG can be determined separately, but 
the total sample   size is too small for the combination of diagnostic and prognostic 
value. 
We showed that C. trachomatis IgG antibodies have comparable diagnostic 
accuracy with HSG in detecting tubal pathology. These findings have been shown 
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by other studies that also compared CAT with HSG and used laparoscopy as 
reference standard3–7. Those authors’ measured C. trachomatis IgG antibodies by 
microimmunofluorescence (MIF) assay, but we used a species-specific (peptide-
based) immunoassay (EIA) as predictor of tubal pathology. These new EIA tests are 
well standardized, less laborious, less expensive, and easier to perform than the MIF 
test16. The disadvantage of using CAT is that there is yet no uniformity in assays 
and   cut-off levels. In addition, Chlamydia antibody testing cannot predict tubal 
factor subfertility due to other causes (previous surgery or endometriosis), and the 
laboratory procedure has its limitations (e.g., cross-reactivity with other Chlamydia 
species such as C. pneumoniae). The greatest advantage of Chlamydia antibody 
testing is its simplicity, limited inconvenience, and no complications. 
We demonstrated that Chlamydia antibody testing and HSG have comparable 
limited value in predicting pregnancy rates. No significant differences were found 
in cumulative pregnancy rate between CtsIgG-negative and CtsIgG-positive results. 
Idahl et al.8 also showed that there were no differences between C. trachomatis 
IgG– negative or –positive women concerning pregnancy rates. There was also no 
difference in cumulative pregnancy rates between normal and abnormal findings at 
HSG. This low prognostic value of HSG was also found in other studies9–12. Only 
one recent prospective study showed results on the diagnostic and prognostic role 
of Chlamydia serology compared with HSG and laparoscopy and supported our 
findings13. That study did not record the definition of tubal pathology found at HSG 
or laparoscopy. 
In conclusion, we assessed two diagnostic methods, CtsIgG and HSG, as a screening 
test for the likelihood of tubal damage or occurrence of pregnancy in subfertile women 
before laparoscopy. The diagnostic accuracy of C. trachomatis– specific IgG antibody 
testing is comparable with HSG, but both show poor performance. The prognostic 
value of occurrence of pregnancy of both tests is also poor. Chlamydia antibody 
testing as screening test to estimate the risk of tubal pathology before laparoscopy is 
preferable to HSG owing to its simplicity and limited inconvenience.  
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Background: The usefulness of hysterosalpingography (HSG) as routine 
investigation in the fertility work-up prior to laparoscopy and dye had been assessed 
in a randomized controlled trial. Recruiting subjects to the study was more difficult 
than anticipated. The objective of this study was to explore possible reasons for non-
participation in the trial. 
Methods: All newly referred subfertile women admitted to the Reproductive 
Medicine Clinic of Leiden University Medical Center between 1 April 1997 and 31 
December 1999, were eligible for the study. The reasons for non-participation were 
evaluated by scrutinizing the medical records. 
Results: Out of 759 women, a total of 127 (17%) agreed to participate in the trial. 
The most important reason for non-participation was because of exclusion criteria 
(73%). Other reasons were inattentive clinicians (3%) and patient-associated reasons 
(24%). Patient refusal and indecisiveness to enroll in the study were the most common 
patient-associated reasons. The most frequently stated reason for trial refusal was 
reluctance to undergo laparoscopy and dye mainly due to issues related to anesthesia 
and scheduling of procedure. 
Conclusion: Almost three-quarters of recruitment difficulties in this study were 
due to unavoidable reasons. To overcome the remaining avoidable reasons for non-
participation, attention should be paid to appropriate instruction of the study protocol 
to the participating doctors and to provide adequate information, in layman’s terms, 
to the patients. Reminding patients by notes or telephone calls for attending the 
clinic are helpful. It may be contingent upon tracing the reasons of clinicians and 
patients for non-participation to improve enrollment during a trial. 
63
Difficulties in recruitment for a randomized controlled trial involving hysterosalpingography 
Background 
Between April 1997 and April 2002 we performed a pragmatic1 multicenter 
randomized controlled trial comparing two different diagnostic strategies in the 
routine fertility work-up2. The hysterosalpingography (HSG) group underwent HSG 
first. If HSG showed normal uterine cavity, patent tubes and no tubal pathology, 
laparoscopy and dye followed after six months. In case of suspected tubal pathology, 
laparoscopy was performed within one or two months after HSG. The laparoscopy 
group did not receive HSG but underwent laparoscopy and dye directly after 
randomisation. 
The power of the trial was based on randomisation of 750 subfertile women. 
Recruitment of patients into the trial was more difficult than expected. We estimated 
the highest recruitment rate from Leiden University Medical Center (LUMC). 
However, about halfway through the trial, we had only recruited 177 women instead 
of an estimated 375. To understand this low recruitment rate, we initiated the current 
study to find strategies to avoid the major reasons for non-participation which could 
be implemented during the second half of the study or later in other studies in 
reproductive medicine. This study identified potential eligible participants visiting 
one of the three participating hospitals (Leiden University Medical Center) during 
the first half of the recruitment period. 
Methods 
All women in our study participated in a multicenter randomized controlled trial with 
or without the performance of HSG to assess the usefulness of hysterosalpingography 
as routine investigation in the fertility work-up prior to laparoscopy and dye. 
Recruitment strategy, description of subjects, and main results of the trial have been 
published elsewhere2. In short, the trial was performed in one university hospital 
(Leiden University Medical Center, Leiden) and two non-university teaching 
hospitals (Medical Center Haaglanden, The Hague and Groene Hart Hospital, 
Gouda). All newly referred subfertile women who visited one of the three hospitals 
between April 1997 and April 2002 were eligible for inclusion in the trial. Exclusion 
criteria were a) subfertility less than 1 year, b) woman older than 37 years at time 
of first visit, c) anovulation in spite of clomifene citrate or bromocriptin use, d) 
abnormal semen analysis according to WHO criteria3, or e) testing of tubal patency 
performed in the past. Women were asked to participate in the trial by their treating 
gynecologist at the time that HSG would normally be planned and informed consent 
was obtained. If the women refused to participate in the trial, the reason for non-
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participation was recorded. A computer-based 1:1 ratio randomisation procedure 
was used to allocate the women into two groups; the HSG group or the laparoscopy 
group. Informed consent was obtained from all women. The Institutional Review 
Boards of each of the three hospitals approved all stages of the trial. 
Recruitment of subjects into the trial was lower than expected. We elucidated this 
current study to explore the determinants of non-participation during the first half of 
the recruitment period among all potentially suitable subjects of Leiden University 
Medical Center to find strategies to avoid the major reasons for non-participation. We 
reviewed the medical records from all newly referred subfertile women who visited 
the Reproductive Medicine Clinic of Leiden University Medical Center from 1 April 
1997 to 31 December 1999. The medical record of each subfertile couple contained 
either a sticker indicating that the woman participated in the study or documented 
the reasons for non-participation. 
Results 
From 1 April 1997 to 31 December 1999, 759 newly referred subfertile women 
visited the Reproductive Medicine clinic of Leiden University Medical Center. A 
total of 127 women (17%) met the inclusion criteria and agreed to participate in 
the trial, the remaining 632 did not. The unavoidable reasons (467 women; 73%) 
and avoidable reasons (165 women; 27%) for non-participation are summarized in 
table 1. Almost three-quarters of the women did not participate due to exclusion 
criteria (73%), 3% due to inattentive doctors and the remaining 153 women (24%) 
due to patient-associated reasons. From these 153 women, 72 of them refused and 
19 women were indecisive to enroll in the study. Fifty women never showed up for 
randomisation after the initial visit. Personal circumstances such as leaving the area 
and relationship problems were also reported (n = 7). 
Table 2 shows reasons for trial refusal among the 72 women. The most frequent 
stated reason was reluctance to laparoscopy and dye (35 women; 49%). Twenty-
seven women (37%) did not state a reason for non-participation. 
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Table 1. Unavoidable and avoidable reasons for non-participation
Unavoidable reasons N = 467 %
Exclusion criteria 460 73
Androgenic factor 173
Tubal testing performed in the past 114
Pregnant before randomisation 91
Women older than 37 years at first visit 55
Anovulation 27
Patient’s reason 7 1
Personal circumstances 7
Avoidable reasons N = 165 %
Doctor’s reason 19 3
Eligible, but not approached 19
Patient’s reason 146 23
Refused to participate 721




Table 2: Patient’s reasons for trial refusal
Reasons N = 72 %
Reluctance to laparoscopy and dye: 35 49
General anesthesia 20
The timing of the laparoscopy is too soon 15
Reluctance to hysterosalpingography: 3 4
Fear for pain 3
Don’t want to be involved in a research 
project 7 10




In retrospect, it seems clear that we had too optimistic recruitment targets. Main 
unavoidable reasons for nonparticipation in the trial were not meeting the inclusion 
criteria and personal circumstances. In 19 of 165 avoidable reasons for non-
participation, it appeared that doctors were inattentive to approach their eligible 
patients for the trial. More details of their negligence were not documented, except 
that in general these doctors appeared to be willingly participating in the trial. 
Attention should be paid to appropriately instruct participating doctors in order to 
increase the recruitment of eligible patients. We have no evidence that physicians’ 
preferences influenced the outcome of the randomized trial4. However, discussing 
the clinical relevance of the question as well as practical issues in the period that 
the protocol of the trial was designed appeared to be essential in the prevention of 
barriers in clinical recruitment5. 
Apprehensiveness towards one of the diagnostic procedures in this trial (laparoscopy) 
was mentioned by the women as the most prominent and avoidable reason for non-
participation in the trial. General anesthesia prior to laparoscopy appeared to be a 
main obstacle for enrolment in the trial. Providing more adequate information on the 
actual procedure and using layman’s terms may improve the rate of participation in 
such a trial. Although well educated and employed persons were more likely to refuse 
randomisation because of preference4, we think that providing more information 
focused on problems that may emerge from questionnaires disseminated among 
potential participants in the development of the trial, may optimize recruitment. 
Some patients did not wish to be involved in a research project. Once patients have 
made up their mind and once they have prepared a distinct preference, it is nearly 
impossible to persuade them for enrolment6. 
One shortcoming of our paper is that we studied the major reasons of non-participation 
of potentially eligible participants visiting only one hospital. Unavoidable reasons of 
non-recruitment accounted for three quarters of the non-participation. The exclusion 
factor might be higher in an academic center due to specific criteria for referrals. The 
referred subfertile couples could have been older, with severe androgenic pathology 
or proven tubal pathology needing specialized assisted reproductive treatments. 
Another objective of this study was to find strategies to avoid the major reasons for 
non-participation which could be implemented during the second half of the study or 
later in other studies focusing on reproductive medicine. We assume that the major 
avoidable reasons of non-participation (like trial refusal) would be equally divided 
among all participating hospitals. 
Planning for recruitment should be an important issue in the preparation period when 
a trial is designed7,8. Attention can also be paid to logistic problems that patients 
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may encounter. To minimize the no-show, reminder notes and telephone calls may 
remind patients to attend the clinic. A member of the research team, who can provide 
the information on a low profile with a high level of communication skills and 
understanding, can support the investigators. This person can deal with practical 
problems, such as patient’s concerns or language barriers. This may contribute to 
solving the problem of women being less likely to participate in clinical trials9. 
Conclusion 
In conclusion, this study showed that almost three-quarters of our recruitment failures 
were due to unavoidable reasons. To overcome the remaining avoidable reasons for 
non-participation and to increase external validity of a trial, it may be contingent 
upon tracing reasons of clinicians and patients for non-participation as well as by 
anticipating practical problems that clinicians and patients may encounter during 
a trial. In the set up of the trial and during the recruitment, communication and 
information are the key words. 
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Objective: To compare the perinatal outcome of singleton and twin pregnancies 
between natural and assisted conceptions. 
Design: Systematic review of controlled studies published 1985-2002. 
Studies reviewed: 25 studies were included of which 17 had matched and 8 had non-
matched controls. 
Main outcome measures: Very preterm birth, preterm birth, very low birth weight, 
low birth weight, small for gestational age, caesarean section, admission to neonatal 
intensive care unit, and perinatal mortality. 
Results: For singletons, studies with matched controls indicated a relative risk of 
3.27 (95% confidence interval 2.03 to 5.28) for very preterm ( < 32 weeks) and 
2.04 (1.80 to 2.32) for preterm ( < 37 weeks) birth in pregnancies after assisted 
conception. Relative risks were 3.00 (2.07 to 4.36) for very low birth weight ( < 1500 
g), 1.70 (1.50 to 1.92) for low birth weight ( < 2500 g), 1.40 (1.15 to 1.71) for small 
for gestational age, 1.54 (1.44 to 1.66) for caesarean section, 1.27 (1.16 to 1.40) 
for admission to a neonatal intensive care unit, and 1.68 (1.11 to 2.55) for perinatal 
mortality. Results of the non-matched studies were similar. In matched studies of 
twin gestations, relative risks were 0.95 (0.78 to 1.15) for very preterm birth, 1.07 
(1.02 to 1.13) for preterm birth, 0.89 (0.74 to 1.07) for very low birth weight, 1.03 
(0.99 to 1.08) for low birth weight, 1.27 (0.97 to 1.65) for small for gestational 
age, 1.21 (1.11 to 1.32) for caesarean section, 1.05 (1.01 to 1.09) for admission to a 
neonatal intensive care unit, and 0.58 (0.44 to 0.77) for perinatal mortality. The non-
matched studies mostly showed similar trends. 
Conclusions: Singleton pregnancies from assisted reproduction have a significantly 
worse perinatal outcome than non-assisted singleton pregnancies, but this is less so 
for twin pregnancies. In twin pregnancies, perinatal mortality is about 40% lower 
after assisted compared with natural conception. 
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Introduction 
Twenty five years of assisted reproductive technology have not freed it from being 
a focus of medical, social, and political debate. Throughout this, reproductive 
technology has stood its ground, predominantly by offering parenthood to people 
who might not otherwise achieve it. However, issues that followed in its wake, such 
as surrogacy and pre-implantation diagnosis, have kept the momentum going on 
what many see as a loaded issue. It may be impossible to forecast where this will 
lead, but it should be possible to assess objectively whether babies born after assisted 
conception fare better or worse than those born after natural conception. 
This question seems to be answered already by the widespread belief that pregnancy 
outcome is substantially worse after assisted conception.1–3 The difference, however, 
relates predominantly to the higher frequency of multiple pregnancies.3 The first 
indication that assisted singleton pregnancies may also have poorer outcomes 
appeared in 1985,2 but it was not clear how much related to assisted reproduction 
or to confounders, such as maternal age and parity. Several matched cohort studies 
have since confirmed these findings.1,4–8 Some studies found an opposite trend,9,10 
while most reported differences that were compatible with chance. Moreover, for 
twin pregnancies the general consensus, with few exceptions,11–13 seems to be that 
assisted twin pregnancies have outcomes that are either similar to or slightly better 
than those conceived naturally.1,9,14–17 
We identified all published studies on birth outcomes after assisted conception 
that distinguished singleton from multiple pregnancies and that incorporated an 
appropriate control group from the same population. We examined whether there 
are genuine differences in outcome between assisted and natural conceptions and 
whether they apply to both singleton and twin pregnancies. 
Methods 
We searched Medline, Embase, LILACS, and POPLINE for 1985-2002 with the 
MESH words perinatal care, fertilization in vitro, and the keywords perinatal 
outcome, perinatal care, assisted reproduction, and IVF, without language limitation. 
This search was supplemented with the references of the articles, review articles, and 
theses. 
We selected reports with categorical data on any of the following outcomes: 
gestational age and weight at birth, caesarean section, perinatal death, and admission 
to neonatal intensive care. Studies without a control group of natural conceptions 
or that did not distinguish singleton from multiple pregnancies were excluded. The 
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remaining studies were controlled and we subdivided them into matched and non-
matched, depending on the nature of the control group. 
All authors read the studies, and at least two authors extracted data separately. 
Disagreements were resolved in discussion, if necessary after we contacted the 
original authors. All outcomes, except caesarean section, were expressed per number 
of infants. 
International definitions were followed for preterm ( < 37 weeks), very preterm ( < 
32 weeks), low birth weight ( < 2500 g), very low birth weight ( < 1500 g), small 
for gestational age (birth weight < 10th centile for gestation), and perinatal mortality 
(stillbirths and deaths in first week ≥ 500 g per 1000 total births ≥ 500 g). We used 
Review Manager (Update Software, Oxford) to calculate relative risks and 95% 
confidence intervals. 
Results 
Nine tables (A-I) of detailed results and a list of excluded studies can be found at 
the end of this chapter. Included studies are listed in tables A and B. Seventeen 
(14 matched and three non-matched) dealt with singleton pregnancies and 17 (10 
matched and seven non-matched) with twin pregnancies. The tables show country 
and years covered by the study, types of assisted conception, number of cases, and 
type of controls. 
Table 1 summarises relative risks of the outcomes in singleton and twin pregnancies 
after assisted and natural conception. Analyses for preterm birth and perinatal mortality 
are presented in tables 2-4, with more details and results for other outcomes in tables 
C-I. After table I the excluded studies with reasons for exclusion are listed. 
Preterm birth 
Very preterm singletons ( < 32 weeks) were reported in only three studies with a 
prevalence of 1.3-2.1% in assisted conceptions and 0.3-2.9% in natural conceptions, 
a relative risk of 3.27 (95% confidence interval 2.03 to 5.28) (table 2).1,9,19 Mildly 
preterm singletons (32-36 weeks) accounted for 6.5-9.2% and 3.8-7.6%, respectively, 
(2.05, 1.71 to 2.47) (see table C).1,9,19 
Preterm singletons ( < 37 weeks) accounted for 5.8-15% and 1.4-10.5%, respectively 
(table 2). The relative risk in both the 12 matched1,4–10,12,19,21,22 and two non-
matched23,25 studies showed a doubling of the risk of preterm birth after assisted 
conception. 
Very preterm twins were reported in three matched studies1,9,19 (detailed in table 3) 
and two non-matched17,26 studies. After we excluded one study that reported live 
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Table 2  Preterm birth in singleton pregnancies after assisted conception 
compared with matched controls (natural conception) 
Table 3  Preterm birth in twin pregnancies after assisted conception 
compared with matched controls (natural conception) 
very low birth weight ( < 1500 ), small for ge tational ag (birth
weight < 10th centile for gestation), nd per natal mortality
(stillbirths and deaths in first week ≥ 500 g per 1000 total births
≥ 500 g). We used Review Manager (Update Software, Oxford) to
calculate relative risks and 95% confidence intervals.
Results
Included studies are listed in tables A and B on www.bmj.com.
Seventeen (14 matched and three non-matched) dealt with
singleton pregnancies and 17 (10 matched and seven
non-matched) with twin pregnancies. The tables show country
and years covered by the study, types of assisted conception,
number of cases, and type of controls.
Table 1 summarises relative risks of the outcomes in
singleton and twin pregnancies after assisted and natural
conception. Analyses for preterm birth and perinatal mortality
are presented in tables 2-4, with more details and results for
other outcomes in web tables C-I (see www.bmj.com). The
website also lists the excluded studies with reasons for exclusion.
Preterm birth
Very preterm singletons ( < 32 weeks) were reported in only
three studies with a prevalence of 1.3-2.1% in assisted
conceptions and 0.3-2.9% in natural conceptions, a relative risk
of 3.27 (95% confidence interval 2.03 to 5.28) (table 2).1 9 19
Mildly preterm singletons (32-36 weeks) accounted for 6.5-9.2%
and 3.8-7.6%, respectively, (2.05, 1.71 to 2.47) (see web table
C).1 9 19 Preterm singletons ( < 37 weeks) accounted for 5.8-15%
and 1.4-10.5%, respectively (table 2). The relative risk in both the
12 matched1 4–10 12 19 21 22 and two non-matched23 25 studies showed
a doubling of the risk of preterm birth after assisted conception.
Very preterm twins were reported in three matched
studies1 9 19 (detailed in table 3) and two non-matched17 26 studies.
After we excluded one study that reported live infants only,19 the
frequency range was 7.0-10.5% in assisted conceptions and 4.9-
10.7% in natural conceptions and was not statistically different
(see web table D). Mildly preterm twins accounted for 41.7-45.2%
of cases and 33.0-40.5% of controls in the matched studies (1.07,
1.00 to 1.14).1 9 19 Preterm twins differed widely in frequency
from 18.8-60.0% and 20.0-52.4%, respectively. The relative risk
was 1.07 (1.02 to 1.13) in the nine matched studies1 4 9–13 19 22
(table 3) and 0.99 (0.80 to 1.23) in the two non-matched studies
(see web table D).17 23
Table 1 Summary of risk of various outcomes in singleton and twin pregnancies after assisted conception compared with those conceived naturally. Figures
are relative risk (95% confidence intervals)
Outcome
Singleton births Twin births
Matched studies Non-matched studies Matched studies Non-matched studies
Gestational age (weeks):
<32 3.27 (2.03 to 5.28) Not tested 0.95 (0.78 to 1.15) 1.20 (0.82 to 1.78)
32-36 2.05 (1.71 to 2.47) Not tested 1.07 (1.00 to 1.14) 0.88 (0.66 to 1.17)
<37 2.04 (1.80 to 2.32) 1.94 (1.31 to 2.88) 1.07 (1.02 to 1.13) 0.99 (0.80 to 1.23)
Birth weight (g):
<1500 3.00 (2.07 to 4.36) 1.57 (0.21 to 11.7) 0.89 (0.74 to 1.07) 1.46 (1.01 to 2.11)
1500-2499 1.54 (1.30 to 1.82) 3.28 (2.04 to 5.27) 1.02 (0.97 to 1.08) 1.05 (0.96 to 1.15)
<2500 1.70 (1.50 to 1.92) 2.58 (1.80 to 3.68) 1.03 (0.99 to 1.08) 1.12 (1.06 to 1.19)
Small for gestational age 1.40 (1.15 to 1.71) 1.46 (0.98 to 2.15) 1.27 (0.97 to 1.65) 0.93 (0.73 to 1.18)
Caesarean section 1.54 (1.44 to 1.66) 2.33 (1.95 to 2.79) 1.21 (1.11 to 1.32) 1.17 (1.06 to 1.29)
Neonatal intensive care unit 1.27 (1.16 to 1.40) 1.38 (0.67 to 2.86) 1.05 (1.01 to 1.09) 1.26 (1.16 to 1.36)
Perinatal mortality 1.68 (1.11 to 2.55) 3.77 (1.15 to 12.4) 0.58 (0.44 to 0.77) 0.84 (0.53 to 1.32)
Table 2 Pr term birth i leton pregnancies after assi ted conception
compared with matched controls ( atural conception)
Study No (%) assisted No (%) natural
Relative risk (95%
CI)
Very preterm (<32 weeks)
Dhont et al1* 63/3048 (2.1) 8/3048 (0.3) 7.88 (3.78 to 16.4)*
Dhont et al9 4/311 (1.3) 18/622 (2.9) 0.44 (0.15 to 1.30)
Koivurova et al19† 3/153 (2.0) 3/287 (1.0) 1.88 (0.38 to 9.18)†
Total 70/3512 (2.0) 29/3957 (0.7) 3.27 (2.03 to 5.28)
Preterm (<37 weeks)
Dhont et al1* 344/3048 (11.3) 125/3048 (4.1) 2.75 (2.26 to 3.36)*
Dhont et al9 26/311 (8.4) 65/622 (10.5) 0.80 (0.52 to 1.23)
Isaksson et al10 4/69 (5.8) 35/345 (10.1) 0.57 (0.21 to 1.56)
Koivurova et al19† 13/153 (8.5) 16/287 (5.6) 1.52 (0.75 to 3.08)†
Koudstaal et al8 46/307 (15.0) 18/307 (5.9) 2.56 (1.52 to 4.30)
Nuojua et al21 8/92 (8.7) 14/276 (5.1) 1.71 (0.74 to 3.96)
Petersen et al22 5/70 (7.1) 3/70 (4.3) 1.67 (0.41 to 6.71)
Reubinoff et al7 23/260 (8.8) 10/260 (3.8) 2.30 (1.12 to 4.74)
Tallo et al12 6/62 (9.7) 1/62 (1.6) 6.00 (0.74 to 48.4)
Tan et al4 69/494 (14.0) 78/978 (8.0) 1.75 (1.29 to 2.38)
Tanbo et al5 53/355 (14.9) 61/643 (9.5) 1.57 (1.12 to 2.22)
Verlaenen et al6 16/140 (11.4) 2/140 (1.4) 8.00 (1.87 to 34.2)
Total 613/5361 (11.4) 428/7038 (6.1) 2.04 (1.80 to 2.32)
*Based on additional data obtained from authors.
†Surviving infants only.
Table 3 Preterm birth in twin pregnancies after assisted conception
compared with matched controls (natural conception)
Study No (%) assisted No (%) natural
Relative risk (95%
CI)
Very preterm (<32 weeks)
Dhont et al1* 173/2482 (7.0) 178/2482 (7.2) 0.97 (0.79 to 1.19)*
Dhont et al9 16/230 (7.0) 12/230 (5.2) 1.33 (0.65 to 2.76)
Koivurova et al19† 2/103 (1.9) 11/103 (10.7) 0.18 (0.04 to 0.80)†
Total 191/2815 (6.8) 201/2815 (7.1) 0.95 (0.78 to 1.15)
Preterm (<37 weeks)
Dhont et al1* 1227/2482 (49.4) 1184/2482 (47.7) 1.04 (0.98 to 1.10)*
Dhont et al9 120/230 (52.2) 98/230 (42.6) 1.22 (1.01 to 1.49)
Isaksson et al10 14/40 (35.0) 82/200 (41.0) 0.85 (0.54 to 1.34)
Koivurova et al19† 45/103 (43.7) 45/103 (43.7) 1.00 (0.73 to 1.36)†
Koudstaal et al13 98/192 (51.0) 80/192 (41.7) 1.23 (0.99 to 1.52)
Moise et al11 24/40 (60.0) 16/80 (20.0) 3.00 (1.81 to 4.98)
Petersen et al22 6/32 (18.8) 12/32 (37.5) 0.50 (0.21 to 1.17)
Tallo et al12† 40/68 (58.8) 25/68 (36.8) 1.60 (1.11 to 2.32)†
Tan et al4 146/250 (58.4) 22/42 (52.4) 1.11 (0.82 to 1.52)
Total 1720/3437 (50.0) 1564/3429 (45.6) 1.07 (1.02 to 1.13)
*Based on additional data obtained from the authors.
†Surviving infants only.
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very low birth weight ( < 1500 g), small for gestational age (birth
weight < 10th centile for gestation), and perinatal mortality
(stillbirths and deaths in first week ≥ 500 g per 1000 total births
≥ 500 g). We used Review Manager (Update Software, Oxford) to
calculate relative risks and 95% confidence intervals.
Results
Included studies are listed in tables A and B on www.bmj.com.
Seventeen (14 matched and three non-matched) dealt with
singleton pregnancies and 17 (10 matched and seven
non-matched) with twin pregnancies. The tables show country
and years covered by the study, types of assisted conception,
number of cases, and type of controls.
Table 1 summarises relative risks of the outcomes in
singleton and twin pregnancies after assisted and natural
conception. Analyses for preterm birth and perinatal mortality
are presented in tables 2-4, with more details and results for
other outcomes in web tables C-I (see www.bmj.com). The
website also lists the excluded studies with reasons for exclusion.
Preterm birth
Very preterm singletons ( < 32 weeks) were reported in only
three studies with a prevalence of 1.3-2.1% in assisted
conceptions and 0.3-2.9% in natural conceptions, a relative risk
of 3.27 (95% confidence interval 2.03 to 5.28) (table 2).1 9 19
Mildly preterm singletons (32-36 weeks) accounted for 6.5-9.2%
and 3.8-7.6%, respectively, (2.05, 1.71 to 2.47) (see web table
C).1 9 19 Preterm singletons ( < 37 weeks) accounted for 5.8-15%
and 1.4-10.5%, respectively (table 2). The relative risk in both the
12 matched1 4–10 12 19 21 22 and two non-matched23 25 studies showed
a doubling of the risk of preterm birth after assisted conception.
Very preterm twins were reported in three matched
studies1 9 19 (detailed in table 3) and two non-matched17 26 studies.
After we excluded one study that reported live infants only,19 the
frequency range was 7.0-10.5% in assisted conceptions and 4.9-
10.7% in natural conceptions and was not statistically different
(see web table D). Mildly preterm twins accounted for 41.7-45.2%
of cases and 33.0-40.5% of controls in the matched studies (1.07,
1.00 to 1.14).1 9 19 Preterm twins differed widely in frequency
from 18.8-60.0% and 20.0-52.4%, respectively. The relative risk
was 1.07 (1.02 to 1.13) in the nine matched studies1 4 9–13 19 22
(table 3) and 0.99 (0.80 to 1.23) in the two non-matched studies
(see web table D).17 23
Table 1 Summary of risk of various outcomes in singleton and twin pregnancies after assisted conception compared with those conceived naturally. Figures
are relative risk (95% confidence intervals)
Outcome
Singleton births Twin births
Matched studies Non-matched studies Matched studies Non-matched studies
Gestational age (weeks):
<32 3.27 (2.03 to 5.28) Not tested 0.95 (0.78 to 1.15) 1.20 (0.82 to 1.78)
32-36 2.05 (1.71 to 2.47) Not tested 1.07 (1.00 to 1.14) 0.88 (0.66 to 1.17)
<37 2.04 (1.80 to 2.32) 1.94 (1.31 to 2.88) 1.07 (1.02 to 1.13) 0.99 (0.80 to 1.23)
Birth weight (g):
<1500 3.00 (2.07 to 4.36) 1.57 (0.21 to 11.7) 0.89 (0.74 to 1.07) 1.46 (1.01 to 2.11)
1500-2499 1.54 (1.30 to 1.82) 3.28 (2.04 to 5.27) 1.02 (0.97 to 1.08) 1.05 (0.96 to 1.15)
<2500 1.70 (1.50 to 1.92) 2.58 (1.80 to 3.68) 1.03 (0.99 to 1.08) 1.12 (1.06 to 1.19)
Small for gestational age 1.40 (1.15 to 1.71) 1.46 (0.98 to 2.15) 1.27 (0.97 to 1.65) 0.93 (0.73 to 1.18)
Caesarean section 1.54 (1.44 to 1.66) 2.33 (1.95 to 2.79) 1.21 (1.11 to 1.32) 1.17 (1.06 to 1.29)
Neonatal intensive care unit 1.27 (1.16 to 1.40) 1.38 (0.67 to 2.86) 1.05 (1.01 to 1.09) 1.26 (1.16 to 1.36)
Perinatal mortality 1.68 (1.11 to 2.55) 3.77 (1.15 to 12.4) 0.58 (0.44 to 0.77) 0.84 (0.53 to 1.32)
Table 2 Preterm birth in singleton pregnancies after assisted conception
compared with matched controls (natural conception)
Study No (%) assisted No (%) natural
Relative risk (95%
CI)
Very preterm (<32 weeks)
Dhont et al1* 63/3048 (2.1) 8/3048 (0.3) 7.88 (3.78 to 16.4)*
Dhont et al9 4/311 (1.3) 18/622 (2.9) 0.44 (0.15 to 1.30)
Koivurova et al19† 3/153 (2.0) 3/287 (1.0) 1.88 (0.38 to 9.18)†
Total 70/3512 (2.0) 29/3957 (0.7) 3.27 (2.03 to 5.28)
Preterm (<37 weeks)
Dhont et al1* 344/3048 (11.3) 125/3048 (4.1) 2.75 (2.26 to 3.36)*
Dhont et al9 26/311 (8.4) 65/622 (10.5) 0.80 (0.52 to 1.23)
Isaksson et al10 4/69 (5.8) 35/345 (10.1) 0.57 (0.21 to 1.56)
Koivurova et al19† 13/153 (8.5) 16/287 (5.6) 1.52 (0.75 to 3.08)†
Koudstaal et al8 46/307 (15.0) 18/307 (5.9) 2.56 (1.52 to 4.30)
Nuojua et al21 8/92 (8.7) 14/276 (5.1) 1.71 (0.74 to 3.96)
Petersen et al22 5/70 (7.1) 3/70 (4.3) 1.67 (0.41 to 6.71)
Reubinoff et al7 23/260 (8.8) 10/260 (3.8) 2.30 (1.12 to 4.74)
Tallo et al12 6/62 (9.7) 1/62 (1.6) 6.00 (0.74 to 48.4)
Tan et al4 69/494 (14.0) 78/978 (8.0) 1.75 (1.29 to 2.38)
Tanbo et al5 53/355 (14.9) 61/643 (9.5) 1.57 (1.12 to 2.22)
Verlaenen et al6 16/140 (11.4) 2/140 (1.4) 8.00 (1.87 to 34.2)
Total 613/5361 (11.4) 428/7038 (6.1) 2.04 (1.80 to 2.32)
*Based on additional data obtained from authors.
†Surviving infants only.
l birth in twin pregnancies after assisted conception
compared with matched controls (natura c nception)
Study No (%) assisted No (%) natural
Relative risk (95%
CI)
Very preterm (<32 weeks)
Dhont et al1* 173/2482 (7.0) 178/2482 (7.2) 0.97 (0.79 to 1.19)*
Dhont et al9 16/230 (7.0) 12/230 (5.2) 1.33 (0.65 to 2.76)
Koivurova et al19† 2/103 (1.9) 11/103 (10.7) 0.18 (0.04 to 0.80)†
Total 191/2815 (6.8) 201/2815 (7.1) 0.95 (0.78 to 1.15)
Preterm (<37 weeks)
Dhont et al1* 1227/2482 (49.4) 1184/2482 (47.7) 1.04 (0.98 to 1.10)*
Dhont et al9 120/230 (52.2) 98/230 (42.6) 1.22 (1.01 to 1.49)
Isaksson et al10 14/40 (35.0) 82/200 (41.0) 0.85 (0.54 to 1.34)
Koivurova et al19† 45/103 (43.7) 45/103 (43.7) 1.00 (0.73 to 1.36)†
Koudstaal et al13 98/192 (51.0) 80/192 (41.7) 1.23 (0.99 to 1.52)
Moise et al11 24/40 (60.0) 16/80 (20.0) 3.00 (1.81 to 4.98)
Petersen et al22 6/32 (18.8) 12/32 (37.5) 0.50 (0.21 to 1.17)
Tallo et al12† 40/68 (58.8) 25/68 (36.8) 1.60 (1.11 to 2.32)†
Tan et al4 146/250 (58.4) 22/42 (52.4) 1.11 (0.82 to 1.52)
Total 1720/3437 (50.0) 1564/3429 (45.6) 1.07 (1.02 to 1.13)
*Based on additional data obtained from the authors.
†Surviving infants only.
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Perinatal outcome of singletons and twins after assisted conception
infants only,19 the frequency range was 7.0-10.5% in assisted conceptions and 4.9-
10.7% in natural conceptions and was not statistically different (see table D). Mildly 
preterm twins accounted for 41.7-45.2% of cases and 33.0-40.5% of controls in the 
matched studies (1.07, 1.00 to 1.14).1,9,19 Preterm twins differed widely in frequency 
from 18.8-60.0% and 20.0-52.4%, respectively. The relative risk was 1.07 (1.02 to 
1.13) in the nine matched studies1,4,9–13,19,22 (table 3) and 0.99 (0.80 to 1.23) in the 
two non-matched studies (see table D).17,23 
Birth weight 
Singletons weighing < 1500 g were reported for six matched studies1,5,6,9,10,19 and one 
non-matched study.25 Frequencies in the matched studies were 1.5-3.9% for assisted 
conceptions and 0.32-7% for natural conceptions with a relative risk of 3.00 (2.07 to 
4.36) (see table E). Singletons weighing < 2500 g were more common among cases 
than among controls in both matched (n = 12)1,4–10,12,19,21,22 and non-matched (n = 
Table 4  Perinatal mortality in singleton and twin pregnancies after assisted conception compared 
with natural conception 
Birth weight
Singletons weighing < 1500 g were reported for six matched
studies1 5 6 9 10 19 and one non-matched study.25 Frequencies in the
matched studies were 1.5-3.9% for assisted conceptions and 0. -
2.7% for natural conceptions with a relative risk of 3.00 (2.07 to
4.36) (see web table E). Singletons weighing < 2500 g were more
common among cases than among controls in both matched
(n = 12)1 4–10 12 19 21 22 and non-matched (n = 2)23 25 studies. Percent-
ages of low birth weight were 2.9-15.7% in cases, 0-11.5% in
matched controls, and 3.6-4.8% in non-matched controls (see
web table E).
Twins < 1500 g accounted for 5.0-25.0% of cases and
3.8-10.4% of controls (omitting one study reporting live infants
only).19 The relative risk was 0.89 (0.74 to 1.07) for the five
matched1 9–11 19 and 1.46 (1.01 to 2.11) for the two non-matched
studies (see web table F).17 27 Twins < 2500 g accounted for 37.5-
70.6% and 50.0-98.6% of cases versus 38.1-58.8% and
52.5-94.5% of controls, with relative risks of 1.03 (0.99 to 1.08)
and 1.12 (1.06 to 1.19), respectively, in the eight matched
studies1 4 9–13 19 22 and the four non-matched studies.17 23 26 27
Small for gestational age
The 12 studies that reported on infants who were small for
gestational age applied various reference charts. The frequency
in singleton cases and controls was 1.6-16.3% versus 1.6-13.1%
with a relative risk of 1.40 and 1.46, respectively, for the six
matched4 6–8 12 20 and two non-matched studies (see web table
G).23 25 The four matched4 11–13 and three non-matched17 23 26 twin
studies showed no significant difference between assisted and
natural conceptions.
Caesarean section
Rates of caesarean section were significantly higher after assisted
than after natural conception (see web table H). The effect was
more marked for singleton than for twin pregnancies in both
matched1 4–8 10 11 13 18 20 21 and non-matched studies.14 17 24–27
NICU admissions
Admissions to neonatal intensive care were more common after
assisted conception in both matched and non-matched studies,
and the difference was larger for singletons1 5–7 9 10 19 21 23 than for
twins (see web table I).1 9–11 14 19 23 26 27
Perinatal mortality
Perinatal mortality differed widely among studies (table 4). In
singleton pregnancies it was significantly higher after assisted
than after natural conception in both matched and non-matched
studies. All of the difference in the matched studies was
accounted for by the study of Dhont et al in 1999, which contrib-
uted 67% of the cases.1 Without this study mortality was 10.4 per
1000 for both cases and controls.
Matched twin studies were also dominated by the same study,
which contributed 78% of the cases,1 and by another with an
extraordinarily high mortality among controls.16 However, most
twin studies showed a lower mortality after assisted than after
natural conception, with a relative risk of 0.58 (0.44 to 0.77) for




Though assisted conception has had many successes, it seems
that resulting singleton pregnancies have a worse outcome com-
pared with naturally conceived singleton pregnancies. We chose
to concentrate on birth issues and ignore early pregnancy
outcomes, which are prone to ascertainment bias because they
are detected more readily after assisted conception. This does
not imply that birth outcomes are free from bias. Women with
assisted preg ancies differ from other women in many
characteristics that influence outcome, including age, parity, and
socioeconomic status,1 2 12 while subfertility itself also contributes
to the difference.29 We therefore subdivided studies into those
with matched and those with non-matched, population specific
controls and placed greater emphasis on the former. These
virtually all matched for prominent confounders, such as age
and parity, but they varied widely in controlling for other known
confounders, such as socioeconomic status, smoking, and
pre-existing disease. Although none controlled for all factors
that might be important, they are likely to estimate true
differences between assisted and natural conceptions better than
the population based studies.
Nevertheless, our study uncovered major limitations of the
matched cohort approach to differences in perinatal outcome
between assisted and natural conceptions. Our summary results
are largely dominated by a matched cohort study from Flanders,
which contributed 54% of the cases in the singleton studies and
68% in the twin studies.1 Its authors used three different control
groups of singletons to match for various combinations of char-
acteristics.1 This led to disparate comparison groups, with
perinatal mortality, for example, being 5.2 per 1000 in controls
matched for maternal age and infant sex and 12.1 per 1000 in
those matched also for parity and gestational age. The validity of
matching for gestational age is questionable because gestational
age is clearly influenced by assisted conception and affects other
outcomes, such as birth weight and mortality. We therefore
Table 4 Perinatal mortality in singleton and twin pregnancies after assisted
conception compared with natural conception





Dhont et al1* 41/3048 (13.5) 18/3048 (5.9) 2.28 (1.31 to 3.96)*
Dhont et al9 2/311 (6.4) 10/622 (16.1) 0.40 (0.09 to 1.81)
Isaksson et al10 1/69 (14.5) 5/345 (14.5) 1.00 (0.12 to 8.43)
Koudstaal et al8 3/307 (9.8) 1/307 (3.3) 3.00 (0.31 to 28.7)
Nuojua et al21 1/92 (10.9) 2/276 (7.2) 1.50 (0.14 to 16.4)
Reubinoff et al7 2/260 (7.7) 1/260 (3.8) 2.00 (0.18 to 21.9)
Tanbo et al5 4/355 (11.3) 6/643 (9.3) 1.21 (0.34 to 4.25)
Verlaenen et al6 3/140 (21.4) 2/140 (14.3) 1.50 (0.25 to 8.84)
Total 57/4582 (12.4) 45/5641 (8.0) 1.68 (1.11 to 2.55)
Non-matched singleton studies:
Olivennes et al25† 3/162 (18.5) 25/5096 (4.9) 3.77 (1.15 to 12.4)
Twins
Matched twin studies:
Dhont et al1* 61/2482 (24.6) 82/2482 (33.0) 0.74 (0.54 to 1.03)*
Dhont et al9 0/230 6/230 (26.1) 0.08 (0.00 to 1.36)
Fitzsimmons et al16 4/112 (35.7) 48/216 (222.2) 0.16 (0.06 to 0.43)
Isaksson et al10 0/40 6/200 (30.0) 0.38 (0.02 to 6.56)
Koudstaal et al13 3/192 (15.6) 1/192 (5.2) 3.00 (0.31 to 28.6)
Tallo et al12 4/72 (55.6) 4/72 (55.6) 1.00 (0.26 to 3.85)
Total 72/3128 (23.0) 147/3392 (43.3) 0.58 (0.44 to 0.77)
Non-matched twin studies:
Agustsson et al14 2/138 (14.5) 16/906 (17.6) 0.82 (0.19 to 3.53)
Lambalk et al28 18/1158 (15.5) 16/884 (18.1) 0.86 (0.44 to 1.67)
Olivennes et al17 10/144 (69.4) 28/328 (85.4) 0.81 (0.41 to 1.63)
Total 30/1440 (20.8) 60/2118 (28.3) 0.84 (0.53 to 1.32)
*Early neonatal deaths in this paper are erroneously labelled as early fetal deaths, but they are
included in perinatal deaths.
†Two cases lost to follow up.
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2)23,25 studies. Percentages of low birth weight were 2.9-15.7% in cases, 0-11.5% in 
matched controls, and 3.6-4.8% in non-matched controls (see table E). 
Twins < 1500 g accounted for 5.0-25.0% of cases and 3.8-10.4% of controls (omitting 
one study reporting live infants only).19 The relative risk was 0.89 (0.74 to 1.07) for 
the five matched1,9–11,19 and 1.46 (1.01 to 2.11) for the two non-matched studies (see 
table F).17,27 Twins < 2500 g accounted for 37.5-70.6% and 50.0-98.6% of cases 
versus 38.1-58.8% and 52.5-94.5% of controls, with relative risks of 1.03 (0.99 to 
1.08) and 1.12 (1.06 to 1.19), respectively, in the eight matched studies1,4,9–13,19,22 
and the four non-matched studies.17,23,26,27 
Small for gestational age 
The 12 studies that reported on infants who were small for gestational age applied 
various reference charts. The frequency in singleton cases and controls was 1.6-
16.3% versus 1.6-13.1% with a relative risk of 1.40 and 1.46, respectively, for 
the six matched4,6–8,12,20 and two non-matched studies (see table G).23,25 The four 
matched4,11–13 and three non-matched17,23,26 twin studies showed no significant 
difference between assisted and natural conceptions. 
Caesarean section 
Rates of caesarean section were significantly higher after assisted than after natural 
conception (see table H). The effect was more marked for singleton than for twin 
pregnancies in both matched1,4–8,10,11,13,18,20,21 and non-matched studies.14,17,24–27 
NICU admissions 
Admissions to neonatal intensive care were more common after assisted conception 
in both matched and non-matched studies, and the difference was larger for 
singletons1,5–7,9,10,19,21,23 than for twins (see table I).1,9–11,14,19,23,26,27 
Perinatal mortality 
Perinatal mortality differed widely among studies (table 4). In singleton pregnancies 
it was significantly higher after assisted than after natural conception in both matched 
and non-matched studies. All of the difference in the matched studies was accounted 
for by the study of Dhont et al in 1999, which contributed 67% of the cases.1 Without 
this study mortality was 10.4 per 1000 for both cases and controls. 
Matched twin studies were also dominated by the same study, which contributed 
78% of the cases,1 and by another with an extraordinarily high mortality among 
controls.16 However, most twin studies showed a lower mortality after assisted than 
after natural conception, with a relative risk of 0.58 (0.44 to 0.77) for matched and 
0.84 (0.53 to 1.32) for non-matched studies (table 4). 
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Discussion 
Bias and confounding 
Though assisted conception has had many successes, it seems that resulting singleton 
pregnancies have a worse outcome compared with naturally conceived singleton 
pregnancies. We chose to concentrate on birth issues and ignore early pregnancy 
outcomes, which are prone to ascertainment bias because they are detected more 
readily after assisted conception. This does not imply that birth outcomes are free 
from bias. Women with assisted pregnancies differ from other women in many 
characteristics that influence outcome, including age, parity, and socioeconomic 
status,1,2,12 while subfertility itself also contributes to the difference.29 We therefore 
subdivided studies into those with matched and those with non-matched, population 
specific controls and placed greater emphasis on the former. These virtually all 
matched for prominent confounders, such as age and parity, but they varied widely 
in controlling for other known confounders, such as socioeconomic status, smoking, 
and pre-existing disease. Although none controlled for all factors that might be 
important, they are likely to estimate true differences between assisted and natural 
conceptions better than the population based studies. 
Nevertheless, our study uncovered major limitations of the matched cohort approach 
to differences in perinatal outcome between assisted and natural conceptions. Our 
summary results are largely dominated by a matched cohort study from Flanders, 
which contributed 54% of the cases in the singleton studies and 68% in the twin 
studies.1 Its authors used three different control groups of singletons to match for 
various combinations of characteristics.1 This led to disparate comparison groups, 
with perinatal mortality, for example, being 5.2 per 1000 in controls matched for 
maternal age and infant sex and 12.1 per 1000 in those matched also for parity 
and gestational age. The validity of matching for gestational age is questionable 
because gestational age is clearly influenced by assisted conception and affects other 
outcomes, such as birth weight and mortality. We therefore included only the controls 
matched for maternal age, infant sex, and parity. In another study, controls, but not 
cases, included several twin to twin transfusions in babies referred for special care.16 
Similar degrees of arbitrariness may have applied to other matched cohort studies 
without being apparent from the data. 
Risk factors 
Despite these limitations it is clear that the rate of preterm birth in singleton 
pregnancies after assisted reproduction is twice that seen with natural conceptions. 
This means that assisted reproduction is as much as a predictor for preterm birth 
as history of preterm birth.30 The effect was larger for very preterm than for mildly 
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preterm births and translated into higher rates of (very) low birth weight, admission 
to intensive care, and perinatal death. However, not all of these should be attributed 
to preterm birth as there were also 40% more infants who were small for gestational 
age after assisted conception. There is some evidence that factors which influence 
gestational age at birth also influence weight for gestation,31 and assisted conception 
may belong to the factors that influence both fetal weight and length of gestation. 
On the other hand, if small for gestation fetuses are detected, this may prompt 
intervention that leads to earlier birth thereby contributing to both preterm and low 
birthweight rates. Unfortunately, we could not distinguish preterm births due to 
obstetric intervention from spontaneous preterm births. Neither could we ascertain 
that all singleton pregnancies, especially after assisted conception, were singleton 
pregnancies from the start rather than what remained after resorption of additional 
gestational sacs. 
Twins 
While the results of the matched and non-matched singleton studies invariably 
supported each other, this was less so for twin pregnancies. Differences between 
assisted and natural conceptions were all much smaller than in singleton pregnancies, 
often with confidence intervals that included unity. This is not due to smaller numbers 
because the overall sample size for twin studies was 84% of that of the singleton 
studies and the confidence intervals were smaller than for singletons. 
An added risk, such as assisted conception, may have a marked impact on a low 
risk singleton pregnancy, but only a small effect on the heavily weighted balance 
of twin pregnancy. Assisted twin pregnancies may actually start off with a relative 
advantage over singleton pregnancies. As these studies were conducted when 85% 
of cycles of in vitro fertilisation entailed transfer of several embryos,3,32 most births 
must have originated from the transfer of more than one embryo. Development of 
two rather than one may reflect an implantation advantage that accounts for the 
smaller difference in outcome between assisted and natural conceptions in twins 
than in singletons. Chorionicity certainly plays a part too. Dichorionic pregnancies 
fare better than monochorionic pregnancies and the latter account for 5-7% of 
assisted compared with 30% of natural twin pregnancies.33 This effect was not 
obvious, though, in the studies that controlled for zygosity.11,13,28 Earlier detection 
of twins with adaptation of antenatal care has been named as another factor,17 but it 
is unclear what adaptations would significantly advantage assisted over natural twin 
pregnancies. However, none of this seems to explain the lower perinatal death rate 
in assisted than in natural twin pregnancies, especially as the other outcomes provide 
no indication how this might be mediated. 
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Conclusions and recommendations 
Whatever the explanation may be, singletons from assisted conception are significantly 
disadvantaged compared with other singletons, but this is substantially less so for 
twins. Women undergoing assisted reproduction should be informed of the increased 
risks in singleton pregnancies. With a twin pregnancy they may be relatively 
advantaged compared with other twin gestations, but this is poor consolation for 
the much greater risks of twin pregnancy overall. Virtually all perinatal and infant 
morbidity occurs more frequently in twins than in singletons.3 
Twenty five years after the birth of the first baby conceived by in vitro fertilisation, 
our data draw attention to three challenges. Firstly, emphasis needs to shift, more 
than it has already,332 from achieving pregnancy to achieving a successful outcome. 
Secondly, it may be timely to consider any multiple pregnancy after assisted 
conception as a failure of that technology to achieve what it ought to achieve. Thirdly, 
there is a need to narrow the gap in perinatal outcome between assisted and other 
singleton pregnancies. This may also enhance understanding of how gestational age, 
fetal growth, and birth weight interact with each other. 
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Extra nine tables (A-I) of detailed results
and list of excluded studies. 
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Table D  Preterm birth in twin pregnancies after assisted versus natural conception   
Study Assisted  Spontaneous  Relative risk (95% CI)
 n/N %  n/N %  
Very preterm (<32 weeks)
Matched studies         
Dhont et al. ’991* 173/2,482 7.0  178/2,482 7.2  0.97 (0.79 to 1.19)*
Dhont et al. ’979 16/230 7.0  12/230 5.2  1.33 (0.65 to 2.76)
Koivurova et al.19 † 2/103 1.9  11/103 10.7  0.18 (0.04 to 0.80)†
Total matched 191/2,815 6.8  201/2,815 7.1  0.95 (0.78 to 1.15)
Non-matched studies         
Bernasko et al.26 22/210 10.5  56/558 10.0  1.04 (0.65 to 1.67)
Olivennes et al. ’9617 ** 12/144 8.3  16/328 4.9  1.71 (0.83 to 3.52)**
Total non-matched 34/354 9.6  72/886 8.1  1.20 (0.82 to 1.78)
Mildly preterm (32-36 weeks)
Matched studies         
Dhont et al. ’991 * 1,054/2,482 42.5  1,006/2,482 40.5  1.05 (0.98 to 1.12)*
Dhont et al. ’979 104/230 45.2  86/230 37.4  1.21 (0.97 to 1.51)
Koivurova et al.19 † 43/103 41.7  34/103 33.0  1.26 (0.88 to 1.81) †
Total matched 1,201/2,815 42.7  1,126/2,815 40.0  1.07 (1.00 to 1.14)
Non-matched studies         
Olivennes et al. ’9617 ** 44/144 30.6  114/328 34.8  0.88 (0.66 to 1.17)**
Preterm (<37 weeks)
Matched studies         
Dhont et al. ’991 * 1,227/2,482 49.4  1,184/2,482 47.7  1.04 (0.98 to 1.10)*
Dhont et al. ’979 120/230 52.2  98/230 42.6  1.22 (1.01 to 1.49)
Isaksson et al.10 14/40 35.0  82/200 41.0  0.85 (0.54 to 1.34)
Koivurova et al19 † 45/103 43.7  45/103 43.7  1.00 (0.73 to 1.36) †
Koudstaal et al.13 98/192 51.0  80/192 41.7  1.23 (0.99 to 1.52)
Moise et al.11 24/40 60.0  16/80 20.0  3.00 (1.81 to 4.98)
Petersen et al.22 6/32 18.8  12/32 37.5  0.50 (0.21 to 1.17)
Tallo et al.12 † 40/68 58.8  25/68 36.8  1.60 (1.11 to 2.32)
Tan et al.4 146/250 58.4  22/42 52.4  1.11 (0.82 to 1.52)
Total matched 1,722/3,437 50.0  1,566/3,429 45.6  1.07 (1.02 to 1.13)
Non-matched studies         
Addor et al.23 12/26 46.2  69/154 44.8  1.03 (0.66 to 1.62)
Olivennes et al. ’9617 ** 56/144 38.9 130/328 39.6 0.98 (0.77 to 1.25)**
Total non-matched 68/170 40.0  199/482 41.3  0.99 (0.80 to 1.23)
*  Based on additional data obtained from the authors.
**  Preterm relates to <36 weeks, very preterm to <31 weeks, and mildly preterm to 32-35 weeks;  
two cases were lost to follow-up.
†  Surviving infants only.
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Table D  Preterm birth in twin pregnancies after assisted versus natural conception   
Study Assisted  Spontaneous  Relative risk (95% CI)
 n/N %  n/N %  
Very preterm (<32 weeks)
Matched studies         
Dhont et al. ’991* 173/2,482 7.0  178/2,482 7.2  0.97 (0.79 to 1.19)*
Dhont et al. ’979 16/230 7.0  12/230 5.2  1.33 (0.65 to 2.76)
Koivurova et al.19 † 2/103 1.9  11/103 10.7  0.18 (0.04 to 0.80)†
Total matched 191/2,815 6.8  201/2,815 7.1  0.95 (0.78 to 1.15)
Non-matched studies         
Bernasko et al.26 22/210 10.5  56/558 10.0  1.04 (0.65 to 1.67)
Olivennes et al. ’9617 ** 12/144 8.3  16/328 4.9  1.71 (0.83 to 3.52)**
Total non-matched 34/354 9.6  72/886 8.1  1.20 (0.82 to 1.78)
Mildly preterm (32-36 weeks)
Matched studies         
Dhont et al. ’991 * 1,054/2,482 42.5  1,006/2,482 40.5  1.05 (0.98 to 1.12)*
Dhont et al. ’979 104/230 45.2  86/230 37.4  1.21 (0.97 to 1.51)
Koivurova et al.19 † 43/103 41.7  34/103 33.0  1.26 (0.88 to 1.81) †
Total matched 1,201/2,815 42.7  1,126/2,815 40.0  1.07 (1.00 to 1.14)
Non-matched studies         
Olivennes et al. ’9617 ** 44/144 30.6  114/328 34.8  0.88 (0.66 to 1.17)**
Preterm (<37 weeks)
Matched studies         
Dhont et al. ’991 * 1,227/2,482 49.4  1,184/2,482 47.7  1.04 (0.98 to 1.10)*
Dhont et al. ’979 120/230 52.2  98/230 42.6  1.22 (1.01 to 1.49)
Isaksson et al.10 14/40 35.0  82/200 41.0  0.85 (0.54 to 1.34)
Koivurova et al19 † 45/103 43.7  45/103 43.7  1.00 (0.73 to 1.36) †
Koudstaal et al.13 98/192 51.0  80/192 41.7  1.23 (0.99 to 1.52)
Moise et al.11 24/40 60.0  16/80 20.0  3.00 (1.81 to 4.98)
Petersen et al.22 6/32 18.8  12/32 37.5  0.50 (0.21 to 1.17)
Tallo et al.12 † 40/68 58.8  25/68 36.8  1.60 (1.11 to 2.32)
Tan et al.4 146/250 58.4  22/42 52.4  1.11 (0.82 to 1.52)
Total matched 1,722/3,437 50.0  1,566/3,429 45.6  1.07 (1.02 to 1.13)
Non-matched studies         
Addor et al.23 12/26 46.2  69/154 44.8  1.03 (0.66 to 1.62)
Olivennes et al. ’9617 ** 56/144 38.9 130/328 39.6 0.98 (0.77 to 1.25)**
Total non-matched 68/170 40.0  199/482 41.3  0.99 (0.80 to 1.23)
*  Based on additional data obtained from the authors.
**  Preterm relates to <36 weeks, very preterm to <31 weeks, and mildly preterm to 32-35 weeks;  
two cases were lost to follow-up.
†  Surviving infants only.
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Table E  Low and very low birth weight in singleton pregnancies after assisted versus natural conception   
Study Assisted  Spontaneous  Relative risk (95% CI)
 n/N %  n/N %  
Birthweight < 1,500 g
Matched studies         
Dhont et al. ‘991 72/3,048 2.4  10/3,048 0.3  7.20 (3.72 to 13.9)
Dhont et al. ‘979 5/311 1.6  17/622 2.7  0.59 (0.22 to 1.58)
Isaksson et al.10 1/69 1.5  4/345 1.2  1.25 (0.14 to 11.0)
Koivurova et al.19 3/153 2.0  2/287 0.7  2.81 (0.48 to 16.7)
Tanbo et al.5 14/355 3.9  15/643 2.3  1.69 (0.83 to 3.46)
Verlaenen et al.6 5/140 3.6  1/140 0.7  5.00 (0.59 to 42.3)
Total matched 100/4,076 2.5  49/5,085 1.0  3.00 (2.07 to 4.36)
Non-matched studies         
Olivennes et al. ’9325 1/162 0.6  20/5,096 0.4  1.57 (0.21 to 11.7)
Total non-matched 1/162 0.6  20/5,096 0.4  1.57 (0.21 to 11.7)
Birthweight 1,500 - 2,499 g
Matched studies         
Dhont et al. ’991 247/3,048 8.1  142/3,048 3.8  1.74 (1.42 to 2.13)
Dhont et al. ’979 19/311 7.7  53/622 11.3  0.72 (0.43 to 1.19)
Isaksson et al.10 1/69 1.4  13/345 3.8  0.38 (0.05 to 2.89)
Koivurova et al.19 6/153 3.9  7/287 2.4  1.61 (0.55 to 4.70)
Tanbo et al.5 27/355 7.6  28/643 4.4  1.75 (1.05 to 2.92)
Verlaenen et al.6 9/140 6.4  5/140 3.6  1.80 (0.62 to 5.24)
Total matched 309/4,076 7.6  248/5,085 4.9  1.54 (1.30 to 1.82)
Non-matched studies         
Olivennes et al. ’9325 17/162 10.5  163/5,096 3.2  3.28 (2.04 to 5.27)
Total non-matched 17/162 10.5  163/5,096 3.2  3.28 (2.04 to 5.27)
Birthweight < 2,500 g
Matched studies         
Dhont et al. ’991 319/3,048 10.5  162/3,048 4.2  1.97 (1.64 to 2.36)
Dhont et al. ’979 24/311 7.7  70/622 11.3  0.69 (0.44 to 1.07)
Isaksson et al.10 2/69 2.9  17/345 5.0  0.59 (0.14 to 2.49)
Koivurova et al.19 9/153 5.9  9/287 3.1  1.88 (0.76 to 4.63)
Koudstaal et al.8 42/307 13.7  21/307 6.8  2.00 (1.21 to 3.30)
Nuojua et al.21 8/92 8.7  17/276 6.2  1.41 (0.63 to 3.16)
Petersen et al.22 11/70 15.7  0/70 0.0  23.0 (1.38 to 382.9)
Reubinoff et al.7 29/260 11.2  30/260 11.5  0.97 (0.60 to 1.56)
Tallo et al.12 3/62 4.8  3/62 4.8  1.00 (0.21 to 4.76)
Tan et al.4 69/494 14.0  68/978 6.9  2.01 (1.46 to 2.76)
Tanbo et al.5 41/355 11.5  43/643 6.7  1.73 (1.15 to 2.60)
Verlaenen et al.6 14/140 10.0  6/140 4.3  2.33 (0.92 to 5.90)
Total matched 571/5,361 10.7  446/7,038 6.4  1.70 (1.50 to 1.92)
Non-matched studies         
Addor et al.23 11/113 9.7  292/6,088 4.8  2.03 (1.14 to 3.60)
Olivennes et al. ’9325 18/162 11.1  183/5096 3.6  3.09 (1.96 to 4.89)
Total non-matched 29/275 10.5 475/11,184 4.2 2.58 (1.80 to 3.68)
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Table E  Low and very low birth weight in singleton pregnancies after assisted versus natural conception   
Study Assisted  Spontaneous  Relative risk (95% CI)
 n/N %  n/N %  
Birthweight < 1,500 g
Matched studies         
Dhont et al. ‘991 72/3,048 2.4  10/3,048 0.3  7.20 (3.72 to 13.9)
Dhont et al. ‘979 5/311 1.6  17/622 2.7  0.59 (0.22 to 1.58)
Isaksson et al.10 1/69 1.5  4/345 1.2  1.25 (0.14 to 11.0)
Koivurova et al.19 3/153 2.0  2/287 0.7  2.81 (0.48 to 16.7)
Tanbo et al.5 14/355 3.9  15/643 2.3  1.69 (0.83 to 3.46)
Verlaenen et al.6 5/140 3.6  1/140 0.7  5.00 (0.59 to 42.3)
Total matched 100/4,076 2.5  49/5,085 1.0  3.00 (2.07 to 4.36)
Non-matched studies         
Olivennes et al. ’9325 1/162 0.6  20/5,096 0.4  1.57 (0.21 to 11.7)
Total non-matched 1/162 0.6  20/5,096 0.4  1.57 (0.21 to 11.7)
Birthweight 1,500 - 2,499 g
Matched studies         
Dhont et al. ’991 247/3,048 8.1  142/3,048 3.8  1.74 (1.42 to 2.13)
Dhont et al. ’979 19/311 7.7  53/622 11.3  0.72 (0.43 to 1.19)
Isaksson et al.10 1/69 1.4  13/345 3.8  0.38 (0.05 to 2.89)
Koivurova et al.19 6/153 3.9  7/287 2.4  1.61 (0.55 to 4.70)
Tanbo et al.5 27/355 7.6  28/643 4.4  1.75 (1.05 to 2.92)
Verlaenen et al.6 9/140 6.4  5/140 3.6  1.80 (0.62 to 5.24)
Total matched 309/4,076 7.6  248/5,085 4.9  1.54 (1.30 to 1.82)
Non-matched studies         
Olivennes et al. ’9325 17/162 10.5  163/5,096 3.2  3.28 (2.04 to 5.27)
Total non-matched 17/162 10.5  163/5,096 3.2  3.28 (2.04 to 5.27)
Birthweight < 2,500 g
Matched studies         
Dhont et al. ’991 319/3,048 10.5  162/3,048 4.2  1.97 (1.64 to 2.36)
Dhont et al. ’979 24/311 7.7  70/622 11.3  0.69 (0.44 to 1.07)
Isaksson et al.10 2/69 2.9  17/345 5.0  0.59 (0.14 to 2.49)
Koivurova et al.19 9/153 5.9  9/287 3.1  1.88 (0.76 to 4.63)
Koudstaal et al.8 42/307 13.7  21/307 6.8  2.00 (1.21 to 3.30)
Nuojua et al.21 8/92 8.7  17/276 6.2  1.41 (0.63 to 3.16)
Petersen et al.22 11/70 15.7  0/70 0.0  23.0 (1.38 to 382.9)
Reubinoff et al.7 29/260 11.2  30/260 11.5  0.97 (0.60 to 1.56)
Tallo et al.12 3/62 4.8  3/62 4.8  1.00 (0.21 to 4.76)
Tan et al.4 69/494 14.0  68/978 6.9  2.01 (1.46 to 2.76)
Tanbo et al.5 41/355 11.5  43/643 6.7  1.73 (1.15 to 2.60)
Verlaenen et al.6 14/140 10.0  6/140 4.3  2.33 (0.92 to 5.90)
Total matched 571/5,361 10.7  446/7,038 6.4  1.70 (1.50 to 1.92)
Non-matched studies         
Addor et al.23 11/113 9.7  292/6,088 4.8  2.03 (1.14 to 3.60)
Olivennes et al. ’9325 18/162 11.1  183/5096 3.6  3.09 (1.96 to 4.89)
Total non-matched 29/275 10.5 475/11,184 4.2 2.58 (1.80 to 3.68)
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Table F  Low and very low birth weight in twin pregnancies after assisted versus natural conception   
Study Assisted  Spontaneous  Relative risk (95% CI)
 n/N %  n/N %  
Birthweight < 1,500 g
Matched studies         
Dhont et al. ’991 166/2,482 6.7  196/2,482 7.9  0.85 (0.69 to 1.03)
Dhont et al. ’979 14/230 6.1  14/230 6.1  1.00 (0.49 to 2.05)
Isaksson et al.10 2/40 5.0  16/200 7.5  0.63 (0.15 to 2.61)
Koivurova et al.19 † 1/103 1.0  5/103 4.9  0.20 (0.02 to 1.68)
Moise et al.11 10/40 25.0  3/80 3.8  6.67 (1.94 to 22.88)
Total matched 193/2,895 6.7  234/3,095 7.6  0.89 (0.74 to 1.07)
Non-matched studies         
Daniel et al.27 26/208 12.5  21/242 8.7  1.44 (0.84 to 2.48)
Olivennes et al. ’9617 22/144 15.3  34/328 10.4  1.47 (0.89 to 2.43)
Total non-matched 48/352 13.6 55/570 9.6 1.46 (1.01 to 2.11)
Birthweight 1,500 - 2,499 g
Matched studies         
Dhont et al. ’991 1,182/2,482 47.6  1,157/2,482 46.6  1.02 (0.96 to 1.08)
Dhont et al. ’979 114/230 49.6  112/230 48.7  1.02 (0.85 to 1.23)
Isaksson et al.10 16/40 40.0  78/200 38.5  1.03 (0.68 to 1.56)
Koivurova et al.19 † 46/103 44.7  42/103 40.8  1.10 (0.80 to 1.50)
Moise et al.11 18/40 45.0  44/80 55.0  0.82 (0.55 to 1.22)
Total matched 1,376/2,895 47.5  1,433/3,095 46.3  1.02 (0.97 to 1.08)
Non-matched studies         
Daniel et al.26 105/208 50.5  106/242 43.8  1.15 (0.95 to 1.40)
Olivennes et al. ’9617 120/144 83.3  276/328 84.1  0.99 (0.91 to 1.08)
Total non-matched 225/352 63.9 382/570 67.0 1.05 (0.96 to 1.15)
Birthweight < 2,500 g
Matched studies         
Dhont et al. ’991 1,348/2,482 54.3  1,353/2,482 54.5  1.00 (0.95 to 1.05)
Dhont et al. ’979 128/230 55.6  126/230 54.8  1.02 (0.86 to 1.20)
Isaksson et al.10 18/40 45.0  92/200 46.0  0.98 (0.67 to 1.42)
Koivurova et al.19 † 47/103 45.6  47/103 45.6  1.00 (0.74 to 1.35)
Koudstaal et al.13 117/192 60.9  85/192 44.3  1.38 (1.13 to 1.67)
Moise et al.11 28/40 70.0  47/80 58.8  1.19 (0.91 to 1.57)
Petersen et al.22 12/32 37.5  15/32 46.9  0.80 (0.45 to 1.43)
Tallo et al.12 † 48/68 70.6  29/68 42.6  1.66 (1.21 to 2.27)
Tan et al.4 132/250 52.8  16/42 38.1  1.39 (0.93 to 2.07)
Total matched 1,878/3,437 54.6  1,810/3,429 52.8  1.03 (0.99 to 1.08)
Non-matched studies         
Addor et al.23 26/52 50.0  166/308 53.9  0.93 (0.69 to 1.24)
Bernasko et al.26 * 148/206 71.8  324/548 59.1  1.22 (1.09 to 1.36)
Daniel et al.27 131/208 63.0  127/242 52.5  1.20 (1.02 to 1.41)
Olivennes et al. ’9617 142/144 98.6  310/328 94.5  1.04 (1.01 to 1.08)
Total non-matched 447/610 73.3  927/1,426 65.0  1.12 (1.06 to 1.19)
* Infants of 2 mothers in the study group and 5 in the control group were excluded because of stillbirth of one or both twins.
† Surviving infants only.
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Table F  Low and very low birth weight in twin pregnancies after assisted versus natural conception   
Study Assisted  Spontaneous  Relative risk (95% CI)
 n/N %  n/N %  
Birthweight < 1,500 g
Matched studies         
Dhont et al. ’991 166/2,482 6.7  196/2,482 7.9  0.85 (0.69 to 1.03)
Dhont et al. ’979 14/230 6.1  14/230 6.1  1.00 (0.49 to 2.05)
Isaksson et al.10 2/40 5.0  16/200 7.5  0.63 (0.15 to 2.61)
Koivurova et al.19 † 1/103 1.0  5/103 4.9  0.20 (0.02 to 1.68)
Moise et al.11 10/40 25.0  3/80 3.8  6.67 (1.94 to 22.88)
Total matched 193/2,895 6.7  234/3,095 7.6  0.89 (0.74 to 1.07)
Non-matched studies         
Daniel et al.27 26/208 12.5  21/242 8.7  1.44 (0.84 to 2.48)
Olivennes et al. ’9617 22/144 15.3  34/328 10.4  1.47 (0.89 to 2.43)
Total non-matched 48/352 13.6 55/570 9.6 1.46 (1.01 to 2.11)
Birthweight 1,500 - 2,499 g
Matched studies         
Dhont et al. ’991 1,182/2,482 47.6  1,157/2,482 46.6  1.02 (0.96 to 1.08)
Dhont et al. ’979 114/230 49.6  112/230 48.7  1.02 (0.85 to 1.23)
Isaksson et al.10 16/40 40.0  78/200 38.5  1.03 (0.68 to 1.56)
Koivurova et al.19 † 46/103 44.7  42/103 40.8  1.10 (0.80 to 1.50)
Moise et al.11 18/40 45.0  44/80 55.0  0.82 (0.55 to 1.22)
Total matched 1,376/2,895 47.5  1,433/3,095 46.3  1.02 (0.97 to 1.08)
Non-matched studies         
Daniel et al.26 105/208 50.5  106/242 43.8  1.15 (0.95 to 1.40)
Olivennes et al. ’9617 120/144 83.3  276/328 84.1  0.99 (0.91 to 1.08)
Total non-matched 225/352 63.9 382/570 67.0 1.05 (0.96 to 1.15)
Birthweight < 2,500 g
Matched studies         
Dhont et al. ’991 1,348/2,482 54.3  1,353/2,482 54.5  1.00 (0.95 to 1.05)
Dhont et al. ’979 128/230 55.6  126/230 54.8  1.02 (0.86 to 1.20)
Isaksson et al.10 18/40 45.0  92/200 46.0  0.98 (0.67 to 1.42)
Koivurova et al.19 † 47/103 45.6  47/103 45.6  1.00 (0.74 to 1.35)
Koudstaal et al.13 117/192 60.9  85/192 44.3  1.38 (1.13 to 1.67)
Moise et al.11 28/40 70.0  47/80 58.8  1.19 (0.91 to 1.57)
Petersen et al.22 12/32 37.5  15/32 46.9  0.80 (0.45 to 1.43)
Tallo et al.12 † 48/68 70.6  29/68 42.6  1.66 (1.21 to 2.27)
Tan et al.4 132/250 52.8  16/42 38.1  1.39 (0.93 to 2.07)
Total matched 1,878/3,437 54.6  1,810/3,429 52.8  1.03 (0.99 to 1.08)
Non-matched studies         
Addor et al.23 26/52 50.0  166/308 53.9  0.93 (0.69 to 1.24)
Bernasko et al.26 * 148/206 71.8  324/548 59.1  1.22 (1.09 to 1.36)
Daniel et al.27 131/208 63.0  127/242 52.5  1.20 (1.02 to 1.41)
Olivennes et al. ’9617 142/144 98.6  310/328 94.5  1.04 (1.01 to 1.08)
Total non-matched 447/610 73.3  927/1,426 65.0  1.12 (1.06 to 1.19)
* Infants of 2 mothers in the study group and 5 in the control group were excluded because of stillbirth of one or both twins.
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The first aim of this thesis was to assess the value of hysterosalpingography 
(HSG) prior to laparoscopy and dye in a routine clinical setting. The results of the 
randomized controlled trial comparing fertility work-ups with or without HSG will 
be discussed in the first part of this chapter. The second aim was to clarify whether 
adverse perinatal outcome is related to assisted conception or other maternal risk 
factors and whether this is for both singleton and twin pregnancies. The results of the 
second study on this subject will be discussed in the last part of this chapter.
7.1  Evaluation of diagnostic strategies in reproductive medicine: a study on 
hysterosalpingography
7.1.1 Study objective and methodology
Routine clinical investigation of subfertile couple consists, apart from ovulation 
detection and sperm analysis, of tubal patency detection. The first objective of this 
thesis was to investigate whether hysterosalpingography (HSG) prior to laparoscopy 
and dye should be maintained as a diagnostic procedure in the routine fertility work-
up. 
Assessment of tubal function is a fundamental part of the diagnostic fertility work-
up. HSG has become the first-line approach to assess the patency of the fallopian 
tubes in routine fertility work-up due to the non-invasive, outpatient procedure and 
low cost1,2 although laparoscopy and dye is the reference standard according to 
WHO criteria3. A reason for performing HSG in stead of or prior to laparoscopy 
and dye cannot be found in the test characteristics of HSG but is based more on 
tradition and personal preference1. Many authors have questioned the validity of 
HSG in the diagnosis of tubal function due to its moderate sensitivity and specificity 
compared to laparoscopy and dye4. Although flushing of the tubes with oil-soluble 
contrast media during HSG has been reported to shorten the period to become 
pregnant5, many women experience HSG as a painful procedure. The availability of 
other investigations for assessing tubal function like Chlamydia antibody testing or 
other new methods (hysterosalpingo-contrast-sonography, falloscopy, transvaginal 
laparoscopy) have provided new modalities to evaluate the tubal function. There are 
many arguments why HSG should or should not be part of the standard diagnostic 
fertility work-up based on its diagnostic value, pregnancy rates, pain, costs and 
alternatives. 
Because the usefulness of HSG was uncertain, a pragmatic multicenter randomized 
controlled trial comparing fertility work-up with or without HSG to assess the value 
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of HSG prior to laparoscopy and dye in a routine clinical setting was carried out. 
A pragmatic effectiveness trial was designed to evaluate whether two commonly 
used diagnostic strategies (HSG and laparoscopy & dye) have a different impact on 
cumulative pregnancy rate of subfertile women (chapter 2). A similar cumulative 
pregnancy rate at 18 months in the intervention (HSG) group (49.1%) and the control 
(non-HSG) group (50.3%) was found. We concluded that routine use of HSG at an 
early stage in the fertility work-up prior to laparoscopy and dye does not influence 
cumulative pregnancy rate compared to routine use of laparoscopy without HSG. 
The design of the trial and thus our conclusion was criticized by Coppus et al.6. 
They argued that clinical outcomes are not affected by the evaluated test but by the 
intervention that follows a normal or abnormal test result. As such, the randomized 
comparisons of the use of diagnostic tests or strategies could only show clinical 
benefits if an abnormal test result is followed by a standardized and explicit treatment 
protocol, according the authors of the letter6. However, the suggestion to change the 
design of the trial by only randomizing patients with discordant test results would 
have resulted in an efficacy trial and would have evaluated the effect of the test under 
ideal circumstances. In such a trial the question ‘can it work?’ is answered7. Our 
trial, however, was an effectiveness trial designed to compare two common clinical 
diagnostic strategies in the setting of daily clinical practice. Hence, in our trial the 
question ‘does it work in practice?’ was answered7. In that setting, a worthwhile test 
plus intervention must have an effect that is robust enough to overcome differences 
in patient choice, local procedures and health care access.
7.1.2 Pain and patient evaluation
Two studies have shown that women may experience HSG as a painful procedure8,9. 
Laparoscopy is invasive and generally needs general anaesthesia. In an additional 
analysis of subfertile women nested in the above mentioned randomized controlled 
trial, pain and patient satisfaction of women undergoing an HSG or laparoscopy and 
dye as routine diagnostic procedures in the fertility work-up was evaluated (chapter 
3). We concluded that both HSG and laparoscopy cause considerable amount of 
physical complaints, but the overall judgment of women undergoing the procedures 
favors laparoscopy.
On the basis of these results, it is difficult to justify the routine performance of 




7.1.3 Alternatives of HSG
Several alternatives can be used to evaluate the tubal function in subfertile women 
like Chlamydia antibody testing (CAT), hysterosalpingo-contrast-sonography or 
transvaginal hydrolaparoscopy, of which CAT is most widely used and has been 
evaluated most extensively.
Chlamydia antibody testing (CAT)
The diagnostic properties of CAT and HSG compared to laparoscopy and dye is well 
established and showed that CAT performs just as well or better than HSG, but both 
have poor performance10-14. However, the prognostic value of both tests in predicting 
occurrence of pregnancy is also poor15. We came to the same conclusion when we 
evaluated the value of CAT as alternative test for HSG (chapter 4). However, CAT 
fails to provide information about the severity of tubal pathology. Furthermore, it 
cannot detect tubal pathology caused by endometriosis or salpingitis due to other 
micro-organism than Chlamydia (C) trachomatis. However, the costs of CAT are 
low (in the Netherlands, about ten euros)16 and patient discomfort is negligible.
CAT as screening test to estimate the risk of tubal pathology prior to laparoscopy is 
preferable to HSG due to its simplicity and limited inconvenience. The predictive 
value of CAT for tubal pathology is limited, because the presence of C. trachomatis 
IgG antibodies reflects a previous infection, but not a persistent infection. Measuring 
serological markers of persistence, of which C-reactive protein (CRP) seems 
promising and may help to identify women at highest risk of tubal pathology17. 
Further evaluation is needed to decide whether serological markers of persistent C. 
trachomatis infections deserve a place in the fertility work-up18.
Endovaginal ultrasound
HSG and laparoscopy are not mutually exclusive, as apart from testing tubal 
patency, they provide different information that may be useful in the evaluation of 
subfertility19. Advantages of HSG relative to laparoscopy are that HSG provides 
information of the uterine cavity and configuration of the mucosal folds. Endovaginal 
ultrasound is also recommended as assessment of uterine cavity abnormalities20. The 
ultrasound approach has the additional advantage that the procedure is non-invasive, 
cheap and may offer supplementary information on tubal and ovarian pathology. 
The configuration of the mucosal folds is only needed if tubal microsurgery (eg 
salpingostomy) is feasible. Only if tubal microsurgery is considered, there is an option 
to perform HSG after a laparoscopy. The success of tubal surgery is determined 
by the degree of mucosal damage rather than the peritubal adhesions visualized at 
laparoscopy21. However, there is no evidence of benefit or disadvantage of tubal 
105
General discussion
surgery in the management of tubal infertility versus no treatment or alternative 
treatments22. 
7.1.4	 Recruitment	difficulties
It was more difficult than anticipated to recruit subjects to the randomized trial. In 
chapter five the results of recruitment difficulties in a randomized trial involving 
HSG are described. Inattentive clinicians and patient-associated reasons (like refusal 
and indecisiveness to enroll) were the most common reasons not to participate in 
the trial. Appropriate instruction of the study protocol to the participating doctors 
and adequate information, in layman’s terms, to the patients can overcome non-
recruitment. In the set up of the trial and during the recruitment, communication and 
information are the key words.
7.1.5 Conclusion
Chlamydia antibody testing (CAT) and endovaginal ultrasound may replace HSG 
as screening test prior to laparoscopy. CAT can be performed in stead of HSG to 
identify women at high risk for tubal pathology. When the Chlamydia serology 
findings are negative an expectant management for laparoscopic assessment of tubal 
pathology may be advised. Likewise, when the Chlamydia serology is abnormal, 
laparoscopic tubal assessment is indicated. For the assessment of uterine cavity 
abnormalities an endovaginal ultrasound can be performed. If pathology of the 
uterine cavity is presumed by ultrasound, hysteroscopy could be performed together 
with the laparoscopy.
In conclusion, HSG can be omitted from the routine investigation in the fertility 
workup and should only be applied for specific conditions like contraindication for 
laparoscopy or examining tubal mucosal fold configuration when tubal microsurgery 
is considered. Further studies are needed to detect better methods and to make clinical 
decisions about management on the basis of Chlamydia serology results.
7.2  Therapeutic strategies in reproductive medicine: a study on assisted 
conception
7.2.1 Perinatal outcome after assisted conception
The second subject presented in this thesis is a systematic review based on 
observational studies that investigated perinatal outcome as a possible adverse effect 
of assisted conception.
In the preparation time of the systematic review, we celebrated 25 years of assisted 
reproduction. The worse perinatal outcome after assisted reproduction was explained 
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by multiple pregnancy, bias and confounding23. In our systematic review of controlled 
studies published between 1985 and 2002, 25 studies were included of which 17 had 
matched and 8 had non-matched controls (chapter six). We concluded that singleton 
pregnancies conceived after assisted conception have significantly worse perinatal 
outcomes than non-assisted singleton pregnancies (Table 1). A few months later Dr. 
Mary Croughan’s group from California, USA, published a systematic review with 
an identical conclusion, using by and large the same studies as we have included, but 
focused only on IVF24. In both reviews the same control group (naturally conceived 
singletons) and definitions were used, and controlled for mostly maternal age and 
parity. Caesarean rate and admission to a neonatal intensive care unit, probably 
consequences of the perinatal problems were also significantly increased. 
Table 1.  Comparison of singletons conceived after assisted conception and spontaneously 
conceived singletons based on data of Helmerhorst et al, BMJ 2004 and Jackson et al, 
Obstet Gynecol 2004
 Helmerhorst Jackson
  OR 95%CI OR 95%CI
LBW <2500g 1.7 1.5-1.9 1.8 1.4-2.2
VLBW <1500g 3.0 2.1-4.4 2.7 2.3-3.1
Preterm <37wks 2.0 1.8-2.3 2.0 1.7-2.2
SGA <P10 1.4 1.2-1.7 1.6 1.3-2.0
PNM † 1.7 1.1-2.6 2.2 1.6-3.0
Can we trust both reviews? Or in other words is the conclusion true? Observational 
studies are considered to suffer heavily from bias in contrast to randomised controlled 
trials. However, the widespread use of hierarchy of evidence that grade research 
studies according to their quality is constructed for intervention studies, not for 
identifying infrequently occurring (unexpected) adverse effects25. In the situation on 
assisted conception we are discussing, it is not only unethical to conduct a randomized 
controlled trial (RCT), even if a RCT could be realized; the daunting number of 
participants that should be included was unrealistic to finish the trial adequately. 
Reasons that the conclusion of both reviews might be true, are that the association 
is consistent in all separate studies, that a dose response gradient is appreciated and 
that the association is observed in different populations, whereas high quality studies 
published higher risks. Treatment bias (preterm birth due to obstetric intervention) 
was not identified by Jackson et al.24. 
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7.2.2 Possible factors related with adverse perinatal outcome
Is the association between assisted reproductive treatments (ART) and worse 
perinatal outcome only valid for the IVF technique? In a retrospective cohort study, 
using data from the regional registry of all hospital deliveries in the Dutch-speaking 
part of Belgium during the period from January 1993 until December 2003, Ombelet 
et al.26 compared 12 021 singletons conceived after ovarian stimulation without IVF 
and 12 021 naturally conceived singletons matched for maternal age, parity, fetal 
sex and year of birth. Their results also showed a significantly higher incidence of 
prematurity (<32 and <37 weeks) as well as low and very low birth weight among 
singletons conceived after ovarian stimulation without IVF compared to naturally 
conceived singletons (Table 2). 
Table 2.  Comparison of singletons conceived after ovarian stimulation 
without IVF and spontaneously conceived singletons (Ombelet 
et al, Hum Reprod 2006)
  OR 95%CI
LBW <2500g 1.9 1.7-2.1
VLBW <1500g 3.2 2.3-4.5
Preterm <37wks 1.9 1.7-2.1
Very preterm <32wks 3.3 2.3-4.6
Two matched controlled studies compared perinatal outcome between IVF and 
IUI singletons and no differences between both groups was observed27,28. We may 
conclude that singleton pregnancies after ovarian stimulation (with or without ART 
procedure) are associated with worse perinatal outcome. So the ART procedure itself 
does not attribute to the adverse perinatal outcome of ART pregnancies.
Specific characteristics of an infertility population, such as higher maternal age 
and lower parity, are well known obstetric risk factors, so that it could a priori 
be expected that pregnancy outcome is poor in this group. Apart from these two 
confounders, couples with assisted pregnancies differ from couples who naturally 
conceive in socioeconomic status and smoking, while fetal sex and date of delivery 
might influence the perinatal outcome23,29-31. The matched controlled studies used 
in both reviews used these additional confounding factors in the studies of Dhont, 
Koivurova, Koudstaal, Maman, Reubinoff and Verlaenen. These factors seem unable 
to explain the difference in perinatal outcome.
Whether subfertility in itself may influence the association between assisted 
conception and worse perinatal outcome is unclear32. In order to investigate whether 
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subfertility explains poor perinatal outcome after assisted conception, Kapiteijn 
et al.33 (using data from a nation-wide historical cohort of 25 152 women treated 
for subfertility in the Netherlands between 1980 and 1995) compared perinatal 
outcome of singletons conceived after controlled ovarian hyperstimulation and 
IVF (IVF+; n = 2239) with perinatal outcome in subfertile women who conceived 
spontaneously (subfertile controls without treatment; n = 6343). The subjects were 
matched for maternal age, BMI, race, education, primiparity, smoking, diabetes, 
sex infant. Singleton IVF+ pregnancies have significantly worse perinatal outcomes 
than those of spontaneously conceived pregnancies in subfertile women (table 3). 
The poor perinatal outcome in this population could not be explained by subfertility 
and suggests that other factors may be important in the known association between 
assisted conception and poor perinatal outcome.
Table 3.  Comparison of singletons conceived after ovarian stimulation 
with IVF and subfertile controls without treatment (Kapiteijn 
et al, Hum Reprod 2006)
  ORadj 95%CI
LBW 1500-2500g 1.7 1.4-2.0
VLBW <1500g 2.7 1.8-4.1
Preterm 32-37wks 1.6 1.3-1.9
Very preterm <32wks 2.2 1.4-3.3
7.2.3. Clinical implications of worse perinatal outcome
What are the clinical implications of worse perinatal outcome after assisted 
conception? That depends on the prevalence of ART (IVF) children and the effects 
of low birth weight in later life. Babies with low birth weight are prone to develop 
cardiovascular disease in later life , i.e. hypertension, obesity and diabetes. This ‘fetal 
origins of adult disease’ or ‘Barker hypothesis’ suggests that several of the major 
diseases of later life, including coronary heart disease, stroke and cardiovascular 
death, originate in impaired intrauterine growth and development34. Furthermore, 
Smith et al.35 found that mothers, who once gave birth to thin babies, have a higher risk 
of developing ischemic heart disease later in life. Because the risk of cardiovascular 
disease is known to increase with an increasing number of risk factors, women with 
a low birth weight should try to avoid acquired risk factors, like smoking and obesity. 
In addition, extra attention should be given in detecting diabetes or hypertension at 
a later stage in life and in detecting exaggerated growth during childhood, as these 
individuals seem most prone to develop cardiovascular disease later on in life.
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7.2.4. Implications for the scientist
One of the criteria to determine causation of an association between two 
epidemiologically found phenomena formulated by Sir Austin Bradford Hill36 is 
to identify a biological mechanism behind the association. In an attempt to find a 
biological plausible explanation for the association between ovarian stimulation 
and low birth weight and to find on which level ovarian stimulation act its negative 
effect, Sibug et al.37-39 started form the observation that birth weight of singletons 
conceived after implanting a cryopreserved embryo is significantly higher than birth 
weight after a fresh embryo transfer40,41. Predominantly, an cryopreserved-thawed 
embryo transfer occurs in a natural cycle, thus without direct effect of ovarian 
stimulation, in contrast to the preceded cycle of IVF where ovarian stimulation is 
needed for producing sufficient oocytes in order to make selection of them. 
One might hypothesize that ovarian hyperstimulation prior to IVF might negatively 
influence uterine receptivity, meaning that ovarian stimulation is associated with low 
birth weight42 and might be considered as a negative effect (“stress factor “) on the 
endometrium43 and as such on the potential of embryonic implantation. Implantation 
implies an interaction between the human blastocyt and maternal endometrium. 
Blastocyts implantation is intimately associated with vascular permeability and 
angiogenesis. The vascular endothelial growth factor (VEGF) is a potent stimulator 
of blastocyt implantation. Ovarian stimulation with gonadotrophins to adult female 
CD1 mice lowered the expression of VEGF and its receptors in embryo implantation 
sites (37,38). Furthermore, embryo implantation was delayed and the area size of 
the embryo implantation site was reduced37. Two types of gonadotrophins were used 
(recombinant gonadotrophins and urinary gonadotrophins) as ovarian stimulation 
in adult female CD1 mice. Urinary gonadotrophins (urinary FSH and urinary hCG) 
but not recombinant gonadotrophins adversely affect the implantation process38. 
However, caution must be taken in interpreting these results and extrapolating them 
to the human situation. 
7.2.5. Alternative explanations for worse perinatal outcome
To reduce multiple and twin pregnancies, transfer of one embryo (single-embryo 
transfer (SET)) is offered in selected patient groups. Because the population of 
patients receiving SET resulting in singleton pregnancies is different from the one 
that would have become pregnant (with a singleton) before SET, de Neubourg et al.44 
prospectively investigated whether the obstetrical outcome of singleton pregnancies 
after SET differed from spontaneously conceived singletons. They concluded that the 
incidence of preterm birth was still worse and significantly higher in SET singletons 
versus spontaneous singletons although the birthweight of these ‘preterm born’ SET 
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singletons was not lower than for the spontaneous singletons.
Another plausible explanation for the poorer outcome in IVF singletons is that a 
sizeable number of IVF singletons origin from twin gestations, where spontaneous 
reduction occurred, leaving the surviving co-twin with an increased risk of adverse 
outcome. Recent studies reported that the survivors of a vanishing co-twin are 
contributing to a higher risk of adverse obstetric outcomes in IVF singletons45-47. 
7.2.6. Conclusion and recommendations
Whatever the explanation may be, singletons conceived after assisted conception have 
worse perinatal outcome than naturally conceived singletons, but this is substantially 
less so for twins. The major reason that the outcomes among twins are reaching unity 
may be found in the assumption that the assisted conception factor among twins 
is apparently overwhelmed by the multiple conception problems: a comparison 
between bad and bad remains equal. But this is poor consolation for the much greater 
risks of twin pregnancy overall (short- and long term outcome measures). Thus the 
adverse outcome carried in twins is still one of the main concerns of ART. 
Our conclusion draw attention to three challenges. Firstly, emphasis needs to 
shift, more than it has already, from achieving pregnancy to achieving a successful 
outcome. Secondly, it may be timely to consider any multiple pregnancy after assisted 
conception as a failure of that technology to achieve what it ought to achieve. Thirdly, 
there is a need to narrow the gap in perinatal outcome between assisted and other 
singleton pregnancies. This may also enhance understanding of how gestational age 
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In this thesis two studies are presented dealing with diagnostic and therapeutic 
strategies in reproductive medicine. The first subject is to investigate whether 
hysterosalpingography (HSG) prior to laparoscopy and dye should be maintained as 
a diagnostic procedure in the routine fertility work-up. The second subject focuses 
on therapy in reproductive medicine with the clinically relevant question whether 
adverse perinatal outcome is related to assisted conception in both singleton and 
twin pregnancies.
Chapter 1, provides an historical overview of the literature regarding evidence in 
reproductive medicine.
Because the usefulness of HSG was uncertain, a multicenter randomised controlled 
trial comparing fertility work-up with or without HSG to assess the value of HSG 
prior to laparoscopy and dye in a routine clinical setting was carried out. A pragmatic 
effectiveness trial was designed to evaluate whether two commonly used diagnostic 
strategies (HSG and laparoscopy & dye) have a different impact on cumulative 
pregnancy rate of subfertile women (chapter 2). A similar cumulative pregnancy 
rate at 18 months in the intervention (HSG) group (49.1%) [95% confidence interval 
(CI) 41.6 to 56.6] and the control (non-HSG) group (50.3%) (95% CI 42.8 to 57.8) 
was found. We concluded that routine use of HSG at an early stage in the fertility 
work-up prior to laparoscopy and dye does not influence cumulative pregnancy rate 
compared to routine use of laparoscopy without HSG. 
Many women experience HSG as a painful procedure, although laparoscopy is 
invasive and generally needs general anaesthesia. In an additional analysis of 
subfertile women nested in the above mentioned randomised controlled trial, pain 
and patient satisfaction of women undergoing an HSG or laparoscopy and dye as 
routine diagnostic procedures in the fertility work-up was evaluated and presented 
in chapter 3. The results showed that the HSG procedure was experienced as more 
painful while laparoscopy and dye was related with more post-procedure complaints. 
The overall judgment of women undergoing the procedures favours laparoscopy. We 
concluded that both HSG and laparoscopy cause considerable amount of physical 
complaints, but the overall judgment of women undergoing the procedures favours 
laparoscopy.
Chlamydia antibody testing (CAT) is an alternative of HSG to evaluate the tubal 
function in subfertile women. Nested in the randomised controlled trial, we assessed 
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in chapter 4 Chlamydia trachomatis specific IgG antibody testing (CAT) and 
HSG as test for the likelihood of tubal damage or occurrence of pregnancy prior to 
laparoscopy and dye. The diagnostic accuracy of both Chlamydia trachomatis specific 
IgG antibody testing and HSG are comparable but showed poor performance. The 
prognostic value of both tests in predicting occurrence of pregnancy was also poor. We 
concluded that CAT as screening test to estimate the risk of tubal pathology prior to 
laparoscopy is preferable to HSG due to its simplicity and limited inconvenience.
It was more difficult than anticipated to recruit subjects to a randomised controlled 
trial with or without the performance of HSG. In chapter 5, the reasons for non-
participation to the randomised trial are described. Inattentive clinicians and patient-
associated reasons (like refusal and indecisiveness to enroll) were the most common 
reasons not to participate in the trial. Appropriate instruction of the study protocol to 
the participating doctors and adequate information, in layman’s terms, to the patients 
can overcome non-recruitment. In the set up of the trial and during the recruitment, 
communication and information are the key words.
Chapter 6 describes the results of a systematic review of 25 controlled studies to 
examine difference in perinatal outcome between assisted and natural conceptions 
and whether they apply to both singleton and twin pregnancies. We concluded that 
singleton pregnancies conceived after assisted conception have significantly worse 
perinatal outcomes than naturally conceived singletons, but this is substantially less 
so for twins. 
In chapter 7, the results of the two studies are summarized and discussed in a broader 
perspective.
In short, the results of the randomised trial involving HSG showed that HSG can be 
omitted from the routine investigation in the fertility work-up and should only be 
applied for specific conditions like contraindication for laparoscopy or examining 
tubal mucosal fold configuration when tubal microsurgery is considered. Chlamydia 
antibody testing (CAT) and endovaginal ultrasound may replace HSG as screening 
test prior to laparoscopy. CAT can be performed in stead of HSG to identify women 
at high risk for tubal pathology. When the Chlamydia serology findings are negative 
an expectant management for laparoscopic assessment of tubal pathology may be 
advised. Likewise, when the Chlamydia serology is abnormal, laparoscopic tubal 
assessment is indicated. For the assessment of uterine cavity abnormality, an 
endovaginal ultrasound can be performed followed by hysteroscopy and laparoscopy 
when pathology of the uterine cavity is presumed .
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The major reason that the outcomes among twins are reaching unity may be found 
in the assumption that the assisted conception factor among twins is apparently 
overwhelmed by the multiple conception problems: a comparison between bad 
and bad remains equal. But this is poor consolation for the much greater risks of 
twin pregnancy overall (short- and long term outcome measures). Thus the adverse 
outcome carried in twins is still one of the main concerns of assisted conception. Our 
conclusion draws attention to three challenges. Firstly, emphasis needs to shift, more 
than it has already, from achieving pregnancy to achieving a successful outcome. 
Secondly, it may be timely to consider any multiple pregnancy after assisted 
conception as a failure of that technology achieve what it ought to achieve. Thirdly, 
there is a need to narrow the gap in perinatal outcome between assisted and other 
singleton pregnancies. This may also enhance understanding of how gestational age 




In dit proefschrift worden twee studies gepresenteerd die diagnostische en therapeu-
tische strategieën in de reproductieve geneeskunde onderzoeken. Het eerste onder-
werp onderzoekt of het verrichten van een hysterosalpingografie (HSG) vóórafgaand 
aan de gouden standaard laparoscopie met tubatesten moet worden gehandhaafd als 
een standaard diagnostisch onderzoek in het fertiliteitonderzoek. Het tweede onder-
werp over behandeling in de reproductieve geneeskunde gaat in op de klinisch re-
levante vraag of een ongunstige perinatale uitkomst gerelateerd is aan geassisteerde 
conceptie bij zowel eenling als tweeling zwangerschappen.
Hoofdstuk 1, verschaft een historisch overzicht van de literatuur over bewijs in de 
reproductieve geneeskunde.
Omdat het nut van HSG twijfelachtig was, werd er een multicenter gerandomiseerd 
gecontroleerde studie opgezet die een vergelijking maakt tussen fertiliteitonderzoe-
ken met of zonder het verrichten van een HSG om de waarde van HSG vóóraf lapa-
roscopie met tubatesten in een routine klinische setting te bepalen. Een pragmatische 
effectiviteitstudie werd ontwikkeld om te evalueren of twee vaak toegepaste diag-
nostische strategieën (HSG en laparoscopie met tubatesten) een verschillende impact 
hebben op de cumulatieve zwangerschapskans van subfertiele vrouwen (hoofdstuk 
2). Er was sprake van een gelijke cumulatieve zwangerschapskans bij 18 maanden 
in zowel de interventie (HSG) groep (49.1%) [95% betrouwbaarheidsinterval (BI) 
41.6 tot 56.6] als de controle (niet-HSG) groep (50.3%) [95% BI 42.8 tot 57.8]. Wij 
concludeerden dat routinematig toepassen van HSG in een vroeg stadium in het 
fertiliteitonderzoek vóór de laparoscopie met tubatesten, de cumulatieve zwanger-
schapskans niet beïnvloedt vergeleken met het routinematig toepassen van laparo-
scopie zonder vooraf HSG. 
Veel vrouwen ervaren het HSG als een pijnlijk onderzoek, maar de laparoscopie 
is een invasieve ingreep dat meestal onder algehele anesthesie plaatsvindt. In een 
additionele analyse van subfertiele vrouwen die afkomstig waren uit de hierboven 
beschreven gerandomiseerd gecontroleerde studie, werd de pijn en tevredenheid ge-
ëvalueerd en gepresenteerd in hoofdstuk 3. Deze groep vrouwen hadden of een 
HSG of een laparoscopie met tubatesten ondergaan als standaard diagnostisch fer-
tiliteitonderzoek. De resultaten toonden aan dat het HSG onderzoek werd ervaren 
als een pijnlijker onderzoek, terwijl laparoscopie met tubatesten gerelateerd was 
aan meer klachten optredend na het onderzoek. De algemene beoordeling van deze 
vrouwen was ten gunste van de laparoscopie. Wij concludeerden dat zowel HSG als 
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laparoscopie een aanzienlijke hoeveelheid fysieke klachten veroorzaakt, maar dat de 
algemene beoordeling van vrouwen die het onderzoek heeft ondergaan ten gunste 
was van de laparoscopie.
Chlamydia IgG antilichaam titer (CAT) bepaling is een alternatief voor het HSG om 
de tuba functie te evalueren bij subfertiele vrouwen. Met gegevens afkomstig uit de 
gerandomiseerd gecontroleerde studie, onderzochten we in hoofdstuk 4 de waarde 
van Chlamydia trachomatis specifieke IgG antilichaam titer bepaling (CAT) en HSG 
als test voor de waarschijnlijkheid van tuba schade of optreden van zwangerschap 
vóór het verrichten van laparoscopie met tubatesten. De diagnostische nauwkeurig-
heid van zowel Chlamydia trachomatis specifieke IgG antilichaam titer bepaling en 
HSG zijn vergelijkbaar maar beide onnauwkeurig. De prognostische waarde van 
beide testen in voorspellen van het optreden van zwangerschap was even onnauw-
keurig. Wij concludeerden dat CAT als test om het risico in te schatten op tuba pa-
thologie vóór de laparoscopie de voorkeur heeft boven HSG vanwege zijn gemak en 
minder invasiviteit.
Het was moeilijker dan vooraf was geschat om patiënten te rekruteren voor een 
gerandomiseerd gecontroleerde studie met of zonder het verrichten van een HSG. 
In hoofdstuk 5, worden de redenen van niet-deelname aan deze gerandomiseerde 
studie beschreven. Onoplettende artsen en patiënt-geassocieerde redenen (zoals wei-
gering en besluiteloosheid om mee te doen) waren de meest voorkomende redenen 
om niet deel te nemen aan de studie. Het geven van goede instructies over het stu-
dieprotocol aan de deelnemende artsen en adequate informatie, in lekentaal aan de 
patiënten, kan het niet-rekruteren ondervangen. 
Hoofdstuk 6 beschrijft de resultaten van een systematische review van 25 gecon-
troleerde studies om het verschil te onderzoeken in perinatale uitkomsten tussen 
geassisteerde en spontane conceptie en of dit ook geldt voor eenling en tweeling 
zwangerschappen. Wij concludeerden dat eenling zwangerschappen ontstaan na 
geassisteerde conceptie significant slechtere perinatale uitkomsten hebben dan na 
spontane conceptie, maar dat dit minder geldt voor tweeling zwangerschappen. 
In hoofdstuk 7 zijn de resultaten van de twee studies samengevat en bediscussi-
eerd.
Kort samengevat, de resultaten van de gerandomiseerde HSG studie laten zien dat 
HSG kan worden weggelaten uit het standaard fertiliteitonderzoek en alleen zou moe-
ten worden verricht om specifieke redenen zoals contra-indicatie voor laparoscopie 
of beoordelen slijmvliespatroon van de tubae als microchirurgie wordt overwogen. 
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Summary & Samenvatting
Chlamydia IgG antilichaam titer (CAT) bepaling en echografisch onderzoek kunnen 
het HSG vervangen als test vóór de laparoscopie. CAT kan in plaats van HSG wor-
den verricht om vrouwen met verhoogd risico voor tubapathologie te identificeren. 
Als de Chlamydia serologie uitslagen negatief zijn, dan kan er een afwachtend beleid 
worden gevoerd ten aanzien van laparoscopische beoordeling voor tubapathologie. 
Evenzo als de Chlamydia serologie abnormaal is, dan is directe laparoscopische be-
oordeling van de tubae geïndiceerd. Voor de beoordeling van afwijkingen aan het 
cavum uteri, kan een echografisch onderzoek worden uitgevoerd gevolgd door hys-
teroscopie indien er afwijkingen aan het cavum uteri worden vermoed. 
De belangrijkste reden dat de resultaten tussen tweelingen een gelijkheid bereiken 
zou gevonden kunnen worden in de veronderstelling dat de geassisteerde conceptie 
factor tussen tweelingen schijnbaar overstelpt wordt door het meerling conceptie 
probleem: een vergelijking tussen slecht en slecht blijft gelijk. Maar dit is schra-
le troost voor de veel grotere risico’s van tweeling zwangerschap in algemene zin 
(korte- en lange termijn uitkomstmaten). Dus de ongunstige uitkomst bij tweelingen 
is nog steeds een van de grootste zorgen van geassisteerde conceptie. Onze conclu-
sie trekt de aandacht naar drie uitdagingen. Als eerste moet de nadruk verschuiven, 
meer dan het thans is, van volbrengen tot een zwangerschap naar volbrengen tot een 
succesvolle uitkomst. Ten tweede wordt het tijd om elke meerling zwangerschap na 
geassisteerde conceptie te zien als een gebrek van de technologie. Als derde is het 
nodig om de ruimte tussen de perinatale uitkomst tussen geassisteerde en spontane 
eenling zwangerschappen te verkleinen. Dit zou dan ook meer duidelijkheid kunnen 





VRAGENLIJST vooraf HSG of laparoscopie
Geachte mevrouw,
Wij vragen u deze vragenlijst voor aanvang van het HSG of laparoscopie in te vullen. 
Sommige van onderstaande woorden omschrijven pijngevoelens, die u heeft gehad 
tijdens de EERSTE DAG van uw laatste menstruatie.
Van de 20 rijtjes woorden mag u er één uitkiezen die het beste bij uw pijn tijdens de 
eerste dag van de laatste menstruatie past. Als er in een rijtje geen enkel woord staat dat 
op uw pijn van toepassing is, ga dan verder met het volgende rijtje.
Het tweede deel van de vragenlijst bestaat uit een lijn met links de woorden “Geen 
enkele” en rechts de woorden “Maximaal voorstelbare”. De bedoeling is dat u op deze 
lijn één kruisje zet om aan te geven hoe pijnlijk de eerste dag van uw laatste menstruatie 
was.
Hartelijk bedankt voor het invullen van de vragenlijst.
Uw pijn tijdens de eerste dag van uw laatste menstruatie is:
(juiste antwoord omcirkelen)
1. kloppend - bonzend - barstend
2. opflikkerend - flitsend - schietend
3.  prikkend - stekend - doorborend
4.  scherp - snijdend - messcherp
5.  drukkend - knellend - snoerend
6.  trekkend - splijtend - scheurend
7.  branderig - brandend - vlammend
8.  broeiend - gloeiend - verschroeiend
9. koud - ijskoud - vriezend
10. tintelend - jeukend - elektrisch
11. stijf - strak - krampend
12.  zeurend - knagend - hardnekkig
13. vermoeiend - afmattend - uitputtend
14. chagrijnig - deprimerend - ziekmakend
15.  gespannen - benauwend - verstikkend
16. verontrustend - beangstigend - angstaanjagend
17.  treiterend - kwellend - martelend
18. licht - matig - erg - enorm
19. draaglijk - hinderlijk - ontzettend - onhoudbaar 
20. vervelend - ellendig - vreselijk – afgrijselijk
Randomisatie nummer:
Datum van invullen van deze vragenlijst:
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Questionnaires used in chapter 3
Wij willen u vragen om op onderstaande meetschaal aan te geven hoe pijnlijk u 
de EERSTE DAG van uw laatste menstruatie heeft ervaren. Op de meetschaal 
betekent ‘100’ ondraaglijke-maximale-pijn en ‘0’ betekent geen pijn. De 
bedoeling is dat u op deze lijn één kruisje tekent dat volgens u de pijn aangeeft die 
u heeft ervaren.
1.
Hoe is de gemiddelde pijn die u op de eerste dag van de laatste menstruatie heeft 
ervaren?
Gemiddelde pijn zoals u die op de eerste dag van de 






Hoe is de maximale pijn die u op de eerste dag van de laatste menstruatie heeft 
ervaren?








VRAGENLIJST na HSG of laparoscopie
Geachte mevrouw,
Wij vragen u deze vragenlijst in te vullen nadat u een HSG of laparoscopie heeft 
ondergaan. 
Het eerste deel van de vragenlijst omschrijft pijngevoelens die u heeft gehad direkt na 
het onderzoek. Van de 20 rijtjes woorden mag u er één uitkiezen die het beste bij uw 
pijn past. Als er in een rijtje geen enkel woord staat dat op uw pijn van toepassing is, ga 
dan verder met het volgende rijtje.
Het tweede deel van de vragenlijst bestaat uit een lijn met links de woorden “Geen 
enkele” en rechts de woorden “Maximaal voorstelbare”. De bedoeling is dat u op deze 
lijn één kruisje zet om aan te geven hoe pijnlijk u het onderzoek heeft ervaren. 
Hartelijk bedankt voor het invullen van de vragenlijst.
Uw pijn na het onderzoek was:
(juiste antwoord omcirkelen)
1. kloppend - bonzend - barstend
2. opflikkerend - flitsend - schietend
3.  prikkend - stekend - doorborend
4.  scherp - snijdend - messcherp
5.  drukkend - knellend - snoerend
6.  trekkend - splijtend - scheurend
7.  branderig - brandend - vlammend
8.  broeiend - gloeiend - verschroeiend
9. koud - ijskoud - vriezend
10. tintelend - jeukend - elektrisch
11. stijf - strak - krampend
12.  zeurend - knagend - hardnekkig
13. vermoeiend - afmattend - uitputtend
14. chagrijnig - deprimerend - ziekmakend
15.  gespannen - benauwend - verstikkend
16. verontrustend - beangstigend - angstaanjagend
17.  treiterend - kwellend - martelend
18. licht - matig - erg - enorm
19. draaglijk - hinderlijk - ontzettend - onhoudbaar 
20. vervelend - ellendig - vreselijk – afgrijselijk
Randomisatie nummer:
Datum van invullen van deze vragenlijst:
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Questionnaires used in chapter 3
Wij willen u vragen om op onderstaande meetschaal aan te geven hoe pijnlijk 
u het onderzoek heeft ervaren. Op de meetschaal betekent ‘100’ ondraaglijke-
maximale-pijn en ‘0’ betekent geen pijn. De bedoeling is dat u op deze lijn één 
kruisje tekent dat volgens u de pijn aangeeft die u heeft ervaren.
1.
Hoe is de gemiddelde pijn die u na het onderzoek heeft ervaren?






Hoe is de maximale pijn die u na het onderzoek heeft ervaren?






Hoe is de pijn zoals u die nu, na het onderzoek, voelt?







VRAGENLIJST 1 week na HSG of laparoscopie
Geachte mevrouw,
Wij vragen u deze vragenlijst in te vullen 1 week nadat u een HSG of laparoscopie 
heeft ondergaan. Er worden een aantal vragen gesteld over de pijn waar u last van heeft 
gehad na het ondergaan van dit onderzoek. Als u alle vragen heeft beantwoord dan kunt 
u met een toegevoegde antwoordenveloppe de brief terugsturen naar het ziekenhuis.
Hartelijk bedankt voor het invullen van de vragenlijst.
Lees elke zin nauwkeurig door en bepaal in hoeverre u last gehad heeft van 
deze bijwerkingen. U kunt de vraag beantwoorden door het juiste antwoord te 
omcirkelen.
1=helemaal niet, 2=een beetje, 3=redelijk wat, 4=veel, 5=heel veel
1. In hoeverre heeft u voldoende informatie 
gekregen over het HSG of laparoscopie 
1 2 3 4 5
2. In hoeverre heeft u last gehad na het 
onderzoek van:
buikpijn 1 2 3 4 5
bloedverlies 1 2 3 4 5
schouderpijn 1 2 3 4 5
misselijkheid 1 2 3 4 5
braken 1 2 3 4 5
duizeligheid 1 2 3 4 5
hoofdpijn 1 2 3 4 5
keelpijn 1 2 3 4 5
spierpijn 1 2 3 4 5
moeheid, algehele malaise 1 2 3 4 5
3a. In hoeverre vond u de volgende 
aspecten van het HSG vervelend:
wachttijd onderzoek 1 2 3 4 5
inbrengen speculum 1 2 3 4 5
doorspuiten eileiders 1 2 3 4 5
plaatsen cupje 1 2 3 4 5
bloedverlies 1 2 3 4 5
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Questionnaires used in chapter 3
3b. In hoeverre vond u de volgende aspecten 
van de laparoscopie vervelend:
wachttijd onderzoek 1 2 3 4 5
opname ziekenhuis 1 2 3 4 5
Het onder narcose moeten 1 2 3 4 5
bloedverlies 1 2 3 4 5
4. In hoeverre is het onderzoek u 
tegengevallen?
1 2 3 4 5
5.   Heeft u nog pijnstillers moeten gebruiken? Ja / nee
6.   Na hoeveel dagen kon u weer normale aktiviteiten 
verrichten?
1-2-3-4-5->5
7.   Als u alles vantevoren had geweten, zou u de ingreep 
opnieuw doen?   
Ja / nee
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